,PageNo,Text
0,page_1,"['Official Protocol Title:', 'A Phase 3, randomized, double-blind trial of pembrolizumab', '(MK-3475) with or without lenvatinib (E7080/MK-7902) in', 'participants with treatment-naïve, metastatic nonsmall cell lung', 'cancer (NSCLC) whose tumors have a tumor proportion score (TPS)', 'greater than or equal to 1% (LEAP-007)', 'NCT number:', 'NCT03829332', 'Document Date:', '15-Sep-2021']"
1,page_2,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '1', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Title Page', 'THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING', 'TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK', 'SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., NJ, U.S.A.', '(MSD).', 'Protocol Title: A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475)', 'with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic', 'nonsmall cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS)', 'greater than or equal to 1% (LEAP-007)', 'Protocol Number: 007-06 (E7080-G000-314)', 'Compound Number: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', 'Sponsor Name:', 'Merk Sharp & Dohme Corp., a subsidiary of Merk & Co., Inc.', '(hereafter referred to as the Sponsor or MSD)', 'The study is co-funded by MSD and Eisai.', 'Legal Registered Address:', 'One Merk Drive', 'P.O. Box 100', 'Whitehouse Station, New Jersey, 08889-0100, U.S.A.', 'Regulatory Agency Identifying Number(s):', 'IND', '140221', 'EudraCT', '2018-003794-98', 'Approval Date: 15 September 2021', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
2,page_3,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '2', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Sponsor Signatory', 'Typed Name:', 'Date', 'Title:', 'Protocol-specific Sponsor contact information can be found in the Investigator Study', 'File Binder (or equivalent).', 'Investigator Signatory', 'I agree to conduct this clinical study in accordance with the design outlined in this protocol', 'and to abide by all provisions of this protocol.', 'Typed Name:', 'Date', 'Title:', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
3,page_4,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '3', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'DOCUMENT HISTORY', 'Document', 'Date of Issue', 'Overall Rationale', 'Amendment 06', '15-SEP-2021', 'Data from an interim safety and futility eDMC for LEAP-007 (data cutoff:', '19-MAY-2021) indicated the study met the prespecified nonbinding', 'futility criteria for OS for the combination of lenvatinib plus', 'pembrolizumab compared with placebo plus pembrolizumab and the', 'benefit-risk assessment was not considered positive to continue the study.', 'This futility analysis was requested at a previous eDMC meeting and', 'conducted as described in the sSAP. Based upon these data, MSD', 'implemented this amendment to unblind the study and remove lenvatinib', 'and matching placebo from the study. In addition, the Second-course', 'Treatment Phase was discontinued and collection of ePRO data stopped.', 'The study will remain open to allow ongoing participants to continue', 'treatment with open-label pembrolizumab monotherapy up to a maximum', 'of 35 administrations.', 'Amendment 05', '02-MAR-2021', 'To update the assumptions and timing of the analyses in the SAP, allow', 'sufficient duration of follow-up, and to remove the initial alpha of ORR', 'and reallocate to primary endpoints of PFS and OS', 'Amendment 04 - China-specific', '11-FEB-2020', 'Extension of the enrollment period beyond the global study to achieve', 'required exposure and number of events to investigate efficacy and safety', 'in Chinese 1L NSCLC participants', 'Amendment 03', '16-DEC-2019', 'Alignment with Lenvatinib and Pembrolizumab (LEAP) program protocol', 'standards and Health Authority request', 'Amendment 02', '27-JUN-2019', 'Alignment with Lenvatinib and Pembrolizumab (LEAP) program protocol', 'standards', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
4,page_5,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '4', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Document', 'Date of Issue', 'Overall Rationale', 'Amendment 01', '17-JAN-2019', 'Alignment with Lenvatinib and Pembrolizumab (LEAP) program protocol', 'standards', 'Original Protocol', '09-NOV-2018', 'N/A', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
5,page_6,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '5', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES', 'Amendment: 06', 'Overall Rationale for the Amendments:', 'Data from an interim safety and futility eDMC for LEAP-007 (data cutoff: 19-MAY-2021) indicated the study met the prespecified', 'nonbinding futility criteria for OS for the combination of lenvatinib plus pembrolizumab compared with placebo plus pembrolizumab', 'and the benefit-risk assessment was not considered positive to continue the study. This futility analysis was requested at a previous', 'eDMC', 'meeting', 'and conducted as described in the sSAP. Based upon these data, MSD implemented this amendment to unblind the', 'study and remove lenvatinib and matching placebo from the study. In addition, the Second-course Treatment Phase was discontinued', 'and collection of ePRO data stopped. The study will remain open to allow ongoing participants to continue treatment with open-label', 'pembrolizumab monotherapy up to a maximum of 35 administrations.', 'Summary of Changes Table:', 'Section # and Name', 'Description of Change', 'Brief Rationale', '1.1 Synopsis', 'Revised text and added notes to clarify the', 'In accordance with the overall rationale for the', '1.2 Schema', 'removal of lenvatinib and placebo', 'amendment, administration of lenvatinib and matching', 'treatments, Second-course Phase,', 'placebo, the Second-course Treatment Phase, and the', 'collection of ePRO, and collection of', 'collection of ePRO data and posttreatment imaging have', 'posttreatment imaging. Extension Study in', 'been removed from the study.', 'China was also stopped', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
6,page_7,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '6', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Section # and Name', 'Description of Change', 'Brief Rationale', '1.3.1 Schedule of Activities', 'Added a clarifying note regarding the', 'In accordance with the overall rationale for the', '- Initial Treatment Phase', 'removal of lenvatinib and matching', 'amendment, lenvatinib and matching placebo', 'placebo. Revised table to remove', 'administration have been removed and', 'lenvatinib and matching placebo', 'assessments/procedures simplified.', 'administration, collection of ePRO data', 'and posttreatment imaging, collection of', 'most of the blood biomarkers, and all', 'procedures/assessments for cycles >36.', 'Updated vital signs, ECG, and urine', 'testing requirements.', '1.3.2 Schedule of Activities', 'Removed table and added a clarifying', 'In accordance with the overall rationale for the', '- Second-course Treatment', 'note.', 'amendment, the Second-course Treatment Phase has', 'Phase', 'been removed from the study.', '2 Introduction', 'Added notes to clarify the removal of', 'In accordance with the overall rationale for the', '2.2 Background', 'lenvatinib and matching placebo. Sections', 'amendment, lenvatinib and matching placebo', 'have been left unchanged for reference.', 'administration have been removed, but background', 'information is maintained for reference.', '2.3 Benefit/Risk Assessment', 'Added a note to clarify that the benefit/risk', 'Lenvatinib and matching placebo have been removed', 'assessment of pembrolizumab plus', 'from the study; thus, benefit/risk assessment of', 'lenvatinib is no longer applicable. Section', 'pembrolizumab plus lenvatinib is no longer relevant.', 'updated accordingly.', '3. Hypotheses, Objectives,', 'Added a note to clarify that efficacy', 'As the study did not meet the prespecified criteria for OS,', 'and Endpoints', 'endpoints will no longer be collected, and', 'the scope of the study is reduced and further collection of', 'exploratory objectives may not be further', 'efficacy data is not required.', 'pursued.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
7,page_8,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '7', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Section # and Name', 'Description of Change', 'Brief Rationale', '4.1 Overall Design', 'Revised text and added notes to clarify the', 'In accordance with the overall rationale for the', 'removal of lenvatinib and placebo', 'amendment, administration of lenvatinib and matching', 'treatments from the study. Extension Study', 'placebo and the Second-course Treatment Phase have', 'in China was also stopped.', 'been removed from the study.', '4.2.1.3 Patient-reported', 'Added note to clarify that PRO data will', 'In accordance with the overall rationale for the', 'Outcomes', 'no longer be collected.', 'amendment, PRO data are no longer being collected.', '8.2.2 Patient-reported', 'Outcomes', '4.3.1 Maximum', 'Revised text and added note to clarify the', 'Administration of lenvatinib and matching placebo and', 'Dose/Exposure for This', 'removal of lenvatinib, placebo, and the', 'the Second-course Treatment Phase have been removed', 'Study', 'Second Course from the study.', 'from the study.', '4.3.2.1 Lenvatinib Dosing', 'Added note stating that this section is no', 'Lenvatinib and matching placebo administration have', 'longer applicable.', 'been removed, but rationale for lenvatinib dosing is', 'maintained for reference.', '6 Study Intervention', 'Added notes to clarify the removal of', 'Lenvatinib and matching placebo have been removed', 'lenvatinib and matching placebo. Section', 'from the study.', 'updated accordingly.', '6.3.3 Blinding', 'Added note to clarify that blinding is no', 'Lenvatinib and matching placebo have been removed', '8.1.10 Participant', 'longer applicable and removed the content', 'from the study. All participants will receive open-label', 'in these sections.', 'Blinding/Unblinding', 'pembrolizumab monotherapy and the study has been', 'unblinded.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
8,page_9,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '8', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Section # and Name', 'Description of Change', 'Brief Rationale', '6.6. Dose Modification', 'Added notes to clarify the removal of', 'Lenvatinib has been removed from the study.', 'lenvatinib and matching placebo.', 'Subsections related to dose modifications', 'due to lenvatinib toxicity or the toxicity of', 'lenvatinib in combination with', 'pembrolizumab removed or updated as', 'appropriate.', '6.8 Clinical Supplies', 'Added note stating that this section is no', 'Lenvatinib and matching placebo have been removed', 'Disclosure', 'longer applicable and removed the content.', 'from the study and the study has been unblinded.', '7.1 Discontinuation of Study', 'Added note to clarify the removal of', 'Lenvatinib has been removed from the study.', 'Intervention', 'lenvatinib and matching placebo.', 'Removed criteria related to ALT/AST', 'elevation specific to toxicity of the', 'combination of lenvatinib +', 'pembrolizumab. Replaced with a general', 'criterion noting that discontinuation', 'criteria specific to pembrolizumab-related', 'toxicity as defined in Section 6.6 should be', 'followed.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
9,page_10,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '9', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Section # and Name', 'Description of Change', 'Brief Rationale', '7.1.1 Second-course', 'Deleted content and added a note to clarify', 'Second-course Treatment Phase has been removed from', 'Treatment Phase', 'that the Second Course has been removed', 'the study.', '8.2.1.4 Second-course', 'from the study.', 'Treatment Tumor Scans', '8.1.5.3 Concomitant', 'Added a note to clarify that the Second', 'Second-course Treatment Phase has been removed from', 'Medications', 'Course has been removed from the study.', 'the study. Recording of concomitant medications for the', 'Section updated accordingly.', 'Second Course is no longer required.', '8.1.8.1.1', 'Added clarifying note due to removal of', 'Lenvatinib and matching placebo have been removed', 'Lenvatinib/Matching', 'lenvatinib and matching placebo from the', 'from the study.', 'Placebo', 'study.', '8.2.1 Tumor Scans and', 'Added a note to clarify that imaging', 'In accordance with the overall rationale for the', 'Assessments of Disease', 'obtained will not be assessed, verification', 'amendment, assessments/procedures have been', 'of PD is no longer needed, and', 'simplified.', 'posttreatment imaging is not required.', 'Subsections and Table 5 updated', 'accordingly. Figure 3 removed.', '8.11.5.2 Efficacy Follow-up', 'Added a note to clarify that imaging', 'Visits', 'obtained will not be assessed, verification', 'of PD is no longer needed, and', 'posttreatment imaging is not required.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
10,page_11,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '10', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Section # and Name', 'Description of Change', 'Brief Rationale', '8.3 Safety Assessments', 'Added notes to clarify the removal of', 'Lenvatinib and matching placebo have been removed', 'lenvatinib and matching placebo and', 'from the study.', 'updated guidelines for BP and ECG', 'measurements to remove', 'assessments/procedures that were specific', 'to lenvatinib safety monitoring.', '8.5 Treatment of Overdose', 'Added note to clarify the removal of', 'Lenvatinib and matching placebo have been removed', 'lenvatinib and matching placebo. Section', 'from the study.', 'left unchanged for reference.', '8.9 Biomarkers', 'Removed the collection of the following', 'In accordance with the overall rationale for the', 'biomarkers:', 'amendment, , assessments/procedures have been', 'simplified.', 'Blood for serum biomarkers', 'Blood for plasma biomarkers', 'Blood for RNA analysis', 'Blood for circulating tumor nucleic', 'acids', '8.11 Visit Requirements', 'Added notes to clarify that the Second-', 'Administration of lenvatinib, matching placebo, and', 'course Treatment Phase has been removed', 'Second-course Treatment Phase have been removed from', 'from the study. Subsections updated', 'the study. Therefore, study visit requirements were', 'accordingly to remove text specific to the', 'updated.', 'Second-course Treatment Phase.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
11,page_12,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '11', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Section # and Name', 'Description of Change', 'Brief Rationale', '9 Statistical Analysis Plan', 'Added notes to clarify that the study has', 'In accordance with the reduced scope of the study and', '9.1 Statistical Analysis Plan', 'been unblinded, enrollment in the', 'discontinuation of efficacy data collection.', 'Summary', 'Extension Study in China has been', 'stopped, and no further prespecified', '9.5 Analysis Populations', 'analysis of primary, secondary, and', 'exploratory endpoints will be performed.', 'Subsections updated accordingly.', '9.2 Responsibility for', 'Added note to clarify that the study has', 'Analyses/In-house Blinding', 'been unblinded. Updated content to reflect', 'the current status of the trial with regards', 'to blinding.', '9.6 Statistical Methods', 'Added note to clarify that the selected', 'analyses of safety and ePRO endpoints', 'will be performed at end of study, and', 'there will be no further analyses of', 'efficacy endpoints. Sections have been', 'retained for reference.', '9.7 Interim Analyses', 'Removed content and added notes to', '9.8 Multiplicity', 'clarify that no interim or final analyses of', 'the study will be performed and sections', '9.9 Sample Size and Power', 'are no longer applicable.', 'Calculations', '10.7.3 Canada-specific', 'Section updated to remove lenvatinib', 'Lenvatinib has been removed from the study.', 'Requirements', 'references.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
12,page_13,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '12', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Throughout', 'All references to lenvatinib and placebo', 'In accordance with the overall rationale for the', 'were removed. Where deletion of text', 'amendment.', 'could cause confusion due to the original', 'design of the study or where text is useful', 'to understand the overall context of the', 'study, the text has been left unchanged and', 'a note was added. Added clarifying notes', 'regarding removal of lenvatinib and', 'matching placebo from the study.', 'Made typographical corrections and minor', 'To correct typographical errors and clarify intended', 'administrative edits.', 'meaning.', 'ADDITIONAL CHANGE(S) FOR THIS AMENDMENT:', 'No additional changes.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
13,page_14,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '13', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table of Contents', 'DOCUMENT HISTORY', '3', 'PROTOCOL AMENDMENT SUMMARY OF CHANGES', '5', '1', 'PROTOCOL SUMMARY', '22', '1.1', 'Synopsis', '22', '1.2', 'Schema', '28', '1.3', 'Schedule of Activities (SoA)', '29', '1.3.1', 'Initial Treatment Phase', '29', '1.3.2', 'Second-course Treatment Phase', '40', '2', 'INTRODUCTION', '41', '2.1', 'Study Rationale', '41', '2.2', 'Background', '43', '2.2.1', 'Pharmaceutical and Therapeutic Background', '43', '2.2.1.1', 'Lenvatinib', '43', '2.2.1.2', 'Pembrolizumab', '44', '2.2.1.3', 'Pembrolizumab With Lenvatinib', '44', '2.2.2', 'Preclinical and Clinical Studies', '45', '2.2.2.1', 'Completed Studies With Pembrolizumab and Lenvatinib', '45', '2.2.3', 'Ongoing Clinical Studies of Pembrolizumab and Lenvatinib', '45', '2.3', 'Benefit/Risk Assessment', '46', '3', 'HYPOTHESES, OBJECTIVES, AND ENDPOINTS', '46', '4', 'STUDY DESIGN', '50', '4.1', 'Overall Design', '50', '4.2', 'Scientific Rationale for Study Design', '51', '4.2.1', 'Rationale for Endpoints', '51', '4.2.1.1', 'Efficacy Endpoints', '51', '4.2.1.1.1', 'RECIST 1.1', '52', '4.2.1.1.2', 'Adjusted RECIST 1.1 for Immune-based Therapeutics', 'iRECIST', '52', '4.2.1.2', 'Safety Endpoints', '52', '4.2.1.3', 'Patient-reported Outcomes', '53', '4.2.1.3.1', 'EORTC QLQ-C30', '53', '4.2.1.3.2', 'EORTC QLQ-LC13', '53', '4.2.1.3.3', 'EuroQoL EQ-5D-5L', '53', '4.2.1.4', 'Pharmacokinetic Endpoints', '54', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
14,page_15,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '14', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.1.5', 'Planned Exploratory Biomarker Research', '54', '4.2.2', 'Rationale for the Use of Comparator/Placebo', '56', '4.3', 'Justification for Dose', '56', '4.3.1', 'Maximum Dose/Exposure for This Study', '56', '4.3.2', 'Rationale for Dose Interval and Study Design', '56', '4.3.2.1', 'Lenvatinib Dosing', '56', '4.3.2.2', 'Pembrolizumab Dosing', '57', '4.4', 'Beginning and End of Study Definition', '58', '4.4.1', 'Clinical Criteria for Early Study Termination', '58', '5', 'STUDY POPULATION', '58', '5.1', 'Inclusion Criteria', '58', '5.2', 'Exclusion Criteria', '63', '5.3', 'Lifestyle Considerations', '66', '5.3.1', 'Meals and Dietary Restrictions', '66', '5.3.2', 'Contraception', '66', '5.3.3', 'Pregnancy', '66', '5.3.4', 'Use in Nursing Women', '67', '5.4', 'Screen Failures', '67', '5.5', 'Participant Replacement Strategy', '67', '6', 'STUDY INTERVENTION', '67', '6.1', 'Study Intervention(s) Administered', '67', '6.1.1', 'Medical Devices', '69', '6.2', 'Preparation/Handling/Storage/Accountability', '69', '6.2.1', 'Dose Preparation', '69', '6.2.2', 'Handling, Storage, and Accountability', '69', '6.3', 'Measures to Minimize Bias: Randomization and Blinding', '70', '6.3.1', 'Intervention Assignment', '70', '6.3.2', 'Stratification', '70', '6.3.3', 'Blinding', '70', '6.3.3.1', 'Pembrolizumab', '70', '6.4', 'Study Intervention Compliance', '71', '6.5', 'Concomitant Therapy', '71', '6.5.1', 'Allowed Concomitant Medications', '71', '6.5.2', 'Prohibited Concomitant Medications', '72', '6.5.3', 'Drug Interactions', '72', '6.5.4', 'Rescue Medications and Supportive Care', '73', '6.5.4.1', 'Systemic Corticosteroid Use', '73', '6.6', 'Dose Modification', '73', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
15,page_16,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '15', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '6.6.1', 'Immune-related Events and Dose Modification (Withhold, Treat,', 'Discontinue)', '73', '6.6.1.1', 'Dose Modification and Toxicity Management for Immune-related', 'AEs Associated with Pembrolizumab', '73', '6.6.1.2', 'Dose Modification and Toxicity Management of Infusion', 'Reactions Related to Pembrolizumab', '79', '6.6.2', 'Other Allowed Dose Interruptions', '82', '6.7', 'Intervention After the End of the Study', '82', '6.8', 'Clinical Supplies Disclosure', '82', '6.9', 'Standard Policies', '82', '7', 'DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT', 'WITHDRAWAL', '82', '7.1', 'Discontinuation of Study Intervention', '82', '7.1.1', 'Second-course Treatment Phase', '83', '7.2', 'Participant Withdrawal From the Study', '83', '7.3', 'Lost to Follow-up', '84', '8', 'STUDY ASSESSMENTS AND PROCEDURES', '84', '8.1', 'Administrative and General Procedures', '85', '8.1.1', 'Informed Consent', '85', '8.1.1.1', 'General Informed Consent', '85', '8.1.2', 'Inclusion/Exclusion Criteria', '86', '8.1.3', 'Participant Identification Card', '86', '8.1.4', 'Medical History', '86', '8.1.4.1', 'General Medical History', '86', '8.1.4.2', 'Oncologic Disease Details', '86', '8.1.5', 'Prior and Concomitant Medications Review', '87', '8.1.5.1', 'Prior Medications', '87', '8.1.5.2', 'Prior Oncologic Treatment', '87', '8.1.5.3', 'Concomitant Medications', '87', '8.1.6', 'Assignment of Screening Number', '87', '8.1.7', 'Assignment of Treatment/Randomization Number', '88', '8.1.8', 'Study Intervention Administration', '88', '8.1.8.1', 'Timing of Dose Administration', '88', '8.1.8.1.1', 'Lenvatinib/Matching Placebo', '88', '8.1.8.1.2', 'Pembrolizumab', '88', '8.1.8.2', 'Lenvatinib Compliance', '89', '8.1.9', 'Discontinuation and Withdrawal', '89', '8.1.10', 'Participant Blinding/Unblinding', '89', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
16,page_17,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '16', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.1.11', 'Calibration of Equipment', '89', '8.2', 'Efficacy/Immunogenicity Assessments', '89', '8.2.1', 'Tumor Scans and Assessment of Disease', '89', '8.2.1.1', 'Initial Tumor Scans', '90', '8.2.1.2', 'Tumor Scans During the Study', '91', '8.2.1.3', 'End of Treatment and Follow-up Tumor Scans', '91', '8.2.1.4', 'Second-course Treatment Tumor Scans', '91', '8.2.1.5', 'RECIST 1.1 Assessment of Disease', '92', '8.2.1.6', 'iRECIST Assessment of Disease', '93', '8.2.1.7', 'Tumor Tissue Collection for PD-L1 Status', '96', '8.2.2', 'Patient-reported Outcomes', '96', '8.3', 'Safety Assessments', '97', '8.3.1', 'Physical Examinations', '97', '8.3.2', 'Vital Signs', '97', '8.3.3', 'Electrocardiograms', '97', '8.3.4', 'Echocardiograms or Multigated Acquisition Scans', '98', '8.3.5', 'Clinical Safety Laboratory Assessments', '98', '8.3.5.1', 'Laboratory Safety Evaluations (Hematology, Chemistry and', 'Urinalysis)', '98', '8.3.5.2', 'Pregnancy Test', '99', '8.4', 'Adverse Events (AEs), Serious Adverse Events (SAEs), and Other', 'Reportable Safety Events', '99', '8.4.1', 'Time Period and Frequency for Collecting AE, SAE, and Other', 'Reportable Safety Event Information', '99', '8.4.2', 'Method of Detecting AEs, SAEs, and Other Reportable Safety Events 102', '8.4.3', 'Follow-up of AE, SAE, and Other Reportable Safety Event Information. 102', '8.4.4', 'Regulatory Reporting Requirements for SAE', '102', '8.4.5', 'Pregnancy and Exposure During Breastfeeding', '102', '8.4.6', 'Disease-related Events and/or Disease-related Outcomes Not Qualifying', 'as AEs or SAEs', '103', '8.4.7', 'Events of Clinical Interest (ECIs)', '103', '8.5', 'Treatment of Overdose', '103', '8.6', 'Pharmacokinetics', '104', '8.7', 'Pharmacodynamics', '104', '8.8', 'Planned Genetic Analysis Sample Collection', '104', '8.9', 'Biomarkers', '104', '8.10', 'Medical Resource Utilization and Health Economics', '105', '8.11', 'Visit Requirements', '105', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
17,page_18,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '17', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.11.1', 'Screening', '105', '8.11.2', 'Initial Treatment Phase', '105', '8.11.3', 'Second-course Treatment Phase', '106', '8.11.4', 'Discontinued Participants Continuing to be Monitored in the Study', '106', '8.11.5', 'Poststudy', '106', '8.11.5.1', 'Safety Follow-up Visit', '106', '8.11.5.2', 'Efficacy Follow-up Visits', '106', '8.11.5.3', 'Survival Follow-up Assessments', '106', '9', 'STATISTICAL ANALYSIS PLAN', '107', '9.1', 'Statistical Analysis Plan Summary', '107', '9.2', 'Responsibility for Analyses/In-house Blinding', '109', '9.3', 'Hypotheses/Estimation', '109', '9.4', 'Analysis Enppoints', '109', '9.4.1', 'Efficacy Endpoints', '109', '9.4.1.1', 'Primary Endpoints', '109', '9.4.1.2', 'Secondary Endpoints', '109', '9.4.1.3', 'Exploratory Endpoints', '110', '9.4.2', 'Safety Endpoints', '110', '9.4.3', 'Patient-reported Outcome Endpoints', '110', '9.5', 'Analysis Populations', '111', '9.5.1', 'Efficacy Analysis Populations', '111', '9.5.2', 'Safety Analysis Populations', '111', '9.5.3', 'Patient-reported Outcome Analysis Population', '111', '9.5.4', 'Pharmacokinetic Analysis Population', '112', '9.6', 'Statistical Methods', '112', '9.6.1', 'Statistical Methods for Efficacy Analyses', '112', '9.6.1.1', 'Progression-free Survival', '113', '9.6.1.2', 'Overall Survival', '114', '9.6.1.3', 'Objective Response Rate', '115', '9.6.1.4', 'Duration of Response', '115', '9.6.2', 'Statistical Methods for Safety Analyses', '115', '9.6.3', 'Statistical Methods for Patient-reported Outcome Analyses', '117', '9.6.4', 'Demographic and Baseline Characteristics', '118', '9.7', 'Interim Analyses', '118', '9.7.1', 'Safety Interim Analyses', '118', '9.8', 'Multiplicity', '118', '9.9', 'Sample Size and Power Calculations', '118', '9.10', 'Subgroup Analyses', '119', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
18,page_19,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '18', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.11', 'Compliance (Medication Adherence)', '120', '9.12', 'Extent of Exposure', '120', '10', 'SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '121', '10.1', 'Appendix 1: Regulatory, Ethical, and Study Oversight Considerations', '121', '10.1.1', 'Code of Conduct for Clinical Trials', '121', '10.1.2', 'Financial Disclosure', '123', '10.1.3', 'Data Protection', '123', '10.1.3.1', 'Confidentiality of Data', '124', '10.1.3.2', 'Confidentiality of Participant Records', '124', '10.1.3.3', 'Confidentiality of IRB/IEC Information', '124', '10.1.4', 'Committees Structure', '124', '10.1.4.1', 'Steering Committee', '124', '10.1.4.2', 'Executive Oversight Committee', '125', '10.1.4.3', 'External Data Monitoring Committee', '125', '10.1.5', 'Publication Policy', '125', '10.1.6', 'Compliance with Study Registration and Results Posting Requirements 126', '10.1.7', 'Compliance with Law, Audit, and Debarment', '126', '10.1.8', 'Data Quality Assurance', '127', '10.1.9', 'Source Documents', '128', '10.1.10', 'Study and Site Closure', '128', '10.2', 'Appendix 2: Clinical Laboratory Tests', '129', '10.3', 'Appendix 3: Adverse Events: Definitions and Procedures for Recording,', 'Evaluating, Follow-up, and Reporting', '131', '10.3.1', 'Definition of AE', '131', '10.3.2', 'Definition of SAE', '132', '10.3.3', 'Additional Events Reported in the Same Manner as SAE', '133', '10.3.4', 'Recording AE and SAE', '133', '10.3.5', 'Reporting of AEs, SAEs, and Other Reportable Safety Events to the', 'Sponsor', '137', '10.4', 'Appendix 4: Device Events, Adverse Device Events, and Medical Device', 'Incidents: Definitions, Collection, and Documentation', '139', '10.5', 'Appendix 5: Contraceptive Guidance and Pregnancy Testing', '140', '10.5.1', 'Definitions', '140', '10.5.2', 'Contraception Requirements', '141', '10.5.3', 'Pregnancy Testing', '141', '10.6', 'Appendix 6: Description of the iRECIST Process for Assessment of', 'Disease Progression', '143', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
19,page_20,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '19', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.7 Appendix 7: Country-specific Requirements', '147', '10.7.1', 'Japan-specific Requirements', '147', '10.7.2', 'France-specific Requirements', '147', '10.7.3', 'Canada-specific Requirements', '147', '10.8', 'Appendix 8: Abbreviations', '148', '11 REFERENCES', '152', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
20,page_21,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '20', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'LIST OF TABLES', 'Table 1', 'Adequate Organ Function Laboratory Values', '62', 'Table 2', 'Study Interventions', '68', 'Table 3', 'Dose Modification and Toxicity Management Guidelines for Immune-', 'related Adverse Events Associated with Pembrolizumab Monotherapy,', 'Coformulations or IO Combinations', '75', 'Table 4', 'Pembrolizumab Infusion Reaction Dose Modification and Treatment', 'Guidelines', '80', 'Table 5', 'Summary of Imaging and Treatment Requirements After First', 'Radiologic Evidence of Progression', '95', 'Table 6', 'Reporting Time Periods and Time Frames for Adverse Events and', 'Other Reportable Safety Events', '101', 'Table 7', 'Analysis Methods for Key Efficacy Endpoints', '113', 'Table 8', 'Censoring Rules for Primary and Sensitivity Analyses of Progression-', 'free Survival', '114', 'Table 9', 'Censoring Rules for Duration of Response', '115', 'Table 10', 'Analysis Strategy for Safety Parameters', '117', 'Table 11', 'Protocol-Required Safety Laboratory Assessments', '130', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
21,page_22,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '21', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'LIST OF FIGURES', 'Figure 1', 'Original and Updated Study Design: Initial Treatment Phase', '28', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
22,page_23,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '22', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '1', 'PROTOCOL SUMMARY', '1.1', 'Synopsis', 'Protocol Title: A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475)', 'with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic', 'nonsmall cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS)', 'greater than or equal to 1% (LEAP-007)', 'Short Title: Pembrolizumab with or without lenvatinib in TPS 1% NSCLC', 'Acronym: Protocol 007 (LEAP-007)', 'Hypotheses, Objectives, and Endpoints:', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. All participants remaining on study will continue on open-label', 'pembrolizumab monotherapy. No further analyses of efficacy endpoints will be', 'performed. Exploratory objectives may not be pursued.', 'Participants were screened for up to 28 days, then randomized, and continued study', 'treatment until discontinuation (defined in Section 7.1) OR stop/unblinding of study', 'intervention due to the futility analysis criterion for os being met.', 'In adult participants with treatment-naïve, metastatic NSCLC expressing PD-L1 (TPS >1%):', 'Primary Objectives', 'Primary Endpoints', '- Objective: To compare progression-free', '- PFS, defined as the time from', 'survival (PFS) as assessed by blinded', 'randomization to the first documented', 'independent central review (BICR) according', 'progressive disease (PD) or death due to any', 'to Response Evaluation Criteria in Solid', 'cause, whichever occurs first*', 'Tumors, version 1.1 (RECIST 1.1), adjusted', 'to follow a maximum of 10 target lesions and', 'a maximum of 5 target lesions per organ, for', 'the combinations of pembrolizumab +', 'lenvatinib versus pembrolizumab + matching', 'placebo', '- Hypothesis (H1): The combination of', 'pembrolizumab + lenvatinib has superior PFS', 'per RECIST 1.1, as defined in Section', '4.2.1.1.1, based on BICR', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
23,page_24,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '23', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '- Objective: To compare overall survival (OS)', '- OS, defined as the time from', 'for the combinations of pembrolizumab +', 'randomization to death due to any cause*', 'lenvatinib versus pembrolizumab + matching', 'placebo.', '- Hypothesis (H2): The combination of', 'pembrolizumab + lenvatinib has superior os', 'Secondary Objectives', 'Secondary Endpoints', '- Objective: To compare objective response', '- Objective response (OR), defined as a', 'rate (ORR) as assessed by BICR according to', 'confirmed complete response (CR) or', 'RECIST 1.1, as defined in Section 4.2.1.1.1,', 'partial response (PR)', 'for the combinations of pembrolizumab +', 'lenvatinib versus pembrolizumab + matching', 'placebo', '- Hypothesis (H3): The combination of', 'pembrolizumab + lenvatinib has superior', 'ORR per RECIST 1.1, as defined in Section', '4.2.1.1.1, based on BICR', '- Objective: To evaluate the safety and', '- Adverse events (AEs) and study', 'tolerability for the combinations of', 'intervention discontinuation due to AEs', 'pembrolizumab + lenvatinib versus', 'pembrolizumab + matching placebo', '- Objective: To compare the mean change', '- Change from baseline for the following', 'from baseline in the global health', 'patient-reported outcomes (PROs)', 'status/quality of life (QoL), cough, chest pain,', 'scales/items: global health status/QoL', 'dyspnea, and physical functioning for the', '(EORTC QLQ-C30 items 29 and 30), cough', 'combinations of pembrolizumab + lenvatinib', '(EORTC QLQ-LC13 item 31), chest pain', 'versus pembrolizumab + matching placebo', '(EORTC QLQ-LC13 item 40), dyspnea', '(EORTC QLQ-C30 item 8), and physical', 'functioning (EORTC QLQ-C30 items 1-5)', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
24,page_25,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '24', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '- Objective: To compare the time to true', '- TTD, defined as the time from baseline to', 'deterioration (TTD) in global health', 'the first onset of a 10-point deterioration', 'status/QoL, cough, chest pain, dyspnea, and', 'from baseline with confirmation by the', 'physical functioning for the combinations of', 'subsequent visit of a 10-point deterioration', 'pembrolizumab + lenvatinib versus', 'from baseline in global health status/QoL', 'pembrolizumab + matching placebo', '(EORTC QLQ-C30 items 29 and 30), cough', '(EORTC QLQ-LC13 item 31), chest pain', '(EORTC QLQ-LC13 item 40), dyspnea', '(EORTC QLQ-C30 item 8), and physical', 'functioning (EORTC QLQ-C30 items 1-5)', '- TTD in the composite endpoint', '(combination of cough [QLQ-LC13 item', '31], chest pain [QLQ-LC13 item 40], or', 'dyspnea [QLQ-C30 item 8]) defined as the', 'time to first onset of a 10-point', 'deterioration from baseline in any one of 3', 'scale items with confirmation by the', 'subsequent visit of a 10-point deterioration', 'from baseline in the same scale as the first', 'onset', '*This study will be considered to have met its success criteria if the combination of', 'pembrolizumab + lenvatinib is superior to pembrolizumab + matching placebo in PFS or OS.', 'Overall Design:', 'Study Phase', 'Phase 3', 'Primary Purpose', 'Treatment', 'Indication', 'First-line treatment of metastatic NSCLC with PD-L1', 'expression (TPS 1%)', 'Population', 'Adult participants with treatment-naïve, metastatic NSCLC', '(TPS 1%)', 'Study Type', 'Interventional', 'Intervention Model', 'Parallel', 'This is a multi-site study.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
25,page_26,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '25', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Type of Control', 'Active Control with Placebo', 'NOTE: As of Amendment 007-06, the placebo treatment', 'is removed from the study.', 'Study Blinding', 'Double-blind', 'NOTE: As of Amendment 007-06, the study is', 'unblinded.', 'Masking', 'Participant or Subject', 'Investigator', 'Sponsor', 'Estimated Duration of Study', 'The Sponsor estimates that the study will require', 'approximately 5 years from the time the first participant (or', 'their legally acceptable representative) provides', ""documented informed consent until the last participant's"", 'last study-related contact.', 'Extension Study in China: The Sponsor estimates that the', 'study will require approximately an additional 1 year', ""(beyond the global study's last participant last study-related"", 'contact) from the time the first participant (or their legally', 'acceptable representative) provides documented informed', ""consent until the last participant's last study-related contact."", 'NOTE: As of Amendment 007-06, enrollment in the', 'Extension Study in China has been stopped.', 'Number of Participants:', 'Global Study: Approximately 620 participants will be randomized.', 'Extension Study in China: Approximately 120 Chinese participants overall will be enrolled', 'in the global study and the extension study.', 'NOTE: As of Amendment 007-06, enrollment in the Extension Study in China has been', 'stopped.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
26,page_27,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '26', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Intervention Groups and Duration:', 'Intervention', 'Groups', 'Regimen/', 'Intervention', 'Dose', 'Dose', 'Route of', 'Treatment', 'Group Name', 'Drug', 'Strength', 'Level', 'Admin.', 'Period', 'Use', 'IV', 'Standard of', 'Pembrolizumab', '100 mg/vial', '200 mg', 'Q3W', 'Infusion', 'Arm A', 'care/Experimental', 'Lenvatinib', '10 mg/4 mg', '20 mg', 'Oral', 'QD', 'Experimental', 'IV', 'Standard of', 'Pembrolizumab', '100 mg/vial', '200 mg', 'Q3W', 'Infusion', 'Arm B', 'care/Experimental', 'Placebo', 'NA', 'NA', 'Oral', 'QD', 'Placebo', 'Abbreviations: NA = not applicable; Q3W = every 3 weeks; QD = daily.', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the treatment groups. Participants remaining on treatment will receive open-label', 'pembrolizumab monotherapy as per protocol.', 'Total', '2 arms', 'Number of', 'Intervention', 'Groups/Arms', 'Duration of', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have', 'Participation', 'been removed from the study. This section has been updated', 'accordingly.', 'After a screening phase of up to 28 days, each participant received assigned', 'study intervention until one of the conditions for discontinuation of study', 'intervention was met (defined in Section 7.1).', 'Participants will be permitted to continue study intervention beyond RECIST', '1.1-defined PD as long as the treating investigator considers that the', 'participant may experience clinical benefit with continued treatment as per', 'iRECIST, and the participant is tolerating study intervention, until PD is', 'confirmed by iRECIST. All decisions to continue treatment beyond', 'confirmed PD by iRECIST must be approved by the Sponsor.', 'Participants who have been on pembrolizumab for at least 24 weeks and', 'attain a CR may consider stopping pembrolizumab treatment.', 'After the end of treatment, each participant will be followed for the', 'occurrence of AEs and spontaneously reported pregnancy, as described in', 'Section 8.4.5. Participants will not be required to continue with posttreatment', 'follow-up imaging for disease status.', 'All participants will be followed for OS until death, withdrawal of consent,', 'lost to follow-up, or the end of the study. The end of the study will be when', 'the last participant completes the last study-related telephone call or visit,', 'withdraws from the study, or is lost to follow-up (ie, the participant is unable', 'to be contacted by the investigator).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
27,page_28,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '27', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Study Governance Committees:', 'Steering Committee', 'Yes', 'Executive Oversight Committee', 'Yes', 'Data Monitoring Committee', 'Yes', 'Clinical Adjudication Committee', 'No', 'Study governance considerations are outlined in Appendix 1.', 'Study Accepts Healthy Volunteers: No', 'A list of abbreviations used in this document can be found in Appendix 8.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
28,page_29,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '28', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '1.2', 'Schema', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo and the Second-course Treatment Phase have been', 'removed from the study. The original study design and updates to this design as of Amendment 007-06 (indicated by', 'strikethrough) are depicted in Figure 1.', 'Figure 1', 'Original and Updated Study Design: Initial Treatment Phase', 'Key Inclusion/Exclusion:', 'Pembrolizumab 200 mg IV Q3W', 'tenvatinib-20-mg-Po-ee-', 'tenvatinib-20-mg-Po-Qe-', 'Safety', 'Follow-', 'Survival', 'Stage IV NSCLC', 'Follow-Up', 'Up', 'Follow-Up', 'Rand', 'Up to 35 cycles or meeting DC*', 'Cycle 36 until meeting DC', 'No prior systemic treatment for stage', 'IV disease', '1:1', 'N=620', 'Post-treatment Phase', 'TPS >1%', 'Measurable disease', 'Pembrolizumab 200 mg IV Q3W', 'Matehing-PlaeebePo-Q-', 'Matching Placebe POQQ', 'Safely', 'Follow-', 'Survival', 'ECOG PS0-1', 'Follow-Up', 'Up', 'Follow-Up', 'EGFR/ALKIROS1 therapy is not', 'Up to 35 cycles or meeting DC', 'Cycle 36 until meeting 9C', 'indicated', 'Stratificationfactors:', '1. Geography Site (East Asian vs Non-East Asian)', '2. ECOG PS (0vs1)', '3. TPS (1%-49% vs >50%)', 'Abbreviations: ALK = ALK receptor tyrosine kinase; DC = discontinuation; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EGFR', '= epidermal growth factor receptor; IV = intravenous; NSCLC = non-small cell lung cancer; PD = progressive disease; PO = orally; Q3W = every 3 weeks;', 'QD = once daily; ROSI = ROS proto-oncogene 1; TPS = tumor proportion score.', '* DC criteria are listed in Section 7.1.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
29,page_30,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '29', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '1.3', 'Schedule of Activities (SoA)', '1.3.1', 'Initial Treatment Phase', 'NOTE:', 'As of Amendment 007-06, lenvatinib and matching placebo have been removed from the study. Participants who', 'remain on treatment will receive open-label pembrolizumab monotherapy as per protocol. Administration', 'of', 'lenvatinib', 'and', 'placebo, collection of ePRO data, and collection of most of the blood biomarkers have been removed from the SoA. Other', 'study procedures specific to lenvatinib/matching have also been removed.', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', 'Every', '-28 to -1', '5', '6 to 35', 'Every', 'Visit Timing/', '1', '2', '3', '4', 'post last', 'administration unless', 'DC', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(+3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '+3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Administrative and General Procedures', 'ICF must be signed', 'before any protocol-', 'specific screening', 'Informed consent', 'X', 'procedures are', 'performed. Additional', 'consent is required at', 'PD.', 'Inclusion/exclusion', 'X', 'criteria', 'Participant', 'X', 'identification card', 'Update at C1D1.', 'Demographic and', 'X', 'medical history', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
30,page_31,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '30', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '5', '6 to 35', 'Every', 'Every', 'Visit Timing/', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '+3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Prior concomitant', 'medications received', 'within 30 days before the', 'first dose of study', 'Prior/concomitant', 'intervention through', 'X', 'medications', '30 days after the last', 'dose of study', 'intervention (or 90 days', 'if used to treat an SAE)', 'will be recorded.', 'Treatment', 'X', 'Dose within 3 days of', 'randomization', 'randomization.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
31,page_32,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '31', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '2', '3', '4', '5', '6 to 35', 'Every', 'Every', 'Visit Timing/', '1', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Study Intervention Administration', 'Pembrolizumab', 'X', 'X', 'X', 'X', 'X', 'Pembrolizumab 200 mg', 'administration', 'IV Q3W.', 'Tumor Scans', '*Perform Q9W', '(63=7 days) from', 'randomization through', 'Week 54, then Q12W', '(84 = 7 days)', 'Tumor scans and', 'subsequently (ie, after', 'Weeks 9, 18, 27, 36, 45,', 'response assessment', 'X*', 'X', '54, 66, 78, 90, etc.).', '(thorax, abdomen,', 'Schedule should be', 'pelvis)', 'followed regardless of', 'treatment delays.', '- -If imaging was obtained', 'within 4 weeks before', 'DC, scan at DC is not', 'mandatory.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
32,page_33,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '32', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', '-Required at screening.', '-Follow-up MRI is', 'required if clinically', 'indicated and at time of', 'CR in participants with', 'brain metastasis at', 'Brain MRI', 'X', 'Screening.', '-If MRI is', 'contraindicated or cannot', 'be performed, CT of the', 'head with contrast is', 'acceptable.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
33,page_34,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '33', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '2', '3', '4', '5', '6 to 35', 'Every', 'Every', 'Visit Timing/', '1', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', '7', '14', '(Days)', 'Efficacy Procedures', '-All anticancer therapy', 'will be recorded until', 'time of death or', 'termination of survival', 'Subsequent', 'X', 'X', 'X', 'X', 'follow-up.', 'antineoplastic', '-If a clinic visit is not', 'therapy status', 'feasible, follow-up', 'information may be', 'obtained via telephone or', 'e-mail.', 'Participants may be', 'contacted for survival', 'Survival status', 'X', 'status at any time during', 'the course of the study.', 'Tumor Tissue Collection', '-May use archival tissue', 'sample obtained before', 'Newly', 'obtained/archival', 'screening period as part', 'X', ""of the participant's SOC."", 'tissue sample for PD-', '-Central PD-L1 result', 'L1 analysis', 'will be blinded to the', 'site.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
34,page_35,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '34', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', '-Not required for', 'participants with', 'squamous histology or', 'K-ras mutation.', 'EGFR, ALK, and', 'ROSI molecular', '-May send tumor tissue', 'X', 'to central laboratory for', 'status', 'molecular testing if', 'status is unknown and', 'cannot be determined', 'locally.', 'All screening', 'procedures should be', 'Clinical Procedures/Assessments', 'performed within', '28 days of', 'randomization, unless', 'otherwise noted.', 'Full physical', '*To be performed within', 'X*', 'X', 'examination', '7 days before start of', 'study intervention.', 'Directed physical', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'examination', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
35,page_36,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '35', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'post last', 'administration unless', 'DC', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Participants will be', 'contacted by telephone', 'on C1D8 to assess for', 'development of early', 'Phone contact', 'X', 'toxicity. If early toxicity', 'is suspected, an', 'unscheduled visit can', 'occur before C1D15 if', 'deemed necessary by the', 'investigator.', 'Height', 'X', 'Vital signs, weight', 'X', 'X', 'X', 'X', 'X', 'X', 'Vital signs must be taken', 'in the clinic.', 'ECG at screening, C1D1,', 'C2D1, D1 of every', 'fourth cycle (12 weeks)', 'thereafter (eg, C6, C10,', '12-lead ECG with', 'X', 'X', 'X', 'X', 'C14, etc.) up until', 'QTc measurement', 'discontinuation. ECGs', 'are only required at the', 'EOT Visit for those', 'participants that had', 'received lenvatinib.', 'Additional assessments', 'ECHO/MUGA', 'X', 'X', 'may be performed as', 'clinically indicated.', 'At screening, perform', 'ECOG performance', 'within 7 days before C1', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'status', 'but before', 'randomization.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
36,page_37,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '36', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '2', '3', '4', '5', '6 to 35', 'Every', 'Every', 'Visit Timing/', '1', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', '-', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'Report AEs occurring', 'within 30 days after the', 'last dose of study', 'intervention.', 'Report SAEs occurring', 'within 90 days after the', 'AE monitoring', 'X', 'X', 'last dose of study', 'intervention, or 30 days', 'after the last dose of', 'study intervention if a', 'new anticancer therapy is', 'initiated, whichever is', 'earlier.', 'All screening', 'procedures should be', 'performed within', 'Laboratory Procedures/Assessments Analysis by Local Laboratory', '28 days of', 'randomization, unless', 'otherwise noted.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
37,page_38,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '37', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'WOCBP require', 'negative test prior to', 'randomization. If more', 'than 24 hours have', 'elapsed prior to first dose', 'of study intervention,', 'Serum ß-HCG or', 'another pregnancy test is', 'urine pregnancy test', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'required prior to starting', '(WOCBP only)', 'study intervention.', 'A serum or urine', 'pregnancy test will be', 'performed per Appendix', '2. Refer to Sections 5.1,', '5.2, 8.3.5 and 10.5.3.', 'Required at baseline if', 'HIV, hepatitis B and', 'X', 'C screen', 'mandated by local health', 'authority.', '-Performed locally', 'Hematology and', 'within 10 days before', 'clinical chemistry', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'first dose.', 'laboratory', '-After C1, collect within', 'assessment', '3 days before dosing.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
38,page_39,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '38', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', '-Performed locally', 'within 7 days before first', 'dose.', 'After C1, collect within', '3 days before dosing.', 'Urinalysis/urine', '-Urinalysis is required at', 'X', 'X', 'X', 'X', 'X', 'X', 'screening and every 4', 'dipstick testing', 'cycles for participants', 'who received', 'lenvatinib/matching', 'placebo. After C1,', 'collect within 3 days', 'before dosing.', '-Screening samples', 'collected within 10 days', 'of treatment initiation.', 'PT/INR and', 'X', '-Additional testing to be', 'aPTT/PTT', 'conducted as clinically', 'indicated for participants', 'taking anticoagulant', 'therapy.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
39,page_40,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '39', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Posttreatment', 'Notes', 'Safety', 'Survival', 'Treatment', 'Follow-', 'Follow-', 'Follow-', 'All procedures are to', 'Study Period', 'Screening', 'Cycle = 21 Days', 'EOT', 'up', 'up', 'up', 'be performed before', '30 Days', 'study intervention', 'At', '-28 to -1', '1', '2', '3', '4', '6 to 35', 'Every', 'Every', 'Visit Timing/', '5', 'DC', 'post last', 'administration unless', '12 weeks', '12 weeks', 'Cycle Number', 'dose', 'otherwise indicated.', 'Cycle Day', 'Refer to Section 8.11', '(=3 days unless', '1', '8', '15', '1', '15', '1', '1', '1', '1', 'for visit details.', 'otherwise specified)', 'Scheduling Window', '+3', '3', '3', '3', '3', '3', '3', '3', '3', '+7', ' 7', '14', '(Days)', 'At Screening, C2D1,', 'then every 2 cycles', 'thereafter.', '-Screening samples to be', 'collected within 10 days', 'before first dose.', '-Participants may be', 'dosed in subsequent', 'cycles after C1D1 while', 'Thyroid function', 'X', 'X', 'X', 'X', 'X', 'X', '(T3, T4, and TSH)', 'thyroid function tests are', 'pending.', '- -After C1, collect within', '3 days before dosing.', '-Free T3 and Free T4 are', 'acceptable.', '-May use central', 'laboratory only if local', 'laboratory is not', 'capable.', 'Biomarkers: Analysis by Central Laboratory', 'Blood for genetic', 'X', '-Collect before study', 'analysis', 'intervention.', 'Abbreviations: AE = adverse event; ALK = anaplastic lymphoma kinase gene; ANC = absolute neutrophil count; aPTT = activated partial thromboplastin time; BP = blood', 'pressure; CT = computed tomography; CXDY= Cycle X Day Y; DC = discontinuation; ECG = electrocardiogram; ECHO = echocardiogram; ECOG = Eastern Cooperative', 'Oncology Group; EGFR = epidermal growth factor receptor; EOT = end of treatment; ePRO = electronic patient-reported outcome; FSH = follicle-stimulating hormone;', 'FT3 = free triiodothyronine; FT4 = free thyroxine; ß-HCG = ß human chorionic gonadotropin; HIV = human immunodeficiency virus; ICF = informed consent form;', 'INR = international normalized ratio; IV = intravenous; K-ras = Kirsten rat sarcoma oncogene; MRI = magnetic resonance imaging; MUGA = multigated acquisition;', 'PD = progressive disease; PD-L1 = programmed cell death ligand 1; PK = pharmacokinetic(s); PO = bral(ly); PT = prothrombin time; PTT = partial thromboplastin time;', 'QXW = every X weeks; QD = once daily; ROSI = ROS proto-oncogene 1; SAE = serious adverse event; ; T3 = triiodothyronine; T4 = thyroxine; WOCBP = women of', 'childbearing potential; SoA = schedule of activities; SOC = standard of care.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
40,page_41,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '40', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '1.3.2', 'Second-course Treatment Phase', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been removed from the study.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
41,page_42,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '41', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '2', 'INTRODUCTION', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. Subsections 2.1 Study Rationale and 2.2 Background are based on the', 'original study design and have been left unchanged for reference.', '2.1', 'Study Rationale', 'The global incidence of lung cancer was 1.8 million in 2012, resulting in an estimated', '1.6 million deaths [World Health Organization 2012]. In the United States, the 2018', 'estimated incidence of new diagnoses was 234,030, and the estimated number of deaths was', '154,050 [National Cancer Institute 2018]. NSCLC represents approximately 80% to 85% of', 'all lung cancers. Of patients with NSCLC, tumor histology is approximately 40% to 60%', 'adenocarcinoma, 10% to 15% squamous, 5% neuroendocrine, and the rest, not otherwise', 'specified [Sulpher, J. A., et al 2013].', 'Approximately 80% of patients with NSCLC have advanced disease not amenable to surgical', 'resection at the time of diagnosis. The 5-year relative survival for patients with any lung', 'cancer overall and metastatic lung cancer specifically has been reported to be 18.6% and', '4.7%, respectively [National Cancer Institute 2018].', 'Pembrolizumab monotherapy is the current standard of care (SOC) for the treatment of', 'patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', 'and previously untreated advanced or metastatic NSCLC with programmed cell death', 'ligand 1 (PD-L1) TPS >50% and with no epidermal growth factor receptor (EGFR) or', 'anaplastic lymphoma kinase (ALK) genomic tumor aberrations. Approximately 30% of', 'patients with newly diagnosed, advanced NSCLC highly express PD-L1 with a TPS >50%', '[Reck, M., et al 2016].', 'KEYNOTE-024, a Phase 3, randomized, open-label study, compared pembrolizumab', 'monotherapy to standard first-line (1L) platinum-doublet therapy in 305 previously untreated', 'participants with advanced NSCLC and PD-L1 TPS >50%. Results from KEYNOTE-024', 'indicated a significant PFS benefit for pembrolizumab over platinum-doublet therapy, with a', 'hazard ratio (HR) of 0.50 (95% confidence interval [CI], 0.37-0.68 p<0.001). Median PFS', 'was 10.3 months (95% CI, 6.7 months to not reached) with pembrolizumab and 6.0 months', '(95% CI, 4.2-6.2 months) with platinum-doublet. Additionally, there was an os benefit, with', 'an HR of 0.60 (95% CI, 0.41-0.89; p=0.005); median os was not reached in either treatment', 'arm. The Kaplan-Meier estimates showed 80.2% (95% CI, 72.9%-85.7%) of participants', 'treated with pembrolizumab and 72.4% (95% CI, 64.5%-78.9%) of participants treated with', 'platinum-doublet therapy were alive at 6 months. Furthermore, the ORR was higher in the', 'pembrolizumab arm than in the platinum-doublet arm (44.8% VS 27.8%, respectively) [Reck,', 'M., et al 2016].', 'The results from KEYNOTE-024 established pembrolizumab as 1L therapy for patients', 'whose tumors have a TPS >50% with no EGFR or ALK genomic tumor aberrations.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
42,page_43,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '42', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Additionally, KEYNOTE-042, a randomized, open-label, Phase 3 study, compared', 'pembrolizumab monotherapy to SOC platinum-based chemotherapy in previously untreated', 'participants with advanced or metastatic NSCLC whose tumors express PD-L1 TPS 1%,', 'confirmed the os treatment effect of pembrolizumab monotherapy observed in participants', 'with TPS >50% NSCLC in KEYNOTE-024, and extended these benefits to a broader', 'population with TPS >1% NSCLC. Results from KEYNOTE-042 indicated a significant os', 'benefit for pembrolizumab over platinum-doublet therapy, with an HR of 0.81 (95% CI,', '0.71-0.93, p=0.0018). Median OS was 16.7 months (95% CI, 13.9-19.7 months) with', 'pembrolizumab and 12.1 months (95% CI, 11.3-13.3 months) with platinum-doublet [Lopes,', 'G., et al 2018]. The Kaplan-Meier estimates showed 39.3% of participants treated with', 'pembrolizumab and 28.0% of participants treated with platinum-doublet therapy were alive', 'at 6 months (data on file).', 'While the benefits observed in KEYNOTE-024 (in participants with advanced or metastatic', 'NSCLC whose tumors expressed PD-L1 TPS 50%) and KEYNOTE-042 (in participants', 'with advanced or metastatic NSCLC whose tumors expressed PD-L1 TPS 1%) were', 'substantial for these participants with NSCLC, the benefits may be improved further in', 'metastatic NSCLC with PD-L1 TPS >1% population, possibly through the combination of', 'pembrolizumab with other therapies such as lenvatinib, a multiple RTKi with a potentially', 'differentiated profile.', 'Lenvatinib has been studied as both monotherapy and in combination with chemotherapy for', 'the treatment of advanced NSCLC. As a single agent, a randomized Phase 2 study of', 'lenvatinib versus placebo was conducted in 135 participants with locally advanced or', 'metastatic nonsquamous NSCLC who had failed to respond to at least 2 systemic anticancer', 'regimens. Eighty-nine participants received 24 mg of lenvatinib QD and 46 received placebo;', 'all participants received best supportive care in addition to study intervention. Median os', 'was 38.4 weeks for lenvatinib and 24.1 weeks for placebo, median PFS was 20.9 weeks for', 'lenvatinib and 7.9 weeks for placebo, ORR was 10.1% for lenvatinib and 2.2% for placebo,', 'and the disease control rate (DCR) was 42.7% for lenvatinib and 19.6% for placebo. Grade 3', 'and/or 4 AEs occurred in 69% of lenvatinib recipients and 50% of placebo recipients. Grade', '3 and/or 4 AEs were dyspnea and pneumonia in both treatment groups, as well as', 'hypertension in the lenvatinib group [Havel, L., et al 2014].', 'Lenvatinib was studied in combination with chemotherapy in a multicenter, open-label,', 'Phase 1, dose-finding study (Study E7080-J081-110 This study, conducted in Japanese', 'participants with chemotherapy-naïve NSCLC, investigated lenvatinib in combination with', 'carboplatin/paclitaxel to establish the maximum tolerated dose (MTD). The MTD of', 'lenvatinib was determined to be 4 mg BID after dose-limiting toxicities (DLTs) were', 'experienced at 6 mg BID (febrile neutropenia, gingival infection [n=2]). A dose-expansion', 'cohort was added and 28 participants were dosed in total: 12 in the dose-finding cohort and', '16 participants in the dose-expansion cohort. In total, 22 participants were dosed at 4 mg BID', 'with 6 at 6 mg BID. The ORR was 61% (95% CI: 41%, 79%) and comprised 1 CR and', '16 partial responses (PRs). The median PFS was reported as 9 months. Of the 22 participants', 'in the 4-mg BID dose level, the most frequently reported AEs were thrombocytopenia,', 'neutropenia, leukopenia, peripheral sensory neuropathy, arthralgia, and alopecia. The most', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
43,page_44,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '43', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'frequently reported Grade 3 or 4 AEs were neutropenia, leukopenia, hypertension,', 'thrombocytopenia, and febrile neutropenia. No AEs resulting in death were reported [Nishio,', 'M., et al 2013].', 'The present study is designed to further evaluate the safety and efficacy of combination', 'therapy of lenvatinib and pembrolizumab in adult participants with treatment-naïve,', 'metastatic NSCLC with a TPS 1%. The outcomes for participants evaluated in this study', 'would be further improved if the safety profile of a pembrolizumab plus lenvatinib', 'combination remains acceptable and is shown to improve outcomes compared with', 'pembrolizumab monotherapy; thus, this study could support the regulatory approval of this', 'combination in this patient population.', '2.2', 'Background', 'Pembrolizumab is a potent humanized IgG4 mAb with high specificity of binding to the', 'PD-1 receptor, thus inhibiting its interaction with PD-L1 and PD-L2. Based on preclinical in', 'vitro data, pembrolizumab has high affinity and potent receptor blocking activity for PD-1.', 'Pembrolizumab has an acceptable preclinical safety profile and is in clinical development as', 'an IV immunotherapy for advanced malignancies. Keytruda® (pembrolizumab) is indicated', 'for the treatment of patients across a number of indications. For more details on specific', ""indications, refer to the pembrolizumab Investigator's Brochure (IB)."", 'Lenvatinib (also known as E7080 or MK-7902) inhibits the kinase activities of vascular', 'endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and', 'VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic', 'angiogenesis, tumor growth, and cancer progression in addition to their normal cellular', 'functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; platelet-', 'derived growth factor receptor alpha (PDGFRa), KIT, and RET. Lenvatinib also exhibited', 'antiproliferative activity in cell lines dependent on activated FGFR signaling with a', 'concurrent inhibition of FGF-receptor substrate 2a phosphorylation. Once daily (QD) dosing', 'of lenvatinib combined with pembrolizumab is currently being developed for the treatment of', 'metastatic NSCLC. Refer to the respective IBs/approved labeling for detailed background', 'information on pembrolizumab and lenvatinib.', '2.2.1', 'Pharmaceutical and Therapeutic Background', '2.2.1.1', 'Lenvatinib', 'Angiogenesis, the formation of new blood vessels from a pre-existing vascular network, is', 'essential for tumor growth and metastasis. VEGF and its family of receptors (VEGFRs 1-3)', 'play a major role in tumor angiogenesis [Ferrara, N., et al 2003] [Ellis, L. M. 2008]', '[Tammela, T. 2010]. Accumulated evidence suggests that FGF and its receptor tyrosine', 'kinase, FGFR, also play important roles in tumor angiogenesis [Cross, M. J. 2001] [Lieu, C.,', 'et al 2011] (Limaverde-Sousa, G., et al 2014].', 'Lenvatinib is a potent multiple RTKi that selectively inhibits VEGF receptors, VEGFR1', '(FLT1), VEGFR2 (KDR), VEGFR3 (FLT4), FGFR1-4 PDGFRa, c-kit, and RET. Among', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
44,page_45,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '44', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'known kinase inhibitors in clinical use, lenvatinib is one of the only inhibitors currently', 'labeled with a mechanism of action as an inhibitor of not only VEGFRs but also FGFRs,', 'both of which are currently believed to be very important for tumor angiogenesis.', 'Lenvatinib inhibited cell free kinase activities for VEGFR1-3 and FGFR1-3 with Ki values', 'around 1 nmol/L, and 8-22 nmol/L, respectively. In cell-based assays, lenvatinib inhibited', 'VEGF-derived and FGF-derived tube formation of HUVEC with IC50 values of 2.1 and 7.3', 'nmol/L, respectively. Analysis of the signal transduction molecules revealed that lenvatinib', 'inhibited both the MAPK pathway and the mTOR-S6K-S6 pathway in HUVECs triggered by', 'activated VEGFR and FGFR. Furthermore, lenvatinib (10, 30 mg/kg) significantly inhibited', 'both VEGF- and FGF-driven angiogenesis in a murine in vivo model [Yamamoto, Y., et al', '2014]. In vivo, lenvatinib exhibited antitumor activity against various human tumor', 'xenografts in athymic mice including 5 types of thyroid carcinomas (differentiated [papillary', 'and follicular], anaplastic, squamous, and medullary thyroid carcinomas), RCC, HCC,', ""melanoma, gastric cancer, NSCLC, ovarian cancer, Ewing's sarcoma, and osteosarcoma. In"", 'addition, the antitumor activity of lenvatinib in combination with other anticancer agents in', 'several xenograft models was greater than that of lenvatinib or the other agents alone.', 'In summary, lenvatinib inhibited VEGF-driven VEGFR2 phosphorylation and suppressed', 'proliferation and tube formation in human umbilical vein endothelial cell (HUVEC) models.', 'Antitumor activity of lenvatinib in vivo has been shown in numerous xenograft animals.', 'These results suggest that lenvatinib may be a novel anticancer therapy through inhibition of', 'angiogenesis and may be useful as either monotherapy or in combination with other', 'anticancer drugs.', '2.2.1.2', 'Pembrolizumab', 'Keytruda® (pembrolizumab) is indicated for the treatment of patients across a number of', 'indications. For more details on specific indications, refer to the pembrolizumab IB.', '2.2.1.3', 'Pembrolizumab With Lenvatinib', 'The importance of intact immune surveillance function in controlling outgrowth of neoplastic', 'transformations has been known for decades [Disis, M. L. 2010]. Accumulating evidence', 'shows a correlation between tumor-infiltrating lymphocytes in cancer tissue and favorable', 'prognosis in various malignancies. In particular, the presence of CD8+ T-cells and the ratio', 'of CD8+ effector T-cells/FoxP3+ regulatory T-cells (T-regs) correlates with improved', 'prognosis and long-term survival in solid malignancies, such as ovarian, colorectal, and', 'pancreatic cancer; hepatocellular carcinoma; malignant melanoma; and renal cell carcinoma.', 'Tumor-infiltrating lymphocytes can be expanded ex vivo and reinfused, inducing durable', 'objective tumor responses in cancers such as melanoma [Dudley, M. E., et al 2005] [Hunder,', 'N. N., et al 2008]. In preclinical models, lenvatinib decreased the tumor-associated', 'macrophage (TAM) population, which is known as an immune-regulator in the tumor', 'microenvironment. The decrease in TAM population was accompanied by increases in', 'activated cytotoxic T-cell populations through stimulation of interferon-gamma signaling,', 'resulting in increased immune activation [Kimura, T., et al 2018]. The immune-modulating', 'effect of lenvatinib may result in a potent combination effect with PD-1/L1 signal inhibitors.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
45,page_46,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '45', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'The effect of combining lenvatinib with an antihuman PD-1 humanized mAb was', 'investigated in 4 murine tumor isograft models, which showed significant tumor growth', 'inhibition compared with control. In the RAG murine tumor isograft tumor model, survival', 'in the group treated with the combination was significantly longer than that of the respective', 'monotherapy groups. In the CT26 murine tumor isograft model, treatment with the', 'combination significantly increased the population of activated cytotoxic T-cells compared', 'with that of the respective monotherapy groups [Kato, Y., et al 2019]. All treatments were', 'well tolerated and severe body weight loss was not observed.', '2.2.2', 'Preclinical and Clinical Studies', '2.2.2.1', 'Completed Studies With Pembrolizumab and Lenvatinib', 'Refer to the respective IBs for further information on completed studies with lenvatinib and', 'pembrolizumab.', '2.2.3', 'Ongoing Clinical Studies of Pembrolizumab and Lenvatinib', 'Pembrolizumab is under evaluation in patients with NSCLC as monotherapy and in', 'combination with chemotherapy, immunotherapy, and targeted therapies. Lenvatinib is being', 'studied in patients with different types of solid tumors, including NSCLC, and in', 'combination with other therapies, including PD-1-targeted therapies. A full list of ongoing', 'studies can be found in the respective IBs of pembrolizumab [IB Edition 16 2018] and', 'lenvatinib [IB Edition 15-Eisai 2018]. Details of the ongoing study 111/KEYNOTE-146 are', 'outlined below.', 'Study 111/KEYNOTE-146', 'Study 111/KEYNOTE-146, is a multicenter, open-label, Phase 1b/2 clinical study to evaluate', 'the efficacy and safety of lenvatinib in combination with pembrolizumab. The primary', 'objective of the Phase 1b portion of the study is to determine the MTD in participants with', 'unresectable solid tumors (endometrial cancer, melanoma, NSCLC, RCC, squamous cell', 'carcinoma of the head and neck, and urothelial cancer) who have progressed after treatment', 'with approved therapies or for which there are no available standard effective therapies. The', 'primary endpoint of the initial part of Phase 2 is ORR after 24 weeks of treatment, with select', 'secondary endpoints, including OR, DCR, PFS, and duration of response (DOR).', 'As of the data cutoff of 01-DEC-2017, 20 participants with NSCLC were enrolled (data on', 'file). Of the enrolled participants, 9 (45%) were PD-L1(+) (TPS 1%), 5 (25%) were', 'PD-L1(-), and 6 (30%) were not tested; 3 (15%) were treatment-naïve; and 6 (30%),', '9 (45%), and 2 (10%) had 1, 2, and >3 prior lines of systemic therapy, respectively. The', 'primary endpoint of ORR at Week 24 was 30.0% (95% CI, 11.9%-54.3%). Grade 3 and 4', 'treatment-related AEs occurred in 11 participants (55%) and 1 participant (5%), respectively', '(ie, increased aspartate aminotransferase [AST]). There was 1 fatal treatment-related AE', '(exsanguination that was deemed possibly related to study intervention). The most common', 'Grade 3 treatment-related AEs were hypertension (30% [6 of 20 subjects]) and fatigue,', 'diarrhea, and hyponatremia (15% [3 of 20 subjects]). These findings indicate that the', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
46,page_47,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '46', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'combination of lenvatinib with pembrolizumab shows promising clinical activity with a', 'manageable safety profile in previously treated patients with metastatic NSCLC who were', 'not preselected for PD-L1 status.', '2.3', 'Benefit/Risk Assessment', 'NOTE: Data from an interim safety and futility eDMC for LEAP-007 (data cutoff:', '19-MAY-2021) indicated that the study met the prespecified nonbinding futility criteria', 'for OS for the combination of lenvatinib plus pembrolizumab compared with placebo', 'plus pembrolizumab and the benefit-risk assessment was not considered positive to', 'continue the study as designed. Therefore, the benefit-risk assessment of', 'pembrolizumab plus lenvatinib is no longer applicable and has been removed from this', 'section.', 'It cannot be guaranteed that participants in clinical studies will directly benefit from', 'treatment during participation, as clinical studies are designed to provide information about', 'the safety and effectiveness of an investigational medicine.', 'Additional details regarding specific benefits and risks for participants participating in this', 'clinical study may be found in the accompanying IB and informed consent documents.', '3', 'HYPOTHESES, OBJECTIVES, AND ENDPOINTS', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. All participants remaining on study will continue on open-label', 'pembrolizumab monotherapy. No further analyses of efficacy endpoints will be', 'performed. Exploratory objectives may not be pursued.', 'Participants were screened for up to 28 days, then randomized, and continued study', 'treatment until discontinuation (defined in Section 7.1) OR stop/unblinding of study', 'intervention due to the futility analysis criterion for OS being met.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
47,page_48,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '47', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'In adult participants with treatment-naïve, metastatic NSCLC expressing PD-L1 (TPS >1%):', 'Objectives', 'Enppoints', 'Primary', 'Objective: To compare progression-free', 'PFS, defined as the time from', 'survival (PFS) as assessed by blinded', 'randomization to the first documented', 'independent central review (BICR)', 'progressive disease (PD) or death due to', 'according to Response Evaluation', 'any cause, whichever occurs first*', 'Criteria in Solid Tumors, version 1.1', '(RECIST 1.1), adjusted to follow a', 'maximum of 10 target lesions and a', 'maximum of 5 target lesions per organ,', 'for the combinations of pembrolizumab +', 'lenvatinib versus pembrolizumab +', 'matching placebo', '- Hypothesis (H1): The combination of', 'pembrolizumab + lenvatinib has', 'superior PFS per RECIST 1.1, as', 'defined in Section 4.2.1.1.1, based on', 'BICR', 'Objective: To compare overall survival', 'OS, defined as the time from', '(OS) for the combinations of', 'randomization to death due to any cause*', 'pembrolizumab + lenvatinib versus', 'pembrolizumab + matching placebo', '- Hypothesis (H2): The combination of', 'pembrolizumab + lenvatinib has', 'superior os', 'Secondary', 'Objective: To compare objective response', 'Objective response (OR), defined as a', 'rate (ORR) as assessed by BICR', 'confirmed complete response (CR) or', 'according to RECIST 1.1, as defined in', 'partial response (PR)', 'Section 4.2.1.1.1, for the combinations of', 'pembrolizumab + lenvatinib versus', 'pembrolizumab + matching placebo', '- Hypothesis (H3): The combination of', 'pembrolizumab + lenvatinib has', 'superior ORR per RECIST 1.1, as', 'defined in Section 4.2.1.1.1, based on', 'BICR', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
48,page_49,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '48', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Objectives', 'Enppoints', 'Objective: To evaluate the safety and', 'Adverse events (AEs) and study', 'tolerability for the combinations of', 'intervention discontinuation due to AEs', 'pembrolizumab + lenvatinib versus', 'pembrolizumab + matching placebo', 'Objective: To compare the mean change', 'Change from baseline for the following', 'from baseline in the global health', 'patient-reported outcomes (PROs)', 'status/quality of life (QoL), cough, chest', 'scales/items: global health status/QoL', 'pain, dyspnea, and physical functioning', '(EORTO QLQ-C30 items 29 and 30),', 'for the combinations of pembrolizumab +', 'cough (EORTC QLQ-LC13 item 31),', 'lenvatinib versus pembrolizumab +', 'chest pain (EORTC QLQ-LC13 item 40),', 'matching placebo', 'dyspnea (EORTO QLQ-C30 item 8), and', 'physical functioning (EORTC QLQ-C30', 'items 1-5)', 'Objective: To compare the time to true', 'TTD, defined as the time from baseline', 'deterioration (TTD) in global health', 'to the first onset of a 10-point', 'status/QoL, cough, chest pain, dyspnea,', 'deterioration from baseline with', 'and physical functioning for the', 'confirmation by the subsequent visit of a', 'combinations of pembrolizumab +', '>10-point deterioration from baseline in', 'lenvatinib versus pembrolizumab +', 'global health status/QoL (EORTC', 'matching placebo', 'QLQ-C30 items 29 and 30), cough', '(EORTC QLQ-LC13 item 31), chest pain', '(EORTC QLQ-LC13 item 40), dyspnea', '(EORTC QLQ-C30 item 8), and physical', 'functioning (EORTO QLQ-C30 items', '1-5)', 'TTD in the composite endpoint', '(combination of cough [QLQ-LC13 item', '31], chest pain [QLQ-LC13 item 40], or', 'dyspnea [QLQ-C30 item 8]) defined as', 'the time to first onset of a 10-point', 'deterioration from baseline in any one of', '3 scale items with confirmation by the', 'subsequent visit of a 10-point', 'deterioration from baseline in the same', 'scale as the first onset', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
49,page_50,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '49', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Objectives', 'Enppoints', 'Tertiary/Exploratory', 'Objective: To compare the PFS and ORR', 'PFS, defined as the time from', 'per adjusted RECIST 1.1 for Immune-', 'randomization to the first documented', 'based Therapeutics (iRECIST) as', 'PD or death due to any cause, whichever', 'assessed by the investigator for the', 'occurs first', 'combinations of pembrolizumab +', 'OR, defined as a confirmed CR or PR', 'lenvatinib versus pembrolizumab +', 'matching placebo', 'Objective: To evaluate DOR per RECIST', 'DOR, defined as the time from the', '1.1, as defined in Section 4.2.1.1.1, for', 'earliest date of qualifying response until', 'the combinations of pembrolizumab +', 'earliest date of PD or death from any', 'lenvatinib and pembrolizumab +', 'cause, whichever comes first', 'matching placebo', 'Objective: To evaluate and compare', 'Health utilities assessed using the', ""participant's health status as assessed by"", 'EuroQoL EQ-5D-5L', 'the EuroQoL 5 Dimensions 5-Level (EQ-', '5D-5L) questionnaire to generate utility', 'scores for use in economic models', 'Objective: To evaluate the', 'Plasma concentration of lenvatinib', 'pharmacokinetics (PK) of lenvatinib', 'versus time', 'when coadministered with', 'pembrolizumab', 'To identify molecular (genomic,', 'Molecular (genomic, metabolic, and/or', 'metabolic, and/or proteomic) biomarkers', 'proteomic) determinants of response or', 'that may be indicative of clinical', 'resistance to treatments, using blood', 'response/resistance, safety, and/or the', 'and/or tumor tissue', 'mechanism of action of pembrolizumab', 'and lenvatinib in all participants', '*This study will be considered to have met its success criteria if the combination of', 'pembrolizumab + lenvatinib is superior to pembrolizumab + matching placebo in PFS or OS.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
50,page_51,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '50', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4', 'STUDY DESIGN', '4.1', 'Overall Design', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. Participants who remain on treatment will receive open-label', 'pembrolizumab monotherapy, as per protocol. The Second-course Treatment Phase is', 'removed from the study. This section has been updated accordingly.', 'The original study design was a randomized, double-blind, active-control with placebo,', 'parallel-group, multisite study of IV pembrolizumab and oral lenvatinib in participants with', 'Stage IV NSCLC and PD-L1 TPS 1% who have not had previously received systemic', 'therapy for metastatic disease, whose tumors express PD-L1 with a TPS 1%, and in whom', 'EGFR-, ALK-, or ROS proto-oncogene 1 (ROS1)-directed therapy is not indicated.', 'Participants were randomized 1:1 to Arm A (pembrolizumab + lenvatinib) or Arm B', '(pembrolizumab + matching placebo). Randomization was stratified by site geographic', 'region (East Asia VS non-East Asia), ECOG PS (0 VS 1), and TPS (1%-49% VS >50%). The', 'original study design is depicted in Figure 1 (Initial Treatment Phase).', 'As of Amendment 007-06, lenvatinib and matching placebo have been removed from the', 'treatment arms (Figure 1). All participants remaining on treatment in the study will receive', 'open-label pembrolizumab monotherapy. Treatment with pembrolizumab will continue up to', 'Cycle 35 or until reaching a discontinuation criterion (defined in Section 7.1). Imaging will', 'continue until progression by local investigator has been determined.', 'Participants will be evaluated with radiographic imaging to assess response to treatment', 'every 9 weeks from randomization through 54 weeks, then every 12 weeks until PD,', 'initiation of a new anticancer regimen, or completion of 35 cycles. All imaging obtained on', 'study will be submitted to the imaging vendor for BICR, which will assess the images using', 'RECIST 1.1 (see Section 8.2.1.5) for determination of OR, PFS, and DOR. After amendment', '007-06, imaging obtained on study will be submitted to the imaging vendor but these will not', 'be assessed, similarly, verification of PD is no longer needed before treatment', 'discontinuation. Treatment-based decisions may use site-assessed iRECIST, as described in', 'Section 8.2.1.6, which allows for participants with initial site-assessed PD to continue', 'treatment until PD is confirmed by the site 4 to 8 weeks later.', 'Adverse event monitoring will be ongoing throughout the study, and AEs will be graded by', 'severity according to the guidelines outlined in the National Cancer Institute (NCI) Common', 'Terminology Criteria for Adverse Events (CTCAE), version 4.0.', 'The study will be conducted in conformance with Good Clinical Practice (GCP).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
51,page_52,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '51', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Extension Study in China', 'NOTE: As of Amendment 007-06, enrollment in the Extension Study in China has been', 'stopped; the planned enrollment goal of 120 participants was not reached.', 'Lenvatinib and matching placebo are removed from the extension study and it will proceed', 'identical to the global study as per this protocol amendment (eg, study endpoints, primary', 'and secondary objectives, study procedures), with the exception of an additional', 'supplemental statistical analysis plan (sSAP), which will provide details of analyses specific', 'to Chinese participants.', 'Specific procedures to be performed during the study, as well as their prescribed times and', 'associated visit windows, are outlined in the SoA in Section 1.3. Details of each procedure', 'are provided in Section 8.', '4.2', 'Scientific Rationale for Study Design', 'This Phase 3 study is being conducted to evaluate the efficacy and safety of pembrolizumab', 'in metastatic NSCLC when administered in combination with lenvatinib. Lenvatinib (20 mg', 'QD) will be evaluated in combination with the standard dose of pembrolizumab (200 mg', 'Q3W).', '4.2.1', 'Rationale for Enppoints', '4.2.1.1', 'Efficacy Enppoints', 'This study will use PFS based on RECIST 1.1 criteria, adjusted to follow a maximum of', '10 target lesions and a maximum of 5 target lesions per organ, as assessed by BICR as a', 'primary endpoint and OR as a secondary efficacy endpoint. PFS and OR are acceptable', 'measures of clinical benefit for a late-stage study that demonstrates superiority of a new', 'antineoplastic therapy, especially if the magnitude of the effect is large and the therapy has', 'an acceptable risk/benefit profile. The use of BICR and RECIST 1.1 to assess PFS and OR', 'are typically considered acceptable by regulatory authorities. Images will be read by a central', 'imaging vendor blinded to treatment assignment to minimize bias in the response', 'assessments. In addition, the final determination of radiologic progression will be based on', 'the central assessment of progression, rather than a local site investigator/radiology', 'assessment. Real time determination of radiologic progression as determined by central', 'review will be communicated to the site.', 'The primary efficacy endpoint os has been recognized as the gold standard for the', 'demonstration of superiority of a new antineoplastic therapy in randomized clinical studies.', 'For additional details about assessing efficacy endpoints using RECIST 1.1 and iRECIST,', 'see Appendix 6.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
52,page_53,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '52', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.1.1.1', 'RECIST 1.1', 'RECIST 1.1 will be used by the BICR when assessing images for efficacy measures and by', 'the local site when determining eligibility (Section 8.2.1.5). Although traditional RECIST 1.1', 'references a maximum of 5 target lesions in total and 2 per organ, this protocol has', 'implemented an adjustment to RECIST 1.1 to follow a maximum of 10 target lesions in total', 'and 5 per organ.', '4.2.1.1.2', 'Adjusted RECIST 1.1 for Immune-based Therapeutics iRECIST', 'RECIST 1.1 will be adapted to account for the unique tumor response characteristics seen', 'following treatment with pembrolizumab (Section 8.2.1.6). Immunotherapeutic agents such', 'as pembrolizumab may produce antitumor effects by potentiating endogenous cancer-specific', 'immune responses. The response patterns seen with such an approach may extend beyond the', 'typical time course of responses seen with cytotoxic agents, and patients treated with', 'pembrolizumab may manifest a clinical response after an initial increase in tumor burden or', 'even the appearance of new lesions. Thus, standard RECIST 1.1 may not fully capture the', 'treatment benefits from immunotherapeutic agents such as pembrolizumab. Based on an', 'analysis of participants with melanoma enrolled in KEYNOTE-001 (KN001), 7% of', 'evaluable participants experienced delayed or early tumor pseudoprogression. Of note,', 'participants who had PD by RECIST 1.1 but not by the immune-related response criteria', '[Wolchok, J. D., et al 2009] had longer OS than participants with PD by both criteria [Hodi,', 'F. S., et al 2014]. Additionally, the data suggest that RECIST 1.1 may underestimate the', 'benefit of pembrolizumab in approximately 15% of participants. These findings support the', 'need to apply an adjustment to RECIST 1.1 that takes into account the unique patterns of', 'atypical responses in immunotherapy and enables treatment beyond initial radiographic', 'progression, if the participant is clinically stable.', 'iRECIST assessment has been developed and published by the RECIST Working Group,', 'with input from leading experts from industry and academia, along with participation from', 'the United States Food and Drug Administration (FDA) and the European Medicines Agency', '(EMA) [Seymour, L., et al 2017]. The unidimensional measurement of target lesions,', 'qualitative assessment of nontarget lesions, and response categories are identical to RECIST', '1.1, until progression is seen by RECIST 1.1. However, if a participant is clinically stable,', 'additional imaging may be performed to confirm radiographic progression. iRECIST will be', 'used by investigators to assess tumor response and progression and make treatment decisions', 'as well as for exploratory efficacy analyses where specified.', '4.2.1.2', 'Safety Enppoints', 'Safety parameters commonly used for evaluating investigational systemic anticancer', 'treatments are included as safety endpoints including, but not limited to, the incidence of,', 'causality, and outcome of AEs/serious AEs (SAEs); and changes in vital signs and laboratory', 'values. Adverse events will be assessed as defined by the NCI Common Terminology', 'Criteria for Adverse Events (CTCAE), Version 4.0.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
53,page_54,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '53', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.1.3', 'Patient-reported Outcomes', 'NOTE: As of Amendment 007-06, ePRO data are no longer being collected.', 'Symptomatic improvement is considered a clinical benefit and accepted by health authorities.', 'As part of the analyses for this study, participants will provide information regarding their', 'health-related quality of life (HRQoL) via the following assessment tools: European', 'Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-', 'LC13, and EuroQoL EQ-5D-5L questionnaires. The ePROs are not pure efficacy or safety', 'endpoints because they are affected by both PD and treatment tolerability.', '4.2.1.3.1', 'EORTC QLQ-C30', 'EORTC QLQ-C30 is the most widely used cancer-specific, HRQoL instrument, which', 'contains 30 items and measures 5 functional dimensions (physical, role, emotional, cognitive,', 'and social), 3 symptom items (fatigue, nausea/vomiting, and pain), 6 single items (dyspnea,', 'sleep disturbance, appetite loss, constipation, diarrhea, and financial impact), and a global', 'health and QoL scale [Aaronson, N. K., et al 1993]. The EORTC QLQ-C30 is a', 'psychometrically and clinically validated instrument appropriate for assessing QoL in', 'oncology studies [Aaronson, N. K., et al 1993].', '4.2.1.3.2', 'EORTC QLQ-LC13', 'The EORTC Quality of Life Questionnaire and Lung Cancer Module 13 (QLQ-LC13), a', 'supplemental lung cancer-specific module used in combination with QLQ-C30, comprises', 'multi-item and single-item measures of lung cancer-associated symptoms (cough,', 'hemoptysis, dyspnea, and site-specific pain) and treatment-related symptoms (sore mouth,', 'dysphagia, peripheral neuropathy, and alopecia) [Bergman, B., et al 1994]. It is scored on a', '4-point scale (1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much) and has been', 'translated and validated into more than 60 languages.', 'The EORTC QLQ-C30 and QLQ-LC13 are the most frequently used PRO measures in lung', 'cancer clinical studies. The reliability, validity, and practicality of these instruments have', 'been reported [Bergman, B., et al 1994) [Aaronson, N. K., et al 1993].', '4.2.1.3.3', 'EuroQoL EQ-5D-5L', 'The EQ-5D-5L is a standardized instrument for use as a measure of health outcome and will', 'provide data to develop health utilities for use in health economic analyses [Rabin, R. 2001].', 'The 5 health state dimensions in the EQ-5D-5L include the following: mobility, self-care,', 'usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 5', 'point scale from 1 (no problem) to 5 (unable to/extreme problems). The EQ-5D-5L also', 'includes a graded (0 to 100) vertical visual analog scale on which the participant rates his or', 'her general state of health at the time of the assessment. This instrument has been used', 'extensively in cancer studies and published results from these studies support its validity and', 'reliability [Pickard, A. S., et al 2007].', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
54,page_55,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '54', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.1.4', 'Pharmacokinetic Enppoints', 'Prior to Amendment 05, blood samples were obtained to measure the PK of pembrolizumab', 'and lenvatinib. The Sponsor has determined sufficient pembrolizumab/lenvatinib PK data in', 'NSCLC participants have been collected. As such, no further PK samples will be collected.', 'Standard PK parameters of clearance (CL) and volume of distribution (V) at steady state are', 'planned to be calculated for lenvatinib when coadministered with pembrolizumab, using the', 'accepted mixed-effects modeling approach. PK data from this study may be combined with', 'data from other studies and analyzed using standard population PK techniques to further', 'characterize basic PK parameters, evaluate the effect of extrinsic and intrinsic factors in', 'support of the proposed dosing regimen, and evaluate safety in the proposed participant', 'population.', '4.2.1.5', 'Planned Exploratory Biomarker Research', 'Cancer immunotherapies represent an important and novel class of antitumor agents.', 'However, the mechanism of action of these exciting new therapies, including novel', 'combinations with antiangiogenesis therapy, is not completely understood and much remains', 'to be learned regarding how best to leverage these new drugs in treating patients. Thus, to aid', 'future patients, it is important to investigate the determinants of response or resistance to', 'cancer immunotherapy and other treatments administered, as well as determinants of AEs in', 'the course of our clinical studies. These efforts may identify novel predictive/PD biomarkers', 'and generate information that may better guide single agent and combination therapy with', 'immuno-oncology drugs. To identify novel biomarkers, biospecimens (ie, blood components,', 'tumor material) will be collected to support analyses of cellular components (eg, protein,', 'deoxyribonucleic acid [DNA], ribonucleic acid [RNA], metabolites) and other circulating', 'molecules. Investigations may include but are not limited to:', 'Germline (blood) genetic analyses (eg, SNP analyses, whole exome sequencing, whole', 'genome sequencing)', 'This research may evaluate whether genetic variation within a clinical study population', 'correlates with response to the treatment(s) under evaluation. If genetic variation is found to', 'predict efficacy or AEs, the data might inform optimal use of therapies in the patient', 'population. Furthermore, it is important to evaluate germline DNA variation across the', 'genome in order to interpret tumor-specific DNA mutations.', 'Genetic (DNA) analyses from tumor', 'The application of new technologies, such as next generation sequencing, has provided', 'scientists the opportunity to identify tumor-specific DNA changes (ie, mutations, methylation', 'status, microsatellite instability) contributing towards the development/progression of cancer', 'and/or driving response to therapy. Key molecular changes of interest to immuno-oncology', 'drug development include the mutational burden of tumors and the clonality of T-cells in the', 'tumor microenvironment. Increased mutational burden (sometimes referred to as a ""hyper-', ""mutated' state) may generate neo-antigen presentation in the tumor microenvironment. To"", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
55,page_56,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '55', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'conduct this type of research, it is important to identify tumor-specific mutations that occur', 'across all genes in the tumor genome. Evaluation of molecular targets and signaling', 'pathways including angiogenesis- or and growth factor related signaling pathways related to', 'pembrolizumab and lenvatinib may also be explored. Thus, genome-wide approaches may be', 'used for this effort. Note that in order to understand tumor-specific mutations, it is necessary', 'to compare the tumor genome with the germline genome. Circulating tumor DNA and/or', 'RNA may also be evaluated from blood samples.', 'Tumor and blood RNA analyses', 'Both genome-wide and targeted messenger RNA (mRNA) expression profiling and', 'sequencing in tumor tissue and in blood may be performed to define gene signatures that', 'correlate to clinical response to treatment with pembrolizumab or other immunotherapies.', 'Pembrolizumab induces a response in tumors that likely reflects an inflamed/immune', 'phenotype. Specific immune-related gene sets (ie, those capturing interferon-gamma', 'transcriptional pathways) may be evaluated and new signatures may be identified. Individual', 'genes related to the immune system and growth factor signaling pathways (eg, VEGF and', 'FGF) may also be evaluated. MicroRNA profiling may also be pursued as well as exosomal', 'profiling.', 'Proteomics and immunohistochemistry (IHC) using blood or tumor', 'Tumor and blood samples from this study may undergo proteomic analyses (eg, PD-L1 IHC).', 'PD-L1 protein level in tumor sections, assessed by IHC, has been shown to correlate with', 'response to pembrolizumab in patients with NSCLC, and an in vitro diagnostic (IVD) device', 'has been developed for use with pembrolizumab in NSCLC. Preliminary data indicates that', 'this association may also be true in additional cancer types (ie, triple negative breast cancer,', 'head and neck, and gastric). Additional tumor or blood-derived proteins may also correlate', 'with response to pembrolizumab and lenvatinib combination therapy. Therefore, tumor tissue', 'may be subjected to proteomic analyses using a variety of platforms that could include but', 'are not limited to immunoassays and liquid chromatography/mass spectrometry. This', 'approach could identify novel protein biomarkers that could aid in patient selection for', 'pembrolizumab (MK-3475) and lenvatinib combination therapy.', 'Other blood-derived biomarkers', 'In addition to expression on the tumor tissue, PD-L1, circulating cytokines and angiogenic', 'factors, and other tumor derived proteins can be shed from tumor and released into the blood.', 'Assays such as enzyme-linked immunoassay (ELISA) measure such proteins in serum.', 'Correlation of expression with response to pembrolizumab and lenvatinib combination', 'therapy may identify new approaches for predictive biomarkers in blood, representing a', ""major advance from today's reliance on assessing tumor biomarkers. This research would"", 'serve to develop such assays for future clinical use.', 'Other molecular changes of interest include the subtype of T-cells in the tumor', 'microenvironment. The T-cell repertoire from tumor tissue and blood components may be', 'evaluated.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
56,page_57,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '56', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '4.2.2', 'Rationale for the Use of Comparator/Placebo', 'Based on the results of KEYNOTE-024, pembrolizumab monotherapy has become the SOC', 'for treating Stage IV NSCLC in patients with PD-L1 TPS >50% with no EGFR or ALK', 'genomic tumor aberrations. The study resulted in a significant PFS benefit for', 'pembrolizumab over the SOC at the time (platinum-doublet therapy), with an HR of', '0.50 (95% CI, 0.37-0.68; p<0.001; median PFS, 10.3 months [95% CI, 6.7 to not reached]', 'with pembrolizumab and 6.0 months [95% CI, 4.2-6.2 months] with platinum-doublet) as', 'well as an OS benefit with an HR of 0.60 (95% CI 0.41-0.89; p=0.005; median OS was not', 'reached in either treatment arm) [Reck, M., et al 2016]. The results from KEYNOTE-024', 'established pembrolizumab as 1L therapy for patients whose tumors have a TPS >50% and in', 'whom EGFR- or ALK-directed therapies are not indicated, and the regimen has received', 'regulatory approval for this use by the FDA and EMA. Additionally, based on results from', 'KEYNOTE-042, pembrolizumab monotherapy is considered one of the treatment options in', 'treating Stage IV NSCLC in patients with PD-L1 TPS 1% with no EGFR or ALK genomic', 'tumor aberrations. The study resulted in a significant os benefit for pembrolizumab over the', 'SOC at the time (platinum-doublet therapy), with an HR of 0.81 (95% CI, 0.71-0.93;', 'p=0.0018). Median OS was 16.7 months (95% CI, 13.9-19.7 months) with pembrolizumab', 'and 12.1 months (95% CI, 11.3-13.3 months) with platinum-doublet therapy [Lopes, G., et al', '2018].', 'The use of a lenvatinib matching placebo in combination with pembrolizumab will ensure the', ""objectivity of the local investigators' treatment decision and AE causality assessments, while"", 'still providing participants the SOC treatment.', '4.3', 'Justification for Dose', '4.3.1', 'Maximum Dose/Exposure for This Study', 'NOTE: As of Amendment 007-06, lenvatinib, matching placebo, and Second-course', 'treatment have been removed from the study. This section has been updated', 'accordingly.', 'The maximum dose/exposure of pembrolizumab allowed in this study is 200 mg Q3W up to', '35 cycles (approximately 2 years) for the Initial Treatment Phase.', '4.3.2', 'Rationale for Dose Interval and Study Design', '4.3.2.1', 'Lenvatinib Dosing', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. This section is no longer applicable, but has been left unchanged for', 'reference.', 'The dosing regimen of lenvatinib was selected based on the results of the Phase 1b portion of', 'Phase 1b/2 Study 111/KEYNOTE-146, of which the primary endpoint was to determine the', 'MTD and RP2D for lenvatinib in combination with pembrolizumab 200 mg Q3W. Thirteen', 'participants (lenvatinib 24 mg/day + pembrolizumab 200 mg IV Q3W: n=3; lenvatinib 20', 'mg/day + pembrolizumab 200 mg: n=10) were enrolled into the Phase 1b portion of the', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
57,page_58,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '57', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'study. Eight of the participants had RCC, 2 had NSCLC, 2 had endometrial cancer, and 1 had', 'melanoma. There were 2 DLTs at the dose of lenvatinib 24 mg/day + pembrolizumab 200 mg', 'IV Q3W (1 participant had Grade 3 arthralgia and another had Grade 3 fatigue); hence, this', 'was defined as the toxic dose. No DLTs were reported in the next 10 participants (expansion', 'part), all of whom received the lenvatinib 20 mg/day + pembrolizumab 200 mg Q3W dose.', 'Based on review of all of the clinical data from these 13 participants, the MTD and RP2D', 'were determined to be 20 mg of lenvatinib daily in combination with a fixed dose of 200 mg', 'of pembrolizumab given Q3W. Based on the promising antitumor efficacy and tolerable', 'safety profile seen in both the endometrial carcinoma and RCC expansion cohorts from', 'Study 111/KEYNOTE-146 [Makker, V., et al 2018], 2 Phase 3 studies have been initiated for', 'both of these tumor types, Study E7080-G000-309/KEYNOTE-775 and Study E7080-G000-', '307/KEYNOTE-581.', '4.3.2.2', 'Pembrolizumab Dosing', 'The rationale for the use of a fixed dose of pembrolizumab in participants with solid tumors', 'was based on the following:', 'Similar efficacy and safety of pembrolizumab when dosed at 2 mg/kg Q3W,', '10 mg/kg Q3W, or 10 mg/kg every 2 weeks in participants with melanoma and', 'NSCLC', 'Flat exposure-response relationships of pembrolizumab for both efficacy and safety in', 'the dose range of 2 mg/kg Q3W to 10 mg/kg Q3W', 'The lack of clinically relevant effect of tumor burden or indication on distribution', 'behavior of pembrolizumab (as assessed by the population pharmacokinetics [PopPK]', 'model)', 'Pharmacology data showing full target saturation in both systemic circulation', '(inferred from PK data) and tumor (inferred from physiologically based PK analysis)', 'at 200 mg Q3W', 'The choice of pembrolizumab 200 mg Q3W as an appropriate fixed dose was based on', 'simulations performed using the PopPK model of pembrolizumab, which showed the', 'following for a fixed dose of 200 mg Q3W:', 'Provide similar control of PK variability as weight-based dosing, with considerable', 'overlap in the distribution of exposures from the 200 mg Q3W fixed dose and', '2 mg/kg Q3W dose', 'Maintain individual participant exposures in the exposure range associated with', 'maximal efficacy response that was established in participants with melanoma and', 'NSCLC', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
58,page_59,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '58', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Result in individual participant exposures within a range that was well tolerated and', 'safe in participants with melanoma and NSCLC', 'Clinical data have shown meaningful improvement in benefit-risk, including OS, at 200 mg', 'Q3W across multiple indications. Additionally, a fixed-dose regimen simplified the dosing', 'regimen to be more convenient for physicians and to reduce the potential for dosing errors. A', 'fixed-dosing scheme also reduced complexity in the logistical chain at treatment facilities', 'and reduced wastage.', '4.4', 'Beginning and End of Study Definition', 'The overall study begins when the first participant (or their legally acceptable representative)', 'provides documented informed consent. The overall study ends when the last participant', 'completes the last study-related contact, withdraws consent, or is lost to follow-up (ie, the', 'participant is unable to be contacted by the investigator).', '4.4.1', 'Clinical Criteria for Early Study Termination', 'The clinical study may be terminated early if the extent (incidence and/or severity) of', 'emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population', 'as a whole is unacceptable. In addition, further recruitment in the study or at (a) particular', 'study site(s) may be stopped due to insufficient compliance with the protocol, Good Clinical', 'Practice (GCP), and/or other applicable regulatory requirements, procedure-related problems', 'or an unacceptably high number of discontinuations or withdrawals due to administrative', 'reasons.', '5', 'STUDY POPULATION', 'Male and female participants with Stage IV NSCLC, who express PD-L1 (TPS 1%), have', 'received no systemic anticancer therapy for their Stage IV NSCLC, and are at least 18 years', 'of age will be enrolled in this study.', 'Prospective approval of protocol deviations to recruitment and enrollment criteria, also', 'known as protocol waivers or exemptions, is not permitted.', '5.1', 'Inclusion Criteria', 'To be eligible for inclusion in this study, the participant must:', 'Type of Participant and Disease Characteristics', '1. Have a histologically or cytologically confirmed diagnosis of NSCLC.', 'Note: Mixed tumors will be categorized by the predominant cell type; if small-cell', 'elements are present, the participant is ineligible.', '2. Have Stage IV NSCLC (American Joint Committee on Cancer [AJCC], version 8).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
59,page_60,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '59', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '3. Have confirmation that EGFR-, ALK-, or ROSI-directed therapy is not indicated as', 'primary therapy (documentation of the absence of tumor-activating EGFR mutations [eg,', 'DEL19 or L858R], AND absence of ALK and ROSI gene rearrangements OR presence of', 'a Kirsten rat sarcoma [K-ras] mutation).', ""Note: If participant's tumor is known to have a predominantly squamous histology,"", 'molecular testing for EGFR mutation and ALK and ROSI translocations will not be', 'required, as this is not part of current diagnostic guidelines.', '4. Have measurable disease based on RECIST 1.1, as determined by the local site.', 'Note: Lesions that appear measurable but are situated in a previously irradiated area can', 'be considered measurable (eligible for selection as target lesions) if they have shown', 'documented growth since the completion of radiation.', '5. Tumor tissue that demonstrates PD-L1 expression in >1% of tumor cells (TPS 1%) as', 'assessed by IHC 22C3 pharmDx at a central laboratory.', 'Note: Assessment of PD-L1 expression must be made from provided archival tumor', 'tissue sample or newly obtained core or excisional biopsy of a tumor lesion not', 'previously irradiated. (A fine-needle aspirate, frozen sample, plastic-embedded sample,', 'cell block, clot, bone, bone marrow, cytologic specimen, or decalcified or formalin-fixed', 'sample that was frozen at any point will not be acceptable for analysis). Formalin-fixed,', 'paraffin-embedded tissue blocks are preferred to slides. Newly obtained biopsies are', 'preferred to archived tissue.', 'Demographics', '6. Be >18 years of age, inclusive, at the time of signing the ICF.', '7. Have a life expectancy of at least 3 months.', '8. Have an ECOG performance status of 0 or 1 within 7 days before the first dose of study', 'intervention but before randomization.', 'Contraceptive use', 'Contraceptive use by men and women should be consistent with local regulations regarding', 'the methods of contraception for those participating in clinical studies. If the contraception', 'requirements in the local label for any of the study interventions is more stringent than the', 'requirements above, the local label requirements are to be followed.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
60,page_61,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '60', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Male Participants', '9. Male participants are eligible to participate if they agree to the following during the', 'intervention period and for at least 7 days after the last dose of lenvatinib/matching', 'placebo:', 'Be abstinent from heterosexual intercourse as their preferred and usual lifestyle', '(abstinent on a long-term and persistent basis) and agree to remain abstinent', 'OR', 'Must agree to use contraception unless confirmed to be azoospermic (vasectomized', 'or secondary to medical cause [Appendix 5]) as detailed below:', '- Agree to use a male condom plus partner use of an additional contraceptive', 'method when having penile-vaginal intercourse with a woman of childbearing', 'potential (WOCBP) who is not currently pregnant.', 'Note: Men with a pregnant or breastfeeding partner must agree to remain', 'abstinent from penile-vaginal intercourse or use a male condom during each', 'episode of penile-vaginal penetration.', '-', 'Please note that 7 days after lenvatinib/matching placebo is stopped, if the', 'participant is on pembrolizumab only, no male contraception measures are', 'needed.', 'Female Participants', '10. A female participant is eligible to participate if she is not pregnant or breastfeeding, and', 'at least one of the following conditions applies:', 'Is not a WOCBP.', 'OR', 'Is a WOCBP and using a contraceptive method that is highly effective (with a failure', 'rate of <1% per year), with low user dependency, or be abstinent from heterosexual', 'intercourse as their preferred and usual lifestyle (abstinent on a long term and', 'persistent basis), as described in Appendix 5 during the intervention period and for at', 'least 120 days post pembrolizumab or 30 days post lenvatinib/matching placebo,', 'whichever occurs last. The investigator should evaluate the potential for contraceptive', 'method failure (ie, noncompliance, recently initiated) in relationship to the first dose', 'of study intervention.', 'A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as', 'required by local regulations) within 24 hours before the first dose of study', 'intervention.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
61,page_62,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '61', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum', 'pregnancy test is required. In such cases, the participant must be excluded from', 'participation if the serum pregnancy result is positive.', 'Additional requirements for pregnancy testing during and after study intervention are', 'located in Appendix 2.', 'The investigator is responsible for review of medical history, menstrual history, and', 'recent sexual activity to decrease the risk for inclusion of a woman with an early', 'undetected pregnancy.', 'Informed Consent', '11. The participant (or legally acceptable representative if applicable) has provided', 'documented informed consent/assent for the study.', 'Additional Categories', '12. Have adequately controlled blood pressure (BP) with or without antihypertensive', 'medications, defined as BP <150/90 mm Hg and no change in antihypertensive', 'medications within 1 week prior to randomization.', '13. Have adequate organ function as defined in the following table (Table 1). Specimens', 'must be collected within 10 days before the start of study intervention.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
62,page_63,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '62', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 1', 'Adequate Organ Function Laboratory Values', 'System', 'Laboratory Value', 'Hematological', 'ANC', '1500/L', 'Platelets', '>100,000/uL', 'Hemoglobin', '9.0g/dL or >5.6 mmol/La', 'Renal', 'Creatinine or', '<1.5 X ULN or', 'Measured or calculated CrCl', '>30 mL/min for participant with creatinine', '(GFR can also be used in place of creatinine or', 'levels >1.5 X institutional ULN', 'CrCl)', 'Hepatic', 'Total bilirubin', '<1.5 X ULN or direct bilirubin >ULN for', 'participants with total bilirubin levels', '>1.5 X ULN', 'AST (SGOT) and ALT (SGPT)', '2.5 X ULN (<5 X ULN for participants with', 'liver metastases)', 'Coagulation', 'INR or PT', '<1.5 X ULN unless participant is receiving', 'aPTT/PTT', 'anticoagulant therapy as long as INR/PT or', 'aPTT/PTT is within therapeutic range of', 'intended use of anticoagulants', 'Abbreviations: ALT (SGPT) = alanine aminotransferase (serum glutamic pyruvic transaminase);', 'ANC = absolute neutrophil count; aPTT = activated partial thromboplastin time; AST (SGOT) = aspartate', 'aminotransferase (serum glutamic oxaloacetic transaminase); CrCl = creatinine clearance; GFR = glomerular', 'filtration rate; INR = international normalized ratio; PT = prothrombin time; ULN = upper limit of normal.', 'Note: This table includes eligibility-defining laboratory value requirements for treatment; laboratory value', 'requirements should be adapted according to local regulations and guidelines for the administration of specific', 'chemotherapies.', 'a', 'Criteria must be met without erythropoietin dependency and without packed red blood cell transfusion', 'within last 2 weeks.', 'b', 'CrCl should be calculated per institutional standard.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
63,page_64,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '63', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '5.2', 'Exclusion Criteria', 'The participant must be excluded from the study if the participant:', 'Medical Conditions', '1. Has known untreated central nervous system metastases and/or carcinomatous', 'meningitis. Participants with previously treated brain metastases may participate provided', 'they are radiologically stable ie, without evidence of progression for at least 4 weeks by', 'repeat imaging (note: repeat imaging should be performed during study screening),', 'clinically stable, and without requirement of steroid treatment for at least 14 days before', 'first dose of study intervention.', '2. Has clinically significant hemoptysis (at least 0.5 teaspoon of bright red blood) or tumor', 'bleeding within 2 weeks before the first dose of study intervention.', '3. Has radiographic evidence of encasement or invasion of a major blood vessel, or of', 'intratumoral cavitation.', 'NOTE:', 'The degree of proximity to major blood vessels should be considered because of', 'the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis', 'following lenvatinib therapy.', 'In the chest, major blood vessels include the main pulmonary artery, the left and', 'right pulmonary arteries, the 4 major pulmonary veins, the superior or inferior', 'vena cava, and the aorta.', '4. Has a known history of an additional malignancy, except if the participant has undergone', 'potentially curative therapy with no evidence of that disease recurrence for at least', '3 years since initiation of that therapy.', 'Note: The time requirement for no evidence of disease for at least 3 years does not apply', 'to the NSCLC for which a participant is enrolled in the study. The time requirement also', 'does not apply to participants who underwent successful definitive resection of basal cell', 'carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in', 'situ cervical cancer, or other in situ cancers.', '5. Has an active autoimmune disease that has required systemic treatment in the past 2 years', '(ie, with the use of disease-modifying agents, corticosteroids, or immunosuppressive', 'drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid', 'replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form', 'of systemic treatment and is allowed.', '6. Has had an allogeneic tissue/solid organ transplant.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
64,page_65,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '64', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '7. Has a known history of human immunodeficiency virus (HIV) infection; HIV testing is', 'not required unless mandated by the local health authority.', '8. Has a history of (noninfectious) pneumonitis that required systemic steroids or current', 'pneumonitis/interstitia lung disease.', '9. Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg]', 'reactive or hepatitis B virus [HBV]-DNA detected) or known active hepatitis C virus', '(HCV, defined as HCV-RNA [qualitative] detected or HCV antibody reactive, if', 'HCV-RNA is not the local SOC) infection.', '-', 'Note: No testing for hepatitis B and hepatitis C is required unless mandated by the', 'local health authority.', '10. Has a history of a gastrointestinal condition or procedure that in the opinion of the', 'investigator may affect oral study drug absorption.', '11. Has significant cardiovascular impairment within 12 months of the first dose of study', 'intervention, such as a history of congestive heart failure greater than New York Heart', 'Association Class II, unstable angina, myocardial infarction, cerebrovascular accident', '(CVA)/stroke, or cardiac arrhythmia associated with hemodynamic instability.', '12. Has not recovered adequately from any toxicity and/or complications from major surgery', 'before starting therapy.', '13. Has a known history of active tuberculosis (TB).', '14. Has an active infection requiring systemic therapy.', '15. Has a known psychiatric or substance abuse disorder that would interfere with the', ""participant's cooperation for the requirements of the study."", '16. Previously had a severe hypersensitivity reaction to treatment with an mAb or has a', 'known sensitivity or intolerance to any component of lenvatinib or pembrolizumab.', '17. WOCBP who has a positive urine pregnancy test within 24 hours before the first dose of', 'study intervention. If the urine test is positive or cannot be confirmed as negative, a', 'serum pregnancy test will be required.', 'Note: If more than 24 hours have elapsed between the screening pregnancy test and the', 'first dose of study intervention, another pregnancy test (urine or serum) must be', 'performed and must be negative for the participant to start receiving study intervention.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
65,page_66,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '65', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Prior/Concomitant Therapy', '18. Has received prior systemic chemotherapy or other targeted or biological antineoplastic', 'therapy for their metastatic NSCLC.', 'Note: Prior treatment with chemotherapy and/or radiation as part of neoadjuvant/adjuvant', 'or chemoradiation therapy for nonmetastatic NSCLC is allowed as long as therapy was', 'completed at least 6 months before the diagnosis of metastatic NSCLC.', '19. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an', 'agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4,', 'OX 40, CD137) or has received lenvatinib as monotherapy or in combination with', 'anti-PD-1 agents.', '20. Has received radiotherapy within 14 days before the first dose of study intervention or', 'received lung radiation therapy of>30 Gy within 6 months before the first dose of study', 'intervention.', 'Note: Participants must have recovered from all radiation-related toxicities to Grade 1 or', 'less, not require corticosteroids, and not have had radiation pneumonitis.', '21. Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive', 'therapy within 7 days before the first dose of study intervention.', '22. Is receiving systemic steroid therapy (doses exceeding 10 mg daily of prednisone', 'equivalent) within 7 days before the first dose of study intervention.', '23. Has received a live or attenuated vaccine within 30 days before the first dose of study', 'intervention. Note: Killed vaccines are allowed.', 'Prior/Concurrent Clinical Study Experience', 'Not applicable.', 'Diagnostic Assessments', '24. Participants with proteinuria > -1+ on urine dipstick testing/urinalysis will undergo', '24-hour urine collection for quantitative assessment of proteinuria. Participants with', 'urine protein >1 g/24 hours will be ineligible.', 'Prolongation of QTc interval to >480 ms and/or left ventricular ejection fraction (LVEF)', 'below the institutional normal range as determined by a multigated acquisition scan', '(MUGA) or echocardiogram (ECHO).', 'Other Exclusions', '25. Has a history or current evidence of any condition, therapy, or laboratory abnormality', ""that might confound the results of the study or interfere with the participant's ability to"", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
66,page_67,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '66', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'participate for the full duration of the study, or it is not in the best interest of the', 'participant to participate, in the opinion of the treating investigator.', '26. Has had major surgery within 3 weeks prior to first dose of study intervention. Note:', 'Adequate wound healing after major surgery must be assessed clinically, independent of', 'time elapsed for eligibility.', '27. Has pre-existing >Grade 3 gastrointestinal or nongastrointestinal fistula.', '5.3', 'Lifestyle Considerations', '5.3.1', 'Meals and Dietary Restrictions', 'Participant should maintain a normal diet unless modifications are required to manage an AE,', 'such as diarrhea, nausea, or vomiting.', '5.3.2', 'Contraception', 'Based on its mechanism of action, lenvatinib can cause fetal harm when administered to a', 'pregnant woman. Lenvatinib may also result in reduced fertility in females of reproductive', 'potential and may result in damage to male reproductive tissues leading to reduced fertility of', 'unknown duration. In animal reproduction studies, oral administration of lenvatinib during', 'organogenesis at doses below the recommended human dose resulted in embryotoxicity,', 'fetotoxicity, and teratogenicity in rats and rabbits.', 'Participants should be informed that taking the study intervention may involve unknown', 'risks to the fetus (unborn baby) if pregnancy were to occur during the study. To participate in', 'the study, WOCBP must adhere to the contraception requirement (Appendix 5) from the day', 'of study intervention initiation throughout the study period up to 120 days post', 'pembrolizumab or 30 days post lenvatinib/matching placebo, whichever occurs last. If there', 'is any question that a WOCBP will not reliably comply with the requirements for', 'contraception, that participant should not be entered into the study.', '5.3.3', 'Pregnancy', 'If a participant inadvertently becomes pregnant while on study intervention, the participant', 'will be immediately discontinued from study intervention. The site will contact the', ""participant at least monthly and document the participant's status until the pregnancy has"", 'been completed or terminated. The outcome of the pregnancy will be reported to the Sponsor', 'without delay and within 24 hours if the outcome is an SAE (eg, death, abortion, congenital', 'anomaly, or other disabling or life-threatening complication to the mother or newborn). The', 'study investigator will make every effort to obtain permission to follow the outcome of the', 'pregnancy and report the condition of the fetus or newborn to the Sponsor. If a male', 'participant impregnates a female partner, the study personnel at the site must be informed', 'immediately, and the pregnancy must be reported to the Sponsor and followed as described', 'in Section 8.4.5.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
67,page_68,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '67', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '5.3.4', 'Use in Nursing Women', 'It is unknown whether lenvatinib or pembrolizumab is excreted in human milk. Since many', 'drugs are excreted in human milk and because of the potential for serious adverse reactions', 'in the nursing infant, participants who are breastfeeding are not eligible for enrollment.', '5.4', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study, but', 'are not subsequently randomized in the study. A minimal set of screen failure information is', 'required to ensure transparent reporting of screen failure participants to meet the', 'Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to', 'respond to queries from regulatory authorities. Minimal information includes demography,', 'screen failure details, eligibility criteria, and any AEs or SAEs meeting reporting', 'requirements as outlined in the data entry guidelines.', '5.5', 'Participant Replacement Strategy', 'A participant who discontinues from study intervention will not be replaced.', '6', 'STUDY INTERVENTION', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study; the portions of this section referring to these treatments are no longer', 'applicable. This section has been updated accordingly.', 'Study intervention is defined as any investigational intervention(s), marketed product(s)', 'placebo, or medical device(s) intended to be administered to a study participant according to', 'the study protocol.', 'Clinical supplies (pembrolizumab ) will be packaged to support enrollment as required.', 'Clinical supplies will be affixed with a clinical label in accordance with regulatory', 'requirements.', '6.1', 'Study Intervention(s) Administered', 'The study interventions to be used in this study are outlined in Table 2.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
68,page_69,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '68', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 2', 'Study Interventions', 'Arm', 'Intervention', 'Dose', 'Unit Dose', 'Regimen/', 'Dosage', 'Route of', 'IMP/', 'Arm Type', 'Type', 'Treatment', 'Use', 'Name', 'Name', 'Formulation', 'Strength(s)', 'Administration', 'Sourcing', 'Level(s)', 'NIMP', 'Period', 'Arm A', 'Experimental', 'Pembrolizumab', 'Drug', 'Solution for', '25 mg/mL', '200 mg', 'IV Infusion', 'Q3W', 'Standard of', 'IMP', 'Provided', 'and B', '(MK-3475)', 'Infusion', 'care/', 'centrally', 'Experimental', 'by the', 'Sponsor', 'ArmA', 'Experimental', 'Lenvatinib', 'Drug', 'Capsule', '10 mg/4 mg', '20 mg', 'Oral', 'QD', 'Experimental', 'IMP', 'Provided', '(E7080/', 'centrally', 'MK -7902)', 'by the', 'Sponsor', 'Arm B', 'Placebo', 'Placebo', 'Drug', 'Capsule', 'NA', 'NA', 'Oral', 'QD', 'Placebo', 'IMP', 'Provided', 'Comparator', 'centrally', 'by the', 'Sponsor', 'Abbreviations: EEA = European Economic Area; IMP = investigational medicinal product; IV = intravenous; NA = not applicable; NIMP = noninvestigational medicinal product;', 'Q3W = every 3 weeks; QD = once daily.', 'The classification of IMP in this table is based on guidance issued by the European Commission and applies to countries in the EEA. Country differences with respect to the', 'definition/classification of IMP/NIMP may exist. In these circumstances, local legislation is followed.', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed from the treatment groups. Participants remaining on treatment will receive', 'open-label pembrolizumab monotherapy as per protocol. The original study interventions and updates are indicated by strikethrough in the table.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
69,page_70,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '69', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'All supplies indicated in Table 2 will be provided per the ""Sourcing"" column depending upon', 'local country operational requirements. If local sourcing, every attempt should be made to', 'source these supplies from a single lot/batch number.', 'Refer to Section 8.1.8 for details regarding administration of the study intervention.', 'All placebos were created by the Sponsor to match the active product.', '6.1.1', 'Medical Devices', 'This section is not applicable.', '6.2', 'rreparation/Handling/Storage/Accountability', '6.2.1', 'Dose Preparation', 'Details on the preparation and administration of pembrolizumab are provided in the', 'Pharmacy Manual. Lenvatinib is a capsule for oral administration and does not require', ""preparation. Before protocol amendment 007-06, site's staff referred to the Pharmacy Manual"", 'for lenvatinib administration.', 'The rationale for selection of doses to be used in this study is provided in Section 4.3.', '6.2.2', 'Handling, Storage, and Accountability', 'Details on preparation and administration of IV pembrolizumab are provided in the', 'Pharmacy Manual. Participants/caregivers were given instructions on how to handle and', 'store lenvatinib/matching placebo capsules at home until it was discontinued as per Protocol', 'Amendment 007-06.', 'The investigator or designee must confirm appropriate temperature conditions have been', 'maintained during transit for all study intervention received, and any discrepancies are', 'reported and resolved before use of the study intervention.', 'Only participants enrolled in the study may receive study intervention, and only authorized', 'site staff may supply or administer study intervention. All study interventions must be stored', 'in a secure, environmentally controlled, and monitored (manual or automated) area in', 'accordance with the labeled storage conditions with access limited to the investigator and', 'authorized site staff.', 'The investigator, institution, or the head of the medical institution (where applicable) is', 'responsible for study intervention accountability, reconciliation, and record maintenance (ie,', 'receipt, reconciliation, and final disposition records).', 'For all study sites, the local country Sponsor personnel or designee will provide appropriate', 'documentation that must be completed for drug accountability and return, or local discard', 'and destruction if appropriate. Where local discard and destruction is appropriate, the', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
70,page_71,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '70', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'investigator is responsible for ensuring that a local discard/destruction procedure is', 'documented.', 'The study site is responsible for recording the lot number, manufacturer, and expiry date for', 'any locally purchased product (if applicable) as per local guidelines unless otherwise', 'instructed by the Sponsor.', 'The investigator shall take responsibility for and shall take all steps to maintain appropriate', 'records and ensure appropriate supply, storage, handling, distribution, and usage of study', 'interventions in accordance with the protocol and any applicable laws and regulations.', '6.3', 'Measures to Minimize Bias: Randomization and Blinding', '6.3.1', 'Intervention Assignment', 'Intervention allocation/randomization will occur centrally using an interactive response', 'technology (IRT) system. There are 2 study intervention arms. Participants will be assigned', 'randomly in a 1:1 ratio to pembrolizumab + lenvatinib or pembrolizumab + matching', 'placebo, respectively.', 'NOTE: as of Amendment 007-06, the study is unblinded. All participants remaining on', 'treatment will receive open-label pembrolizumab monotherapy.', '6.3.2', 'Stratification', 'Intervention allocation/randomization will be stratified according to the following factors:', '1. Geographic region of the enrolling site: East Asia VS non-East Asia', '2. ECOG Performance Score: 0 vs 1', '3. TPS: 1% to 49% VS >50%', '6.3.3', 'Blinding', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study and the study is unblinded. This section has been updated accordingly.', '6.3.3.1', 'Pembrolizumab', 'Pembrolizumab will be administered open label; therefore, its identity will be known by the', 'participant, the investigator, the Sponsor, and delegate(s) who are involved in study', 'intervention administration or the clinical evaluation of participants.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
71,page_72,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '71', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '6.4', 'Study Intervention Compliance', 'Interruptions from the protocol-specified treatment plan for >12 weeks (pembrolizumab)', 'require consultation between the investigator and the Sponsor and written documentation of', 'the collaborative decision on participant management.', '6.5', 'Concomitant Therapy', 'Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed', 'during the treatment period. If there is a clinical indication for any medication or vaccination', 'specifically prohibited, discontinuation from study intervention may be required. The', ""investigator is to discuss prohibited medication/vaccination with the Sponsor's Clinical"", 'Director. The final decision on any supportive therapy or vaccination rests with the', ""investigator and/or the participant's primary physician, but the decision to continue the"", 'participant on study intervention requires the mutual agreement of the investigator, the', 'Sponsor, and the participant.', 'All prior medications (including over-the-counter medications) administered within 30 days', 'before the first dose of study drug and any concomitant therapy administered to the', 'participant during the course of the study (starting at the date of informed consent) until', '30 days after the final dose (or 90 days if used to treat an SAE) of study drug will be', 'recorded. Additionally, all diagnostic, therapeutic, or surgical procedures relating to', 'malignancy should be recorded. Any medication that is considered necessary for the', ""participant's health and that is not expected to interfere with the evaluation of or interact with"", 'the study interventions may be continued during the study.', '6.5.1 Allowed Concomitant Medications', 'Treatment of complications or AEs, or therapy to ameliorate symptoms (including blood', 'products, blood transfusions, fluid transfusions, antibiotics, and antidiarrheal drugs), may be', 'given at the discretion of the investigator, unless it is expected to interfere with the evaluation', 'of (or to interact with) the study intervention. Antiemetic or any other prophylaxis should be', 'considered in accordance with institutional guidelines.', 'The following concomitant medications are also allowed:', 'Hormone replacement therapy (HRT)', 'Thyroid hormone suppressive therapy', 'Anticoagulants, including low molecular weight heparin, warfarin, and anti-Xa agents', 'Anti-inflammatory agents', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
72,page_73,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '72', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Bisphosphonates or denosumab', 'Antihypertensive therapy (including additional antihypertensive treatment as', 'appropriate if BP increases once the participant is enrolled)', '6.5.2', 'Prohibited Concomitant Medications', 'Participants are prohibited from receiving the following therapies during the screening and', 'treatment phases of the study:', 'Concurrent anticancer therapies, such as chemotherapy, targeted therapies, antitumor', 'interventions (surgical resection, surgical debulking of tumor, etc.), or cancer', 'immunotherapy not specified in this protocol', '- Note: Topical anticancer agents to treat skin lesions (eg, in situ melanoma or', 'squamous cell carcinoma) are allowed, excluding skin metastasis of melanoma.', 'Other concurrent investigational drugs', 'Live or attenuated vaccines within 30 days and while participating in the study. Note:', 'killed vaccines are allowed.', 'Systemic glucocorticoids for any purpose other than those listed in Section 6.5.4.1', 'Radiation therapy for disease control', '-', 'Note: Palliative radiotherapy is permitted for nontarget lesions if considered', 'medically necessary by the treating physician and upon discussion with the', 'Sponsor.', 'For participants who, in an assessment by the investigator, require the use of any of the', 'aforementioned treatments for clinical management, continuation of the study intervention', 'and further participation in the study must be discussed and agreed upon with the Sponsor.', 'If participants receive additional anticancer therapies, this will be judged to represent', 'evidence of PD, and study intervention will be discontinued. These participants should', 'complete all end-of-treatment assessments and continue to be followed for survival during', 'the follow-up period.', '6.5.3 Drug Interactions', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. This section is no longer applicable, but has been left unchanged for', 'reference.', 'There are no DDI-related concomitant medication prohibitions or restrictions.', 'Lenvatinib is not expected to clinically meaningfully alter exposure to CYP3A4/', 'P-glycoprotein (Pgp) substrates based on results from a lenvatinib drug-drug interaction', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
73,page_74,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '73', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '(DDI) study with midazolam (a sensitive CYP3A and Pgp substrate). Clinical studies also', 'showed that co-administration of lenvatinib with either inducers or inhibitors of', 'CYP3A4/Pgp are not of clinical concern.', 'No drug interaction is expected between pembrolizumab and lenvatinib because of divergent', 'metabolic pathways. Pembrolizumab is a monoclonal antibody and is primarily catabolized', 'like other proteins, while lenvatinib is metabolized by enzymatic (CYP3A and aldehyde', 'oxidase) and nonenzymatic processes (see lenvatinib IB).', '6.5.4', 'Rescue Medications and Supportive Care', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. This section has been updated accordingly.', 'Participants should receive appropriate supportive care measures as deemed necessary by the', 'treating investigator. Suggested supportive care measures for the management of AEs with', 'potential immunologic etiology are outlined in Section 6.6.1.', '6.5.4.1', 'Systemic Corticosteroid Use', 'Systemic corticosteroids are permitted in the following situations:', 'To mediate potential immune-related adverse events (irAEs) as guided in Table 3.', 'As pre- or postmedication to prevent AEs associated with IV contrast.', 'Brief, limited use of systemic corticosteroids (7 days) are permitted where such use', 'is considered SOC (eg, for chronic obstructive pulmonary disease [COPD]', 'exacerbation).', 'Replacement doses of steroids (for example, prednisone 10 mg daily) are permitted', 'while on study, as is the use of local steroid injections and topical steroids.', '6.6', 'Dose Modification', 'NOTE: As of Amendment 007-06, text in this section relating to dose modification and', 'other allowed dose interruptions of lenvatinib/matching placebo is no longer applicable.', 'This section has been updated accordingly.', '6.6.1 Immune-related Events and Dose Modification (Withhold, Treat, Discontinue)', '6.6.1.1', 'Dose Modification and Toxicity Management for Immune-related AEs', 'Associated with Pembrolizumab', 'AEs associated with pembrolizumab exposure may represent an immune-related response.', 'These irAEs may occur shortly after the first dose or several months after the last dose of', 'pembrolizumab treatment and may affect more than one body system simultaneously.', 'Therefore, early recognition and initiation of treatment is critical to reduce complications.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
74,page_75,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '74', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Based on existing clinical study data, most irAEs were reversible and could be managed with', 'interruptions of pembrolizumab, administration of corticosteroids and/or other supportive', 'care. For suspected irAEs, ensure adequate evaluation to confirm etiology or exclude other', 'causes. Additional procedures or tests such as bronchoscopy, endoscopy, skin biopsy may be', 'included as part of the evaluation. Based on the severity of irAEs, withhold or permanently', 'discontinue pembrolizumab and administer corticosteroids.', 'Modification and toxicity management guidelines for irAEs associated with pembrolizumab', 'monotherapy, coformulations, or IO combinations are provided in Table 3.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
75,page_76,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '75', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 3', 'Dose Modification and Toxicity Management Guidelines for Immune-related Adverse Events Associated with', 'Pembrolizumab Monotherapy, Coformulations or IO Combinations', 'General instructions:', '1. Severe and life-threatening irAEs should be treated with IV corticosteroids followed by oral steroids. Other immunosuppressive treatment', 'should', 'begin', 'if', 'the', 'irAEs are not controlled by corticosteroids.', '2. Pembrolizumab monotherapy, coformulations or IO combinations must be permanently discontinued if the irAE does not resolve or the corticosteroid dose', 'is not 10 mg/day within 12 weeks of the last treatment.', '3.', 'The corticosteroid taper should begin when the irAE is VI Grade 1 and continue at least 4 weeks.', '4. If pembrolizumab monotherapy, coformulations or IO combinations have been withheld, treatment may resume after the irAE decreased', 'to', 'VI', 'Grade', '1', 'after', 'corticosteroid taper.', 'Action With', 'Pembrolizumab', 'Monotherapy,', 'Toxicity Grade', 'Coformulations or', 'irAEs', '(CTCAEv4.0)', 'IO Combinations', 'Corticosteroid and/or Other therapies', 'Monitoring and Follow-up', 'Pneumonitis', 'Grade 2', 'Withhold', 'Administer corticosteroids (initial dose', 'Monitor participants for signs and symptoms of', 'of 1-2 mg/kg prednisone or', 'pneumonitis', 'equivalent) followed by taper', 'Evaluate participants with suspected pneumonitis', 'Recurrent Grade 2', 'Permanently', 'with radiographic imaging and initiate', 'or Grade 3 or 4', 'discontinue', 'corticosteroid treatment', 'Add prophylactic antibiotics for opportunistic', 'infections', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
76,page_77,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '76', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Action With', 'Pembrolizumab', 'Monotherapy,', 'Toxicity Grade', 'Coformulations or', 'irAEs', '(CTCAEv4.0)', 'IO Combinations', 'Corticosteroid and/or Other therapies', 'Monitoring and Follow-up', 'Diarrhea/Colitis', 'Grade 2 or 3', 'Withhold', 'Administer corticosteroids (initial dose', 'Monitor participants for signs and symptoms of', 'of 1-2 mg/kg prednisone or', 'enterocolitis (ie, diarrhea, abdominal pain,', 'equivalent) followed by taper', 'blood or mucus in stool with or without fever)', 'and of bowel perforation (ie, peritoneal signs', 'and ileus)', 'Participants with Grade 2 diarrhea suspecting', 'Recurrent Grade 3', 'Permanently', 'colitis should consider GI consultation and', 'or Grade 4', 'discontinue', 'performing endoscopy to rule out colitis', 'Participants with diarrhea/colitis should be advised', 'to drink liberal quantities of clear fluids. If', 'sufficient oral fluid intake is not feasible, fluid', 'and electrolytes should be substituted via IV', 'infusion.', 'AST/ALT', 'Grade 2', 'Withhold', 'Administer corticosteroids (initial dose', 'Monitor with liver function tests (consider weekly', 'Elevation or', 'of 0.5-1 mg/kg prednisone or', 'or more frequently until liver enzyme value', 'Increased', 'equivalent) followed by taper', 'returned to baseline or is stable)', 'Bilirubin', 'Grade 3 or 4', 'Permanently', 'Administer corticosteroids (initial dose', 'discontinue', 'of 1-2 mg/kg prednisone or', 'equivalent) followed by taper', 'T1DM or', 'New onset T1DM', 'Withhold a', 'Initiate insulin replacement therapy for', 'Monitor participants for hyperglycemia or other', 'Hyperglycemia', 'or', 'participants with T1DM', 'signs and symptoms of diabetes', 'Grade 3 or 4', 'hyperglycemia', 'Administer antihyperglycemic in', 'associated with', 'participants with hyperglycemia', 'evidence of ß-cell', 'failure', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
77,page_78,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '77', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Action With', 'Pembrolizumab', 'Monotherapy,', 'Toxicity Grade', 'Coformulations or', 'irAEs', '(CTCAEv4.0)', 'IO Combinations', 'Corticosteroid and/or Other therapies', 'Monitoring and Follow-up', 'Hypophysitis', 'Grade 2', 'Withhold', 'Administer corticosteroids and initiate', 'Monitor for signs and symptoms of hypophysitis', 'hormonal replacements as clinically', '(including hypopituitarism and adrenal', 'indicated', 'insufficiency)', 'Grade 3 or 4', 'Withhold or', 'permanently', 'discontinue a', 'Hyperthyroidism', 'Grade 2', 'Continue', 'Treat with nonselective beta-blockers', 'Monitor for signs and symptoms of thyroid', '(eg, propranolol) or thionamides as', 'disorders', 'appropriate', 'Grade 3 or 4', 'Withhold or', 'Permanently', 'discontinue a', 'Hypothyroidism', 'Grade 2-4', 'Continue', 'Initiate thyroid replacement hormones', 'Monitor for signs and symptoms of thyroid', '(eg, levothyroxine or liothyronine)', 'disorders', 'per standard of care', 'Nephritis and', 'Grade 2', 'Withhold', 'Administer corticosteroids (prednisone', 'Monitor changes of renal function', 'renal dysfunction', '1-2 mg/kg or equivalent) followed', 'Grade 3 or 4', 'Permanently', 'by taper', 'discontinue', 'Myocarditis', 'Grade 1', 'Withhold', 'Based on severity of AE administer', 'Ensure adequate evaluation to confirm etiology', 'corticosteroids', 'and/or exclude other causes', 'Grade 2, 3 or 4', 'Permanently', 'discontinue', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
78,page_79,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '78', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Action With', 'Pembrolizumab', 'Monotherapy,', 'Toxicity Grade', 'Coformulations or', 'irAEs', '(CTCAEv4.0)', 'IO Combinations', 'Corticosteroid and/or Other therapies', 'Monitoring and Follow-up', 'All Other irAEs', 'Persistent Grade 2', 'Withhold', 'Based on severity of AE administer', 'Ensure adequate evaluation to confirm etiology or', 'corticosteroids', 'exclude other causes', 'Grade 3', 'Withhold or', 'discontinue b', 'Recurrent Grade 3', 'Permanently', 'or Grade 4', 'discontinue', 'AE(s)=adverse event(s); ALT= alanine aminotransferase; AST=aspartate aminotransferase; CTCAE=Common Terminology Criteria for Adverse Events; DRESS=Drug Rash', 'with Eosinophilia and Systemic Symptom; Gl=gastrointestinal; 10=immuno-oncology; ir=immune-related; IV=intravenous; SJS=Stevens-Johnson Syndrome; T1DM=type 1', 'diabetes mellitus; TEN=Toxic Epidermal Necrolysis; ULN=upper limit of normal.', 'Note: Non-irAE will be managed as appropriate, following clinical practice recommendations.', 'a The decision to withhold or permanently discontinue pembrolizumab monotherapy, coformulations or IO combinations is at the discretion of the investigator or treating', 'physician. If control achieved or VI Grade 2, pembrolizumab monotherapy, coformulations or IO combinations may be resumed.', 'b', 'Events that require discontinuation include, but are not limited to: Guillain-Barre Syndrome, encephalitis, myelitis, DRESS, SJS, TEN and other clinically', 'important', 'irAEs', '(eg, vasculitis and sclerosing cholangitis).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
79,page_80,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '79', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '6.6.1.2', 'Dose Modification and Toxicity Management of Infusion Reactions Related', 'to Pembrolizumab', 'Pembrolizumab may cause severe or life-threatening infusion reactions, including severe', 'hypersensitivity or anaphylaxis. Signs and symptoms usually develop during or shortly after', 'drug infusion and generally resolve completely within 24 hours of completion of infusion.', 'Dose modification and toxicity management guidelines for pembrolizumab-associated', 'infusion reactions are provided in Table 4.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
80,page_81,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '80', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 4', 'Pembrolizumab Infusion Reaction Dose Modification and Treatment Guidelines', 'NCI CTCAE Grade', 'Treatment', 'Premedication at Subsequent Dosing', 'Grade 1', 'Increase monitoring of vital signs as medically indicated until the participant is', 'None', 'Mild reaction; infusion', 'deemed medically stable in the opinion of the investigator.', 'interruption not indicated;', 'intervention not indicated', 'Grade 2', 'Stop Infusion.', 'Participant may be premedicated 1.5 h', 'Requires therapy or infusion', 'Additional appropriate medical therapy may include but is not limited to the', '( 30 minutes) before infusion of', 'interruption but responds', 'following:', 'pembrolizumab with:', 'promptly to symptomatic', '-', 'IV fluids', '-', 'Diphenhydramine, 50 mg PO (or', 'treatment (eg, antihistamines,', '-', 'Antihistamines', 'equivalent dose of antihistamine).', 'NSAIDs, narcotics, IV fluids);', '-', 'NSAIDs', '-', 'Acetaminophen, 500-1000 mg PO (or', 'prophylactic medications', '-', 'Acetaminophen', 'equivalent dose of analgesic).', 'indicated for <24 h', '-', 'Narcotics', 'Increase monitoring of vital signs as medically indicated until the participant is', 'deemed medically stable in the opinion of the investigator.', 'If symptoms resolve within 1 hour of stopping drug infusion, the infusion may', 'be restarted at 50% of the original infusion rate (eg, from 100 mL/h to', '50 mL/h). Otherwise, dosing will be held until symptoms resolve and the', 'participant should be premedicated for the next scheduled dose.', 'Participants who develop Grade 2 toxicity despite adequate premedication', 'should be permanently discontinued from further pembrolizumab', 'treatment.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
81,page_82,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '81', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'NCI CTCAE Grade', 'Treatment', 'Premedication at Subsequent Dosing', 'Grades 3 or 4', 'Stop Infusion.', 'No subsequent dosing', 'Grade 3:', 'Additional appropriate medical therapy may include but is not limited to:', 'Prolonged (ie, not rapidly', '-', 'Epinephrine**', 'responsive to symptomatic', '-', 'IV fluids', 'medication and/or brief', '-', 'Antihistamines', 'interruption of infusion);', '-', 'NSAIDs', 'recurrence of symptoms', '-', 'Acetaminophen', 'following initial improvement;', '-', 'Narcotics', 'hospitalization indicated for', '-', 'Oxygen', 'other clinical sequelae (eg, renal', '-', 'Pressors', 'impairment, pulmonary', '-', 'Corticosteroids', 'infiltrates)', 'Increase monitoring of vital signs as medically indicated until the participant is', 'Grade 4:', 'deemed medically stable in the opinion of the investigator.', 'Life-threatening; pressor or', 'Hospitalization may be indicated.', 'ventilatory support indicated', '**In cases of anaphylaxis, epinephrine should be used immediately.', 'Participant is permanently discontinued from further pembrolizumab', 'treatment.', 'Abbreviations: CTCAE = Common Terminology Criteria for Adverse Events; IV = intravenous; NCI = National Cancer Institute; NSAIDs = nonsteroidal anti-', 'inflammatory drugs; PO = by mouth.', 'Appropriate resuscitation equipment should be available at the bedside and a physician readily available during the period of drug administration.', 'For further information, please refer to the CTCAE, version 4.0, at http://ctep.cancer.gov', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
82,page_83,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '82', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '6.6.2', 'Other Allowed Dose Interruptions', 'Pembrolizumab may be interrupted for situations other than treatment-related AEs, such as', 'medical/surgical events or logistical reasons not related to study therapy. Participants should', 'be placed back on study therapy within 3 weeks of the scheduled interruption, unless', 'otherwise discussed with the Sponsor. The reason for interruption should be documented in', ""the participant's study record. Scans should not be delayed for delays in cycle treatment."", '6.7', 'Intervention After the End of the Study', 'There is no study-specified intervention after the end of the study.', '6.8', 'Clinical Supplies Disclosure', 'NOTE: As of Amendment 007-06, the study is unblinded and this section is no longer', 'applicable.', '6.9', 'Standard Policies', 'At the close of the study after unblinding, a letter is to be sent by the investigator to those', ""participants who received placebo in the image of the competitor's product to provide the"", 'following advice:', '""You have participated in a study conducted by the Sponsor. This letter is to advise you that', 'you were among those who received a look-alike capsule provided by the Sponsor to', 'resemble the drug lenvatinib as much as possible. You did not receive the active drug', 'lenvatinib as provided by Merck.""', '7', 'DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT', 'WITHDRAWAL', '7.1', 'Discontinuation of Study Intervention', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study and participants stopped receiving those. This section has been updated', 'accordingly.', 'Discontinuation of study intervention does not represent withdrawal from the study.', 'As certain data on clinical events beyond study intervention discontinuation may be', ""important to the study, they must be collected through the participant's last scheduled follow-"", 'up, even if the participant has discontinued study intervention. Therefore, all participants', 'who discontinue study intervention prior to completion of the protocol-specified treatment', 'period will still continue to participate in the study as specified in Sections 1.3 and 8.11.4', 'unless the participant has withdrawn from the study (Section 7.2).', 'Participants may discontinue study intervention at any time for any reason or be discontinued', 'from the study intervention at the discretion of the investigator should any untoward effect', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
83,page_84,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '83', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'occur. In addition, a participant may be discontinued from study intervention by the', 'investigator or the Sponsor if study intervention is inappropriate, the study plan is violated, or', 'for administrative and/or other safety reasons. Specific details regarding procedures to be', 'performed at study intervention discontinuation are provided in Sections 8.1.9 and 8.11.4.', 'A participant must be discontinued from study intervention but continue to be monitored in', 'the study for any of the following reasons:', ""The participant or participant's legally acceptable representative requests to"", 'discontinue study intervention.', 'The participant interrupts study intervention administration for more than 12 weeks,', 'except if agreed to by the Sponsor.', 'The participant has a medical condition or personal circumstance that, in the opinion', 'of the investigator and/or Sponsor, places the participant at unnecessary risk from', 'continued administration of the study intervention.', 'The participant has a confirmed positive serum pregnancy test.', 'The participant has intercurrent illness that prevents further administration of', 'treatment.', 'The participant has any progression or recurrence of any malignancy or occurrence of', 'another malignancy that requires active treatment. Exceptions to malignancy include', 'basal cell carcinoma of the skin, squamous cell carcinoma of the skin, new', 'nonulcerated primary melanoma <1 mm in depth with no nodal involvement, or', 'carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone', 'potentially curative therapy. Exceptions should be discussed with the Sponsor before', 'continuing therapy or remaining in follow-up.', 'The participant has unacceptable AE(s) or toxicities.', 'Any study intervention-related toxicity specified as a reason for permanent', 'discontinuation as defined in the guidelines for dose modification due to AEs in', 'Section 6.6.', '7.1.1', 'Second-course Treatment Phase', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been', 'removed from the study.', '7.2', 'Participant Withdrawal From the Study', ""A participant must be withdrawn from the study if the participant or participant's legally"", 'acceptable representative withdraws consent from the study.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
84,page_85,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '84', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'If a participant withdraws from the study, they will no longer receive study intervention or be', 'followed at scheduled protocol visits.', 'Specific details regarding procedures to be performed at the time of withdrawal from the', 'study are outlined in Section 8.1.9. The procedures to be performed should a participant', 'repeatedly fail to return for scheduled visits and/or if the study site is unable to contact the', 'participant are outlined in Section 7.3.', '7.3', 'Lost to Follow-up', 'If a participant fails to return to the clinic for a required study visit and/or if the site is unable', 'to contact the participant, the following procedures are to be performed:', 'The site must attempt to contact the participant and reschedule the missed visit. If the', 'participant is contacted, the participant should be counseled on the importance of', 'maintaining the protocol-specified visit schedule.', 'The investigator or designee must make every effort to regain contact with the', 'participant at each missed visit (eg, telephone calls and/or a certified letter to the', ""participant's last known mailing address or locally equivalent methods). These"", ""contact attempts should be documented in the participant's medical record."", 'Note: A participant is not considered lost to follow-up until the last scheduled visit for', 'the individual participant. The missing data for the participant will be managed via', 'the prespecified statistical data handling and analysis guidelines.', '8', 'STUDY ASSESSMENTS AND PROCEDURES', 'Study procedures and their timing are summarized in the SoA.', 'Adherence to the study design requirements, including those specified in the SoA, is', 'essential and required for study conduct.', 'The investigator is responsible for ensuring that procedures are conducted by', 'appropriately qualified or trained staff. Delegation of study site personnel', 'responsibilities will be documented in the Investigator Trial File Binder (or', 'equivalent).', 'All study-related medical decisions must be made by an investigator who is a', 'qualified physician.', 'All screening evaluations must be completed and reviewed to confirm that potential', 'participants meet all eligibility criteria. The investigator will maintain a screening log', 'to record details of all participants screened and to confirm eligibility or record', 'reasons for screening failure, as applicable.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
85,page_86,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '85', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', ""Procedures conducted as part of the participant's routine clinical management (eg,"", 'blood count) and obtained before signing of ICF may be utilized for screening or', 'baseline purposes provided the procedure met the protocol-specified criteria and were', 'performed within the time frame defined in the SoA.', 'Additional evaluations/testing may be deemed necessary by the investigator and or', 'the Sponsor for reasons related to participant safety. In some cases, such', 'evaluation/testing may be potentially sensitive in nature (eg, HIV, hepatitis C), and', 'thus local regulations may require that additional informed consent be obtained from', 'the participant. In these cases, such evaluations/testing will be performed in', 'accordance with those regulations.', 'Repeat or unscheduled samples may be taken for safety reasons or for technical issues with', 'the samples.', '8.1', 'Administrative and General Procedures', '8.1.1', 'Informed Consent', 'The investigator or medically qualified designee (consistent with local requirements) must', 'obtain documented informed consent from each potential participant or their legally', 'acceptable representative prior to participating in this clinical study or future biomedical', ""research. If there are changes to the participant's status during the study (eg, health or age of"", 'majority requirements), the investigator or medically qualified designee must ensure the', 'appropriate documented informed consent is in place.', '8.1.1.1', 'General Informed Consent', 'Informed consent given by the participant or their legally acceptable representative must be', 'documented on a consent form. The form must include the trial protocol number, trial', 'protocol title, dated signature, and /agreement of the participant (or his/her legally acceptable', 'representative) and of the person conducting the consent discussion.', 'A copy of the signed and dated informed consent form should be given to the participant (or', 'their legally acceptable representative) before participation in the study.', 'The initial ICF, any subsequent revised written ICF, and any written information provided to', ""the participant must receive the IRB/IEC's approval/favorable opinion in advance of use. The"", 'participant or his/her legally acceptable representative should be informed in a timely manner', ""if new information becomes available that may be relevant to the participant's willingness to"", 'continue participation in the study. The communication of this information will be provided', 'and documented via a revised consent form or addendum to the original consent form that', ""captures the participant's or the participant's legally acceptable representative's dated"", 'signature.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
86,page_87,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '86', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'If the investigator recommends continuation of study intervention beyond disease', 'progression, the participant or his/her legally acceptable representative will be asked to sign', 'consent.', 'Specifics about the study and the study population are to be included in the study informed', 'consent form.', 'Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and', 'Sponsor requirements.', '8.1.2', 'Inclusion/Exclusion Criteria', 'All inclusion and exclusion criteria will be reviewed by the investigator who is a qualified', 'physician to ensure that the participant qualifies for the study.', '8.1.3', 'Participant Identification Card', 'All participants will be given a participant identification card identifying them as participants', 'in a research study. The card will contain study site contact information (including direct', 'telephone numbers) to be used in the event of an emergency. The investigator or qualified', 'designee will provide the participant with a participant identification card immediately after', 'the participant provides documented informed consent. At the time of intervention', 'allocation/randomization, site personnel will add the treatment/randomization number to the', 'participant identification card.', 'The participant identification card also contains contact information for the emergency', 'unblinding call center so that a healthcare provider can obtain information about study', 'intervention in emergency situations where the investigator is not available.', '8.1.4', 'Medical History', '8.1.4.1', 'General Medical History', 'A medical history will be obtained by the investigator or qualified designee.', 'Medical history will include all active conditions, drug allergies, significant medical', 'procedures, and any condition diagnosed within the previous 10 years that are considered to', 'be clinically important by the investigator. Any cancer, other than the cancer under study,', 'will be recorded as medical history, even if diagnosed greater than 10 years before', 'enrollment. Details regarding the cancer under study will be recorded separately and not', 'listed as medical history. The medical history will also include an assessment of smoking', 'history.', '8.1.4.2', 'Oncologic Disease Details', 'The investigator or qualified designee will obtain historic and current details of the', ""participant's cancer under study. This information will include, but is not limited to, date of"", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
87,page_88,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '87', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'diagnosis, stage, histology, locations of primary lesions, and location of metastases, if', 'applicable.', '8.1.5', 'Prior and Concomitant Medications Review', '8.1.5.1', 'Prior Medications', 'The investigator or qualified designee will review prior medication use, including any', 'protocol-specified washout requirement, and record prior medication taken by the participant', 'within 30 days before the first dose of study intervention. Treatment for the disease for which', 'the participant has enrolled in the study will be recorded separately and not listed as a prior', 'medication.', '8.1.5.2', 'Prior Oncologic Treatment', 'The investigator or qualified designee will review and record all treatments for the cancer', 'under study, including systemic and local treatment, vaccinations, radiation, and surgeries.', 'Additional information collected on these treatments will include, but is not limited to,', 'reason for discontinuation, best response, and date of progression after each treatment as', 'applicable.', '8.1.5.3', 'Concomitant Medications', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been', 'removed from the study. This section has been updated accordingly.', 'The investigator or qualified designee will record medication, if any, taken by the participant', 'during the study. Concomitant medications will be recorded for 30 days after the last dose of', 'study intervention (or 90 days if used to treat an SAE).', ""Any new anticancer therapy started after the participant's discontinuation from the treatment"", 'period will be recorded separately. Additional information collected on this treatment will', 'include, but is not limited to, best response and date of progression.', '8.1.6', 'Assignment of Screening Number', 'All consented participants will be given a unique screening number that will be used to', 'identify the participant for all procedures that occur prior to randomization. Each participant', 'will be assigned only 1 screening number. Screening numbers must not be re-used for', 'different participants.', 'Any participant who is screened multiple times will retain the original screening number', 'assigned at the initial screening visit. Specific details on the screening/rescreening visit', 'requirements are provided in Section 8.11.1.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
88,page_89,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '88', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.1.7', 'Assignment of Treatment/Randomization Number', 'All eligible participants will be randomly allocated and will receive a', 'treatment/randomization number. The treatment/randomization number identifies the', 'participant for all procedures occurring after treatment allocation/randomization. Once a', 'treatment/randomization number is assigned to a participant, it can never be re-assigned to', 'another participant.', 'A single participant cannot be assigned more than 1 treatment/randomization number.', '8.1.8', 'Study Intervention Administration', 'Study intervention should begin within 3 days of randomization.', 'Study intervention will be administered by the investigator and/or study staff according to the', 'specifications within the Pharmacy Manual.', '8.1.8.1', 'Timing of Dose Administration', '8.1.8.1.1', 'Lenvatinib/Matching Placebo', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. This section is no longer applicable.', 'Lenvatinib/matching placebo 20 mg (two 10-mg capsules) QD will be taken orally with', 'water (with or without food) in 21-day cycles at approximately the same time each day. On', 'Day 1 of each pembrolizumab cycle, lenvatinib/matching placebo will be administered 0-4', 'hours after pembrolizumab.', 'If a lenvatinib/matching placebo dose is missed and cannot be taken within 12 hours, then', 'that dose should be skipped and the next dose should be taken at the usual time of', 'administration.', 'For nonvisit days, lenvatinib will be taken at home.', 'When a participant attends a study visit, he or she will bring any unused capsules.', '8.1.8.1.2', 'Pembrolizumab', 'Pembrolizumab will be administered as a 30-minute IV infusion on Day 1 of each 21-day', 'cycle. Sites should make every effort to target infusion timing to be as close to 30 minutes as', 'possible. However, given the variability of infusion pumps from site to site, a window of', '-5 minutes and +10 minutes is permitted (ie, infusion time is 30 minutes: -5 - min/+10 min).', 'After Cycle 1 Day 1, pembrolizumab may be administered up to 3 days before or after the', 'scheduled Day 1 of each subsequent cycle for administrative reasons.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
89,page_90,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '89', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Administration of pembrolizumab will be witnessed by the investigator and/or study staff.', 'The total volume of study treatment infused will be compared with the total volume prepared', 'to determine compliance with each dose administered.', '8.1.8.2', 'Lenvatinib Compliance', 'Lenvatinib compliance will be calculated by the Sponsor until discontinuation, based on the', 'drug accountability documented by the site staff and monitored by the Sponsor/designee. The', 'objective is 100% compliance, and investigators and their staff should evaluate compliance at', 'each visit and take appropriate steps to optimize compliance.', '8.1.9', 'Discontinuation and Withdrawal', 'Participants who discontinue study intervention prior to completion of the treatment period', 'should be encouraged to continue to be followed for all remaining study visits as outlined in', 'the SoA and Section 8.11.4.', 'When a participant withdraws from participation in the study, all applicable activities', 'scheduled for the final study visit should be performed (at the time of withdrawal). Any AEs', 'that are present at the time of withdrawal should be followed in accordance with the safety', 'requirements outlined in Section 8.4.3.', '8.1.10', 'Participant Blinding/Unblinding', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study and the study is unblinded. Participants who remain on treatment will', 'receive open-label pembrolizumab monotherapy as per protocol.', '8.1.11', 'Calibration of Equipment', 'The investigator or qualified designee has the responsibility to ensure that any device or', 'instrument used for a clinical evaluation/test during a clinical study that provides information', 'about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably', 'calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible.', 'Documentation of equipment calibration must be retained as source documentation at the', 'study site.', '8.2', 'Efficacy/Immunogenicity Assessments', '8.2.1', 'Tumor Scans and Assessment of Disease', 'NOTE: After amendment 007-06, imaging obtained on study will be submitted to the', 'imaging vendor but these will not be assessed; similarly, verification of PD is no longer', 'needed before treatment discontinuation. This section was updated accordingly.', 'Throughout this section, the term ""scan"" refers to any medical imaging data used to assess', 'tumor burden and may include cross-sectional imaging (such as CT or MRI), or other', 'methods as specified in this protocol.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
90,page_91,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '90', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'The process for scan collection and transmission to the central imaging vendor can be found', 'in the Site Imaging Manual. Tumor scans are strongly preferred to be acquired by computed', 'tomography (CT). For the abdomen and pelvis, contrast-enhanced MRI may be used when', 'CT with iodinated contrast is contraindicated, or when mandated by local practice. The same', 'scan technique regarding modality, ideally the same scanner, and the use of contrast should', 'be used in a participant throughout the study to optimize the reproducibility of the assessment', 'of existing and new tumor burden and improve the accuracy of the assessment of response or', 'progression based on scans. Note: for the purposes of assessing tumor scans, the term', '""investigator"" refers to the local investigator at the site and/or the radiological reviewer', 'located at the site or at an offsite facility.', 'MRI is preferred for brain scans; however, CT scans will be acceptable, if MRI is medically', 'contraindicated.', 'Bone scans may be performed to evaluate bone metastases. Any supplemental scans', 'performed to support a positive or negative bone scan, such as plain X-rays acquired for', 'correlation, should be submitted to the central imaging vendor.', 'Participant eligibility will be determined using local assessment (investigator assessment)', 'based on RECIST 1.1. All scheduled scans for each participant will be submitted to the', 'central imaging vendor. In addition, unscheduled scans to determine PD and scans obtained', 'for other reasons, but demonstrate radiologic progression, are to be submitted to the central', 'imaging vendor.', 'When the investigator identifies disease progression per RECIST 1.1, but elects to implement', 'iRECIST, the investigator will assess for confirmation of progression by iRECIST at', 'subsequent time points. Images should continue to be submitted to the central imaging', 'vendor.', '8.2.1.1', 'Initial Tumor Scans', 'Initial tumor scans at screening must be performed within 28 days before the date of', 'randomization. The site study team must review screening scans to confirm the participant', 'has measurable disease per RECIST 1.1.', 'The screening scans must be submitted to the central imaging vendor for retrospective', 'eligibility review.', 'Tumor scans performed as part of routine clinical management is acceptable for use as', 'screening tumor scans if it is of diagnostic quality and performed within 28 days before the', 'date of randomization and can be assessed by the central imaging vendor.', 'If brain scan is performed to document the stability of existing metastases, an MRI scan', 'should be used if possible. If MRI is medically contraindicated, CT with contrast is an', 'acceptable alternative.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
91,page_92,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '91', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.2.1.2', 'Tumor Scans During the Study', 'The first on-study scan assessment should be performed at 9 weeks (63 days 7 days) from', 'the date of randomization. Subsequent tumor scans should be performed every 9 weeks (63', 'days 7 days) or more frequently if clinically indicated. After 54 weeks, participants who', 'remain on treatment will have scans performed every 12 weeks (84 days 7 days). Scan', 'timing should follow calendar days and should not be adjusted for delays in cycle starts.', 'Scans should continue to be performed until PD is identified by the investigator (unless the', 'investigator elects to continue treatment and follow iRECIST), the start of new anticancer', 'treatment, withdrawal of consent, death, or any other reason for discontinuation of', 'pembrolizumab listed in Section 7.1 is met, whichever occurs first. All supplemental scans', 'must be submitted to the central imaging vendor.', 'OR should be confirmed by a repeat scan assessment. Tumor scans to confirm PR or CR', 'should be performed at least 4 weeks after the first indication of a response is observed.', 'Participants will then return to regular scheduled scans, starting with the next scheduled time', 'point. Participants who receive additional scans for confirmation do not need to undergo the', 'next scheduled tumor scan if it is less than 4 weeks later; tumor scans may resume at the', 'subsequent scheduled time point. Note: Response does not need to be verified in real time by', 'the central imaging vendor.', 'Per iRECIST (Section 8.2.1.6), PD should be confirmed by the site 4 to 8 weeks after site-', 'assessed first radiologic evidence of PD in clinically stable participants. Participants who', 'have unconfirmed PD may continue on treatment at the discretion of the investigator until PD', 'is confirmed by the site, provided they have met the conditions detailed in Section 8.2.1.6.', 'Participants who receive confirmatory scans do not need to undergo the next scheduled', 'tumor scan if it is less than 4 weeks later; tumor scans may resume at the subsequent', 'scheduled time point, if clinically stable. Participants who have confirmed PD by iRECIST,', 'as assessed by the site, will discontinue study intervention. Exceptions are detailed in', 'Section 8.2.1.6.', '8.2.1.3', 'End of Treatment and Follow-up Tumor Scans', 'For participants who discontinue study intervention, tumor scans should be performed at the', 'time of treatment discontinuation (+4-week window). If previous scans were obtained within', '4 weeks before the date of discontinuation, then scans at treatment discontinuation is not', 'mandatory. For participants who discontinue study intervention because of documented PD,', 'this is the final required tumor scan.', 'After amendment 007-06, imaging obtained on study will be submitted to the imaging', 'vendor but these will not be assessed; similarly, verification of PD is no longer needed', 'before treatment discontinuation.', '8.2.1.4', 'Second-course Treatment Tumor Scans', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been', 'removed from this study. This section is no longer applicable.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
92,page_93,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '92', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.2.1.5', 'RECIST 1.1 Assessment of Disease', 'RECIST 1.1 will be used by BICR as the primary measure for assessment of tumor response', 'and date of PD, and as a basis for all protocol guidelines related to disease status (eg,', 'discontinuation of study intervention). Although RECIST 1.1 references a maximum of', '5 target lesions in total and 2 per organ, this protocol follows a maximum of 10 target lesions', 'and a maximum of 5 target lesions per organ, if clinically relevant to enable a broader', 'sampling of tumor burden.', 'If disease progression has been assessed by the investigator, the process continues as follows:', 'If participant is clinically stable, continue study intervention per protocol', '-', 'Resume imaging per protocol schedule (>4 weeks to next scan)', '-', 'Send scans to imaging vendor', '-', 'Continue local assessment', '-', 'Do not change investigator assessment of progression', '-', 'If subsequent scan(s) indicate progression, submit scan(s) to imaging vendor', 'If the participant is not clinically stable, best medical practice is to be applied', 'Before stopping study intervention or imaging or starting new anticancer therapy in a', 'participant who is clinically stable, communication with the Sponsor is required.', 'Investigator judgment will determine action', 'Note: the reconsent addendum may be signed any time after investigator-assessed', 'progression is identified, but must be signed prior to starting study intervention.', '-', 'Obtain scans locally per original protocol schedule', '-', 'Do not send scans to imaging vendor', 'For the purpose of this decision process, lack of clinical stability is defined as:', 'Unacceptable toxicity', 'Clinical signs or symptoms indicating clinically significant disease progression', 'Decline in performance status', 'Rapid disease progression or threat to vital organs or critical anatomical sites (eg,', 'CNS metastasis, respiratory failure due to tumor compression, spinal cord', 'compression) requiring urgent alternative medical intervention', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
93,page_94,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '93', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.2.1.6', 'iRECIST Assessment of Disease', 'NOTE: After amendment 007-06, imaging obtained on study will be submitted to the', 'imaging vendor but these will not be assessed, verification of PD is no longer needed', 'before treatment discontinuation, and posttreatment imaging is no longer required.', 'This section has been updated accordingly.', 'iRECIST is based on RECIST 1.1 but adapted to account for the unique tumor response seen', 'with immunotherapeutic drugs. iRECIST will be used by the investigator to assess tumor', 'response and progression and make treatment decisions [Seymour, L., et al 2017]. When', 'clinically stable, participants will continue study intervention beyond RECIST 1.1 PD with', 'continuous assessment of response according to the rules outlined in Appendix 6. iRECIST', 'reflects some participants can have a transient tumor flare after the start of immunotherapy,', 'then experience subsequent disease response. This data will be captured in the clinical', 'database.', 'Clinical stability is defined as the following:', 'Absence of symptoms and signs indicating clinically significant PD', 'No decline in ECOG performance status', 'No requirements for intensified management, including increased analgesia,', 'radiation, or other palliative care', 'Any participant deemed clinically unstable should be discontinued from study intervention at', 'site-assessed first radiologic evidence of PD and is not required to have repeat tumor scans', 'for confirmation of PD by iRECIST.', 'If the investigator decides to continue treatment, the participant may continue to receive', 'study intervention and the tumor assessment should be repeated 4 to 8 weeks later to confirm', 'PD by iRECIST, per investigator assessment. Scans should continue to be sent in to the', 'central imaging vendor', 'If repeat scans do not confirm PD per iRECIST, as assessed by the investigator, and the', 'participant continues to be clinically stable, study intervention may continue and follow the', 'regular scan schedule. If PD is confirmed, participants will be discontinued from study', 'intervention.', 'If a participant has iRECIST-confirmed radiographic progression (iCPD) as defined in', 'Appendix 6, study intervention should be discontinued; however, if the participant is', 'achieving a clinically meaningful benefit, an exception to continue study intervention may be', 'considered following consultation with the Sponsor. In this case, if study intervention is', 'continued, tumor scans should continue to be performed following the intervals as outlined in', 'Section 1 and submitted to the central imaging vendor.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
94,page_95,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '94', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'A description of the adaptations and iRECIST process is provided in Appendix 6, with', 'additional details in the iRECIST publication [Seymour, L., et al 2017]. A summary of scans', 'and treatment requirements after first radiologic evidence of progression is provided in', 'Table 5.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
95,page_96,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '95', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 5 Summary of Imaging and Treatment Requirements After First Radiologic Evidence of Progression', 'Clinically Stable', 'Clinically Unstable', 'Imaging', 'Treatment', 'Imaging', 'Treatment', 'First radiologic evidence of PD', 'Submit the imaging to BICR', 'May continue study intervention at', 'No additional imaging', 'Discontinue treatment', 'by RECIST 1.1 per investigator', 'for verification.', 'the discretion of the investigator', 'required.', 'assessment', 'Repeat imaging at 4 to', ""and after obtaining participant's"", '8 weeks to confirm PD per', 'consent.', 'iRECIST.', 'Repeat tumor imaging', 'No additional imaging', 'Discontinue treatment (exception is', 'No additional imaging', 'Not applicable', 'confirms PD (iCPD) by', 'required.', 'possible upon consultation with', 'required.', 'iRECIST per investigator', 'Sponsor).', 'assessment', 'Repeat tumor imaging shows', 'Repeat imaging at 4 to', 'Continue study intervention at the', 'No additional imaging', 'Discontinue treatment', 'iUPD by iRECIST per', '8 weeks to confirm PD.', ""investigator's discretion."", 'required.', 'investigator assessment', 'Repeat tumor imaging shows', 'Continue regularly scheduled', 'Continue study intervention at the', 'No additional imaging', 'Discontinue treatment', 'iSD, iPR, or iCR by iRECIST', 'imaging assessments.', ""investigator's discretion."", 'required.', 'per investigator assessment.', 'Abbreviations: iCPD = IRECIST-confirmed progressive disease; iCR = iRECIST complete response; iRECIST = adjusted Response Evaluation Criteria in Solid Tumors 1.1', 'for', 'immune-based therapeutics; iSD = iRECIST stable disease; iUPD = iRECIST unconfirmed progressive disease; PD = progressive disease; RECIST 1.1 = Response Evaluation', 'Criteria in Solid Tumors, version 1.1; VOP = verification of progression.', 'Note: If PD has been centrally verified, further management is performed by the site, based on iRECIST. Any further imaging should still be submitted to the central imaging', 'vendor, but no rapid review will occur. If RECIST 1.1 PD has not been centrally verified, ideally the site should continue treatment. Whether or not treatment continues, imaging', 'should be collected and submitted to the central imaging vendor with VOP request until RECIST 1.1 PD is verified by BICR.', 'As of amendment 007-06, imaging obtained on study will be submitted to the imaging vendor but these will not be assessed for verification of progression. This table was', 'updated accordingly.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
96,page_97,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '96', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.2.1.7', 'Tumor Tissue Collection for PD-L1 Status', 'Participation in this study will be dependent upon supplying tumor tissue for PD-L1 testing', 'from locations not radiated before biopsy; formalin-fixed specimens after the participant has', 'been diagnosed with metastatic disease will be preferred for determination of PD-L1 status', 'before randomization. Biopsies obtained before receipt of fadjuvant/neoadjuvant', 'chemotherapy will be permitted if recent biopsy is not feasible.', 'All participants should submit either a newly obtained core or excisional biopsy or archival', 'tissue (fine-needle aspiration is not adequate for both archival and new tissue samples) to a', 'central laboratory for characterization of PD-L1 status before treatment allocation.', 'A fine-needle aspirate, frozen sample, plastic-embedded sample, cell block, clot, bone, bone', 'marrow, cytologic specimen, decalcified or formalin-fixed sample that was frozen at any', 'point will not be acceptable for analysis.', 'Note: Submission of formalin-fixed paraffin-embedded tumor tissue sample blocks are', 'preferred; if submitting unstained slides, the slides should be freshly cut and submitted to the', 'testing laboratory within 14 days from the site slide section date; otherwise, a new specimen', 'will be requested.', 'If the sample is determined to be nonevaluable before testing by the central laboratory, a new', 'sample should be submitted if available.', 'The central vendor PD-L1 TPS results of participants will be blinded to the investigator. The', 'Sponsor acknowledges that because of the commercial availability of PD-L1 testing assays, it', ""is possible that the investigator may know a participant's TPS before screening. This risk is"", 'seen as acceptable, as the treatment interventions are hypothesized to provide benefit', 'regardless of TPS.', '8.2.2', 'Patient-reported Outcomes', 'NOTE: As of Amendment 007-06, PROs will no longer be collected. This section is no', 'longer applicable.', 'The EORTC QLQ-C30, EORTC QLQ-LC13, and EQ-5D-5L questionnaires will be', 'administered by trained site personnel and completed electronically by participants in the', 'following order: EORTC QLQ-C30, EORTC QLQ-LC13, and lastly EQ-5D-5L. The', 'questionnaires should be administered before dosing at every cycle through Cycle 17, then', 'every other cycle through Cycle 35 (eg, Cycles 1-17, 19, 21, 23, 25, 27, 29, 31, 33, and 35),', 'at the Treatment Discontinuation Visit, and at the 30-day Safety Follow-up Visit.', 'If the Treatment Discontinuation Visit occurs 30 days from the last dose of study', 'intervention, at the time of the mandatory Safety Follow-up Visit, the electronic', 'patient-reported outcomes (ePROs) do not need to be repeated.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
97,page_98,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '97', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'It is best practice and strongly recommended that the ePROs are administered to randomized', 'participants before drug administration, AE evaluation, and disease status notification. If the', 'participant does not complete the ePROs at a scheduled time point, the MISS MODE form', 'must be completed to capture the reason the assessment was not performed.', '8.3', 'Safety Assessments', 'Details regarding specific safety procedures/assessments to be performed in this study are', 'provided. Planned time points for all safety assessments are provided in the SoA.', '8.3.1', 'Physical Examinations', 'The investigator or qualified designee will perform a complete physical examination during', 'the screening period. Clinically significant abnormal findings should be recorded as medical', 'history. The time points for full physical examination are described in the SoA (Section 1.3).', 'After the first dose of study treatment, new clinically significant abnormal findings should be', 'recorded as AEs.', 'For cycles that do not require a full physical examination per the SoA (Section 1.3), the', 'investigator or qualified designee will perform a directed physical examination as clinically', 'indicated before study treatment administration. New clinically significant abnormal findings', 'should be recorded as AEs.', 'Investigators should pay special attention to clinical signs related to previous serious', 'illnesses.', '8.3.2', 'Vital Signs', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. Repeat BP measurements for monitoring participants receiving', 'lenvatinib are no longer required. This section has been updated accordingly.', 'The investigator or qualified designee will take vital signs at screening, before the', 'administration of each dose of study treatment and during the follow-up period, as specified', 'in the SoA (Section 1.3). Vital signs include temperature, heart rate, respiratory rate, weight,', 'and blood pressure. Height will be measured at Visit 1 only.', '8.3.3', 'Electrocardiograms', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. Additional ECG measurements for monitoring participants receiving', 'lenvatinib are no longer required. This section has been updated accordingly.', 'Electrocardiograms (ECGs) will be obtained as designated in the SoA (Section 1.3).', 'Complete, standardized, 12-lead ECG recordings that permit all 12 leads to be displayed on a', 'single page with an accompanying lead II rhythm strip below the customary 3 X 4 lead', 'format are to be used. In addition to a rhythm strip, a minimum of 3 full complexes should be', 'recorded from each lead simultaneously. Participants must be in the recumbent position for a', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
98,page_99,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '98', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'period of 5 minutes prior to the ECG. The Fridericia correction method for calculating QTc', 'will be used.', 'An ECG abnormality may meet the criteria of an AE as described in this protocol (see', 'Appendix 3) and the eCRF Entry Guidelines. In these instances, the AE corresponding to the', 'ECG abnormality will be recorded on the appropriate case report form (CRF).', '8.3.4 Echocardiograms or Multigated Acquisition Scans', 'A MUGA scan (using a technetium-based tracer) or an ECHO will be performed to assess', 'LVEF as designated in the SoA (Section 1.3). Additional assessments may be performed as', 'clinically indicated.', ""MUGA scans or ECHOs should be performed locally in accordance with the institution's"", 'standard practice. MUGA scans are the preferred modality. However, whichever modality is', 'used for an individual participant at baseline should be repeated for all subsequent LVEF', 'assessments for that participant.', 'LVEF, as assessed by the institution, will be entered in the electronic case report form', '(eCRF). Investigator assessment will be based on institutional reports.', '8.3.5', 'Clinical Safety Laboratory Assessments', '8.3.5.1', 'Laboratory Safety Evaluations (Hematology, Chemistry and Urinalysis)', 'Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to the', 'SoA for the timing and frequency.', 'The investigator or medically qualified designee (consistent with local requirements)', 'must review the laboratory report, document this review, and record any clinically', 'relevant changes occurring during the study in the AE section of the case report form', '(CRF). The laboratory reports must be filed with the source documents. Clinically', 'significant abnormal laboratory findings are those which are not associated with the', 'underlying disease, unless judged by the investigator to be more severe than expected', ""for the participant's condition."", 'CBC with differential and clinical chemistry results must be reviewed before', 'administration of study intervention. Electrolytes such as potassium, calcium, and', 'magnesium should be monitored and abnormalities, when considered clinically', 'significant, should be corrected in all participants before starting study intervention.', 'All protocol-required laboratory assessments, as defined in Appendix 2, must be', 'conducted in accordance with the laboratory manual and the SoA.', 'If laboratory values from nonprotocol specified laboratory assessments performed at', ""the institution's local laboratory require a change in study participant management or"", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
99,page_100,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '99', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'are considered clinically significant by the investigator (eg, SAE or AE or dose', 'modification), then the results must be recorded in the appropriate CRF (eg, SLAB).', 'For any laboratory tests with values considered clinically significantly abnormal', 'during participation in the study or within 30 days after the last dose of study', 'intervention, every attempt should be made to perform repeat assessments until the', 'values return to normal or baseline or if a new baseline is established as determined', 'by the investigator.', '8.3.5.2 Pregnancy Test', 'All women who are being considered for participation in the study, and who are not', 'surgically sterilized or postmenopausal, must be tested for pregnancy within 24 hours of the', 'first dose of study intervention. If a urine test is positive or not evaluable, a serum test will be', 'required. Participants must be excluded/discontinued from the study in the event of a positive', 'test result. Repeated pregnancy test (such as monthly testing) may be conducted if required', 'by local regulations.', '8.4', 'Adverse Events (AEs), Serious Adverse Events (SAEs), and Other Reportable', 'Safety Events', 'The definitions of an AE or SAE, as well as the method of recording, evaluating, and', 'assessing causality of AE and SAE and the procedures for completing and transmitting AE,', 'SAE, and other reportable safety event reports can be found in Appendix 3.', 'Progression of the cancer under study is not considered an AE as described in Section 8.4.6', 'and Appendix 3.', 'Adverse events, SAEs, and other reportable safety events will be reported by the participant', ""(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized"", 'representative).', 'The investigator and any designees are responsible for detecting, documenting, and reporting', 'events that meet the definition of an AE or SAE as well as other reportable safety events.', 'Investigators remain responsible for following up AEs, SAEs, and other reportable safety', 'events for outcome according to Section 8.4.3.', 'The investigator, who is a qualified physician, will assess events that meet the definition of', 'an AE or SAE as well as other reportable safety events with respect to seriousness,', 'intensity/toxicity and causality.', '8.4.1', 'Time Period and Frequency for Collecting AE, SAE, and Other Reportable', 'Safety Event Information', 'All AEs, SAEs, and other reportable safety events that occur after the participant provides', 'documented informed consent but before intervention allocation/randomization must be', 'reported by the investigator if the participant is receiving placebo run-in or other run-in', 'treatment, if the event cause the participant to be excluded from the study, or is the result of a', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
100,page_101,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '100', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'protocol-specified intervention, including but not limited to washout or discontinuation of', 'usual therapy, diet, or a procedure.', 'All AEs from the time of intervention allocation/randomization through 30 days', 'following cessation of study intervention must be reported by the investigator.', 'All AEs meeting serious criteria, from the time of intervention', 'allocation/randomization through 90 days following cessation of study intervention or', '30 days following cessation of study intervention if the participant initiates new', 'anticancer therapy, whichever is earlier, must be reported by the investigator.', 'All pregnancies and exposure during breastfeeding, from the time of treatment', 'allocation/randomization through 120 days following pembrolizumab/placebo or 30', 'days following cessation of lenvatinib/placebo, whichever occurs last, must be', 'reported by the investigator. If the participant initiates new anticancer therapy', 'following discontinuation of study intervention, the time period for reporting', 'pregnancies and exposure during breastfeeding is reduced to 30 days following', 'cessation of study intervention.', 'Exception: A positive pregnancy test at the time of initial screening is not a reportable', 'event unless the participant has received study intervention.', 'Additionally, any SAE brought to the attention of an investigator at any time outside', 'the time period specified above must be reported immediately to the Sponsor if the', 'event is considered related to study intervention.', 'Investigators are not obligated to actively seek AEs or SAEs or other reportable safety events', 'in former study participants. However, if the investigator learns of any SAE, including a', 'death, at any time after a participant has been discharged from the study, and he/she', 'considers the event to be reasonably related to the study intervention or study participation,', 'the investigator must promptly notify the Sponsor.', 'All initial and follow-up AEs, SAEs, and other reportable safety events will be recorded and', 'reported to the Sponsor or designee within the time frames as indicated in Table 6.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
101,page_102,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '101', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 6 Reporting Time Periods and Time Frames for Adverse Events and Other', 'Reportable Safety Events', 'Reporting Time', 'Reporting Time', 'Time Frame to', 'Period:', 'Period:', 'Reporting Time Period:', 'Report Event', 'Randomization/', 'Type of Event', 'Consent to', 'After the Protocol-', 'and Follow-up', 'Randomization/', 'Allocation through', 'specified Follow-up Period', 'Information to', 'Protocol-specified', 'Allocation', 'Sponsor:', 'Follow-up Period', 'Nonserious Adverse', 'Report if:', 'Report all', 'Not required', 'Per data entry', 'Event (NSAE)', '- due to protocol-', 'guidelines', 'specified', 'intervention', '- causes exclusion', '- participant is', 'receiving placebo', 'run-in or other run-', 'in treatment', 'Serious Adverse Event', 'Report if:', 'Report all SAEs,', 'Report if:', 'Within 24', '(SAE) including Cancer', '- due to protocol-', 'cancer, overdose', '- drug/vaccine related.', 'hours of', 'and Overdose', 'specified', 'associated with', '(Follow ongoing to', 'learning of', 'intervention', 'pembrolizumab and', 'outcome)', 'event', '- causes exclusion', 'overdose associated', '- participant is', 'with lenvatinib with', 'receiving placebo', 'an AE', 'run-in or other run-', 'in treatment', 'Pregnancy/', 'Report if:', 'Report all', 'Previously reported -', 'Within 24', 'Lactation Exposure', '- participant has', 'Follow to', 'hours of', 'been exposed to any', 'completion/termination;', 'learning of', 'protocol-specified', 'report outcome', 'event', 'intervention (eg,', 'procedure, washout', 'or run-in treatment', 'including placebo', 'run-in)', 'Exception: A', 'positive pregnancy', 'test at the time of', 'initial screening is', 'not a reportable', 'event.', 'Event of Clinical Interest', 'Report if:', 'Report', 'Not required', 'Within 24', '(require regulatory', '- due to intervention', '- potential drug-', 'hours of', 'reporting)', '- causes exclusion', 'induced liver injury', 'learning of', '(DILI)', 'event', '- require regulatory', 'reporting', 'Event of Clinical Interest', 'Report if:', 'Report', 'Not required', 'Within 5', '(do not require regulatory', '- due to intervention', '- non-DILI ECIs', 'calendar days', 'reporting)', '- causes exclusion', 'and those not', 'of learning of', 'requiring regulatory', 'event', 'reporting', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
102,page_103,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '102', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.4.2', 'Method of Detecting AEs, SAEs, and Other Reportable Safety Events', 'Care will be taken not to introduce bias when detecting AEs and/or SAEs and other', 'reportable safety events. Open-ended and nonleading verbal questioning of the participant is', 'the preferred method to inquire about AE occurrence.', '8.4.3', 'Follow-up of AE, SAE, and Other Reportable Safety Event Information', 'After the initial AE/SAE report, the investigator is required to proactively follow each', 'participant at subsequent visits/contacts. All AEs, SAEs, and other reportable safety events', 'including pregnancy and exposure during breastfeeding, events of clinical interest (ECIs),', 'cancer, and overdose will be followed until resolution, stabilization, until the event is', 'otherwise explained, or the participant is lost to follow-up (as defined in Section 7.3). In', 'addition, the investigator will make every attempt to follow all nonserious AEs that occur in', 'randomized participants for outcome. Further information on follow-up procedures is given', 'in Appendix 3.', '8.4.4', 'Regulatory Reporting Requirements for SAE', 'Prompt notification (within 24 hours) by the investigator to the Sponsor of SAE is essential', 'so that legal obligations and ethical responsibilities towards the safety of participants and the', 'safety of a study intervention under clinical investigation are met.', 'The Sponsor has a legal responsibility to notify both the local regulatory authority and other', 'regulatory agencies about the safety of a study intervention under clinical investigation. The', 'Sponsor will comply with country-specific regulatory requirements and global laws and', 'regulations relating to safety reporting to regulatory authorities, IRB/IECs, and investigators.', 'Investigator safety reports must be prepared for suspected unexpected serious adverse', 'reactions (SUSARs) according to local regulatory requirements and Sponsor policy and', 'forwarded to investigators as necessary.', 'An investigator who receives an investigator safety report describing an SAE or other', 'specific safety information (eg, summary or listing of SAE) from the Sponsor will file it', 'along with the IB and will notify the IRB/IEC, if appropriate according to local requirements.', '8.4.5', 'Pregnancy and Exposure During Breastfeeding', 'Although pregnancy and infant exposure during breastfeeding are not considered AEs, any', 'pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to', 'the investigator or their designee) that occurs during the study are reportable to the Sponsor.', 'All reported pregnancies must be followed to the completion/termination of the pregnancy.', 'Pregnancy outcomes of spontaneous abortion, missed abortion, benign hydatidiform mole,', 'blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as', 'serious events (Important Medical Events). If the pregnancy continues to term, the outcome', '(health of infant) must also be reported.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
103,page_104,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '103', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.4.6', 'Disease-related Events and/or Disease-related Outcomes Not Qualifying as', 'AEs or SAEs', 'Efficacy endpoints as outlined in this section will not be reported to the Sponsor, as described', 'in Section 8.4.1.', 'Specifically, the suspected/actual events covered in this exception include any event that is', 'progression of the cancer under study.', 'The Sponsor will monitor unblinded aggregated efficacy endpoint events and safety data to', 'ensure the safety of the participants in the study.', '8.4.7', 'Events of Clinical Interest (ECIs)', 'Selected nonserious and SAEs are also known as ECIs and must be reported to the Sponsor.', 'Events of clinical interest for this study include:', '1.', 'An overdose of pembrolizumab, as defined in Section 8.5, that is not associated with', 'clinical symptoms or abnormal laboratory results.', '2.', 'Any dose over the prescribed dose of lenvatinib associated with an AE.', '3.', 'An elevated AST or ALT lab value that is greater than or equal to 3X the upper limit', 'of normal and an elevated total bilirubin lab value that is greater than or equal to 2X', 'the upper limit of normal and, at the same time, an alkaline phosphatase lab value that', 'is less than 2X the upper limit of normal, as determined by way of protocol-specified', 'laboratory testing or unscheduled laboratory testing.*', '*Note: These criteria are based upon available regulatory guidance documents. The', 'purpose of the criteria is to specify a threshold of abnormal hepatic tests that may', 'require an additional evaluation for an underlying etiology. The study site guidance', 'for assessment and follow-up of these criteria can be found in the Investigator Study', 'File Binder (or equivalent).', '8.5', 'Treatment of Overdose', 'NOTE: After amendment 007-06, lenvatinib and matching placebo were discontinued.', 'This section was left unchanged for reference.', 'For purposes of this study, an overdose will be defined as any dose exceeding the prescribed', 'dose as follows:', 'Pembrolizumab: >5 times the protocol-specified dose.', 'Lenvatinib: any dose above the protocol-specified dose if associated with an adverse', 'event.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
104,page_105,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '104', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'There is no specific antidote for an overdose of lenvatinib. Due to its high degree of plasma', 'protein binding, lenvatinib is not expected to be dialyzable. Adverse reactions in patients', 'receiving single doses of lenvatinib as high as 40 mg were similar to those in clinical studies', 'at the recommended dose for differentiated thyroid cancer and RCC.', 'No specific information is available on the treatment of overdose of pembrolizumab or', 'lenvatinib. In the event of overdose, the participant should be observed closely for signs of', 'toxicity. Appropriate supportive treatment should be provided if clinically indicated.', 'All reports of pembrolizumab overdose with and without an AE and all reports of lenvatinib', 'overdose with an AE must be reported by the investigator within 24 hours to the Sponsor', 'either by electronic media or paper.', 'Reports of pembrolizumab overdose without any associated clinical symptoms or abnormal', 'laboratory results, should be reported using the terminology ""accidental or intentional', 'overdose without adverse effect.""', '8.6', 'Pharmacokinetics', 'As of Protocol Amendment 05, the Sponsor has determined that there is sufficient', 'pembrolizumab/lenvatinib PK data in NSCLC participants. Consequently, no further PK', 'samples for pembrolizumab and lenvatinib or ADA samples for pembrolizumab will be', 'collected.', '8.7', 'Pharmacodynamics', 'Pharmacodynamic parameters will not be evaluated in this study.', '8.8', 'Planned Genetic Analysis Sample Collection', 'Samples are to be collected for planned analysis of associations between genetic variants in', 'germline/tumor DNA and drug response. If a documented law or regulation prohibits (or', 'local IRB/IEC does not approve) sample collection for these purposes, then such samples are', 'not be collected at the corresponding sites.', '8.9', 'Biomarkers', 'To identify novel biomarkers, the following biospecimens to support exploratory analyses of', 'cellular components (eg, protein, RNA, DNA, metabolites) and other circulating molecules', 'will be collected from all participants as specified in the SoA:', 'Blood for genetic analysis', 'Newly obtained/archival tissue sample for PD-L1 analysis', 'Sample collection, storage, and shipment instructions for the exploratory biomarker', 'specimens will be provided in the laboratory manual.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
105,page_106,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '105', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.10', 'Medical Resource Utilization and Health Economics', 'All-cause hospitalizations and emergency room visits must be reported in the eCRF, from the', 'time of treatment randomization through 90 days after cessation of study intervention, or', '30 days after cessation of study intervention, if the participant initiates new anticancer', 'therapy, whichever is earlier.', '8.11', 'Visit Requirements', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been', 'removed from the study. The following subsections have been updated accordingly.', 'Visit requirements are outlined in the SoA (Section 1.3). Specific procedure-related details', 'are provided in Section 8.', 'Unscheduled visits are permitted at any time during the course of the study.', '8.11.1', 'Screening', 'Documented informed consent must be provided before performing any protocol-specific', 'procedure. Results of a test performed before the participant signs the ICF as part of routine', 'clinical management are acceptable in lieu of a screening test if performed within the', 'specified time frame. Screening procedures are to be completed within 28 days before the', 'first dose of study intervention except for the following:', 'Laboratory tests are to be performed per the SoA (Section 1.3).', 'Evaluation of ECOG is to be performed at screening, within 7 days before Cycle 1', 'but before randomization.', 'For WOCBP, a urine or serum pregnancy test will be performed within 24 hours', 'before the first dose of study intervention. If urine pregnancy results cannot be', 'confirmed as negative, a serum pregnancy test will be required (performed by the', 'local study site laboratory).', 'Participants may be rescreened after initially failing to meet the inclusion/exclusion criteria.', 'Results from assessments during the initial screening period are acceptable in lieu of a repeat', 'screening test if performed within the specified time frame and the corresponding', 'inclusion/exclusion criteria are met. Participants who are rescreened will retain their original', 'screening number.', '8.11.2', 'Initial Treatment Phase', 'Visit requirements are outlined in the SoA (Section 1.3). Specific procedure-related details', 'are provided in Section 8.1.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
106,page_107,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '106', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '8.11.3', 'Second-course Treatment Phase', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been', 'removed from the study.', '8.11.4', 'Discontinued Participants Continuing to be Monitored in the Study', 'The Discontinuation Visit should occur at the time study intervention is discontinued for any', 'reason. If the Discontinuation Visit occurs 30 days from the last dose of study intervention, at', 'the time of the mandatory Safety Follow-up Visit, the Discontinuation Visit procedures and', 'any additional safety follow-up procedures should be performed.', 'Visit requirements are outlined in the SoA. Additional details regarding participant', 'withdrawal and discontinuation are presented in Section 8.1.9.', '8.11.5', 'Poststudy', '8.11.5.1', 'Safety Follow-up Visit', 'The mandatory Safety Follow-up Visits should be conducted approximately 30 days after the', 'last dose of study intervention or before the initiation of a new anticancer treatment,', 'whichever comes first.', '8.11.5.2', 'Efficacy Follow-up Visits', 'NOTE: After amendment 007-06, imaging obtained on study will be submitted to the', 'imaging vendor but these will not be assessed, verification of PD is no longer needed', 'before treatment discontinuation, and posttreatment imaging is no longer required.', 'Participants who complete the protocol-required cycles of study intervention or who', 'discontinue study intervention for a reason other than PD will move into Efficacy Follow-up', 'Phase and should be assessed as outlined in the SoA (Section 1.3) to monitor disease status.', 'Every effort should be made to collect information regarding disease status until the start of', 'new anticancer therapy, PD, death, or end of study. Information regarding poststudy', 'anticancer treatment will be collected if new treatment is initiated. Participants who', 'completed all efficacy assessments and/or will not have further efficacy assessments must', 'enter Survival Follow-up Phase.', '8.11.5.3', 'Survival Follow-up Assessments', 'Participants who experience confirmed PD or start a new anticancer therapy will move into', 'the Survival Follow-Up Phase and should be contacted by telephone approximately every', '12 weeks (or more often as required) to assess survival status until death, withdrawal of', 'consent, or the end of the study, whichever occurs first. Participants may be contacted for', 'survival status at any time during the course of the study.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
107,page_108,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '107', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9', 'STATISTICAL ANALYSIS PLAN', 'NOTE: Data from an interim safety and futility eDMC for LEAP-007 (data cutoff: 19-', 'MAY-2021) indicated that the study met the prespecified nonbinding futility criteria for', 'os for the combination of lenvatinib plus pembrolizumab compared with placebo plus', 'pembrolizumab. This futility analysis was requested at a previous eDMC meeting and', 'conducted as described in the sSAP. Based upon these data and the recommendation of', 'the eDMC, Amendment 007-06 was implemented to unblind the study and remove', 'lenvatinib and matching placebo from the treatment arms. The prespecified interim', 'and final analyses of the study described in the statistical analysis plan (SAP) will not be', 'performed. Selected analyses of safety and ePRO endpoints will be performed at the', 'end of the study; there will be no further analyses of efficacy endpoints.', 'This section outlines the statistical analysis strategy and procedures for the study. As of', 'Amendment 007-06, the study has been unblinded. Changes made to primary and/or key', 'secondary hypotheses, or the statistical methods related to those hypotheses, that occurred', 'prior to study unblinding were documented in previous protocol amendment(s) (consistent', 'with International Council for Harmonisation [ICH] of Technical Requirements for', 'Pharmaceuticals for Human Use Guideline E9). Changes to exploratory or other', 'nonconfirmatory analyses made after the protocol has been finalized, but before', 'unblinding/final database lock, will be documented in a supplemental statistical analysis plan', '(sSAP) and referenced in the clinical study report (CSR) for the study. Post hoc exploratory', 'analyses will be clearly identified in the CSR. Separate analysis plans (ie, separate', 'documents from the sSAP) will be developed to detail PK and biomarker analyses. The', 'ePRO analysis plan will be included in the sSAP.', '9.1', 'Statistical Analysis Plan Summary', 'Key elements of the SAP are summarized below. The comprehensive plan is provided in', 'Sections 9.2 through 9.12. As of Amendment 007-06, the prespecified interim and final', 'analyses of the study described in SAP will not be performed. Selected analyses of', 'safety and ePRO endpoints will be performed at the end of the study; there will be no', 'further analyses of efficacy endpoints. The SAP summary has been updated', 'accordingly.', 'Study Design Overview', 'Phase 3 study of pembrolizumab plus lenvatinib VS pembrolizumab plus placebo', 'for 1L treatment of metastatic NSCLC in participants whose tumors express', 'PD-L1 (TPS 21%)', 'Treatment Assignment', 'Approximately 620 participants will be randomized in a 1:1 ratio between', '2 treatment arms: (1) pembrolizumab + lenvatinib and (2) pembrolizumab +', 'placebo.', 'Stratification factors are as follows:', 'Geographic region (East Asia VS non-East Asia)', 'ECOG PS (0 VS 1)', 'TPS (1%-49% vs >50%)', 'As of Amendment 007-06, the study is unblinded and all ongoing participants', 'will continue treatment with open-label pembrolizumab monotherapy.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
108,page_109,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '108', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Analysis Populations', 'Efficacy: Intention-to-Treat (ITT)', 'Safety: All Participants as Treated (APaT)', 'Primary Endpoints', 'PFS per RECIST 1.1 based on BICR', 'os', 'Secondary Endpoints', 'OR per RECIST 1.1 based on BICR', 'Safety and tolerability', 'Change from baseline in Global health status/QoL, cough, chest pain, dyspnea', 'and physical functioning scores', 'Time to True Deterioration (TTD) in global health status/QoL, cough, chest', 'pain, dyspnea, and physical functioning', 'TTD in the composite endpoint of cough, chest pain, or dyspnea items', 'Statistical Methods for', 'As of Amendment 007-06, the prespecified interim and final analyses of the', 'Key Efficacy Analyses', 'study will not be performed. There will be no further analyses of efficacy', 'endpoints.', 'The primary hypotheses will be evaluated by comparing pembrolizumab +', 'lenvatinib to pembrolizumab + placebo in PFS and os using a stratified log-rank', 'test and in ORR using the stratified Miettinen and Nurminen method [Miettinen,', 'O. 1985]. The HR will be estimated using a stratified Cox regression model. Event', 'rates over time will be estimated within each treatment group using the Kaplan-', 'Meier method. The difference in ORR will be estimated using the stratified', 'Miettinen and Nurminen method with strata weighting by sample size.', 'Statistical Methods for', 'The analysis of safety results will follow a tiered approach. The tiers differ with', 'Key Safety Analyses', 'respect to the analyses that will be performed. There are no events of interest that', 'warrant elevation to Tier 1 events in this study. Tier 2 parameters will be assessed', 'via point estimates with 95% CIs provided for between-group comparisons; only', 'point estimates by treatment group are provided for Tier 3 safety parameters. The', '95% CIs for the between-treatment differences in percentages will be provided', 'using the Miettinen and Nurminen method.', 'Interim Analyses', 'As of Amendment 007-06, no interim analyses of the study will be performed.', 'Multiplicity', 'As of Amendment 007-06, no interim or final analyses of the study will be', 'performed.', 'Sample Size and Power', 'As of Amendment 007-06, no interim or final analyses of the study will be', 'performed.', 'The planned sample size is approximately 620 participants. For PFS, based on 416', 'events, the study has 86.5% power to detect a HR of 0.7 (pembrolizumab +', 'lenvatinib VS pembrolizumab + placebo) at a=0.55% (1-sided). For OS, based on', '388 events, the study has 90% power to detect a HR of 0.71 (pembrolizumab +', 'lenvatinib VS pembrolizumab + placebo) at =1.95% (1-sided).', 'China Extension Study', 'As of Amendment 007-06, enrollment in the Extension Study in China has', 'been stopped.', 'China participants randomized during the global study phase will be included in', 'all global study analyses (efficacy and safety). China participants randomized', 'during the China extension phase will be excluded from all global study analyses.', 'China participants randomized during global and extension phases will both be', 'included in any China-specific analyses.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
109,page_110,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '109', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.2', 'Responsibility for Analyses/In-house Blinding', 'Note: As of Amendment 007-06, the study is unblinded to the Sponsor, the', 'investigational sites, and the participants. This section has been updated accordingly.', 'The statistical analysis of the data obtained from this study will be the responsibility of the', 'Clinical Biostatistics department of the Sponsor.', 'This study was conducted as a double-blind study under in-house blinding procedures until', 'after the eDMC recommended study unblinding.', 'The Sponsor generated the randomized allocation schedule(s) for study intervention', 'assignment. Blinding issues related to the planned interim analyses are described in Section', '9.7, but are no longer applicable as of Amendment 007-06.', 'Extension Study in China', 'For all participants in China, including participants randomized in the global study and the', 'extension study, statistician(s)/programmers were blinded to participant level treatment', 'randomization and this information had been clearly documented.', '9.3', 'Hypotheses/Estimation', 'Objectives and hypotheses of the study are stated in Section 3.', '9.4', 'Analysis Endpoints', 'Efficacy and safety endpoints that will be evaluated for within- and/or between-treatment', 'differences are listed below.', '9.4.1', 'Efficacy Enppoints', '9.4.1.1', 'Primary Enppoints', 'PFS: the time from randomization to the first documented PD per RECIST 1.1, adjusted to', 'follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, based', 'on BICR or death due to any cause, whichever occurs first. See Section 9.6.1 for the', 'definition of censoring.', 'OS: the time from randomization to death due to any cause.', '9.4.1.2', 'Secondary Enppoints', 'OR: a confirmed CR or PR per RECIST 1.1, adjusted to follow a maximum of 10 target', 'lesions and a maximum of 5 target lesions per organ, based on BICR.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
110,page_111,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '110', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.4.1.3', 'Exploratory Enppoints', 'DOR: the time from the earliest date of qualifying response until earliest date of PD or death', 'from any cause, whichever comes first.', '9.4.2', 'Safety Enppoints', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs, SAEs, fatal AEs, laboratory tests, and vital signs. Furthermore, specific events will be', 'collected and designated as ECIs as described in Section 8.4.7.', '9.4.3', 'Patient-reported Outcome Enppoints', 'The following secondary PRO endpoints will be evaluated as described in Section 4.2.1.3', 'and analyzed as described in Section 9.6.3:', 'Change from baseline in', 'Global Health Status/QoL scale (QLQ-C30 items 29-30)', 'Single-item symptom scales: cough (QLQ-LC13 item 31), chest pain (QLQ-LC13', 'item 40), and dyspnea (QLQ-C30 item 8)', 'Physical functioning scale (QLQ-C30 items 1-5)', 'Time to true deterioration (TTD) in', 'Global Health Status/QoL scale (QLQ-C30 items 29-30)', 'Single-item symptom scales: cough (QLQ-LC13 item 31), chest pain (QLQ-LC13', 'item 40), and dyspnea (QLQ-C30 item 8)', 'Physical functioning scale (QLQ-C30 items 1-5)', 'Composite symptom endpoint: cough (QLQ-LC13 item 31), chest pain (QLQ-LC13', 'item 40), or dyspnea (QLQ-C30 item 8)', 'The TTD in global health status/QoL, cough, chest pain, dyspnea, and physical functioning is', 'defined as the time from baseline to the first onset of a 10 or more points deterioration from', 'baseline with confirmation by the subsequent visit of a 10 or more points deterioration from', 'baseline. The TTD in the composite endpoint of cough, chest pain, or dyspnea is defined as', 'the time to first onset of 10 or more points deterioration from baseline in any one of 3 scale', 'items with confirmation by the subsequent visit of 10 points or more deterioration from', 'baseline in the same scale as the first onset. The EQ-5D-5L will be evaluated as an', 'exploratory endpoint. These analyses and other supportive PRO analyses will be described in', 'the sSAP.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
111,page_112,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '111', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.5', 'Analysis Populations', '9.5.1', 'Efficacy Analysis Populations', 'The analyses of the primary efficacy endpoints are based on the ITT population. All', 'randomized participants will be included in this population. Participants will be analyzed in', 'the treatment group to which they are randomized. Details on the approach to handling', 'missing data are provided in Section 9.6.', 'Extension Study in China', 'NOTE: As of Amendment 007-06, enrollment in the Extension Study in China has been', 'stopped. This section has been updated accordingly.', 'The participants in China who were randomized in the extension study will not be included', 'in the above global study primary efficacy analysis population. The ITT participants in China,', 'including all participants in China randomized in the global study and the extension study,', 'will be analyzed.', '9.5.2 Safety Analysis Populations', 'Safety analyses will be conducted in the APaT population, which consists of all randomized', 'participants who received at least 1 dose of study intervention. Participants will be included', 'in the treatment group corresponding to the study intervention they actually received for the', 'analysis of safety data using the APaT population. This will be the treatment group to which', 'they were randomized, except for participants who take incorrect study intervention for the', 'entire treatment period; such participants will be included in the treatment group', 'corresponding to the study intervention actually received. Any participant who receives the', 'incorrect study intervention for 1 cycle, but receives the randomized treatment for all other', 'cycles, will be analyzed according to the randomized treatment group, and a narrative will be', 'provided for any events that occur during the cycle for which the participant is incorrectly', 'dosed.', 'At least 1 laboratory, vital sign, or ECG measurement obtained after at least 1 dose of study', 'intervention is required for inclusion in the analysis of the respective safety parameter. To', 'assess change from baseline, a baseline measurement is also required.', 'Extension Study in China', 'The participants in China who were randomized and treated in the extension study will not be', 'included in the above global study primary safety analysis population. The APaT participants', 'in China, including all randomized participants in China (in the global study and extension', 'study) who received at least 1 dose of study treatment, will be analyzed.', '9.5.3 Patient-reported Outcome Analysis Population', 'The analyses of PRO endpoints will be based on the PRO full analysis set (FAS) population', 'following the ITT principle and ICH E9 guidelines. The PRO FAS population consists of all', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
112,page_113,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '112', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'randomized participants who have received at least 1 dose of study intervention and have', 'completed at least 1 PRO assessment.', '9.5.4 Pharmacokinetic Analysis Population', 'The population of PK analysis set includes all the participants who have received at least', '1 dose of study intervention with documented dosing history in the lenvatinib +', 'pembrolizumab arm and have measurable plasma levels of lenvatinib or serum levels of', 'pembrolizumab.', '9.6', 'Statistical Methods', 'NOTE: As of Amendment 007-06, the prespecified interim and final analyses of the', 'study will not be performed. Selected analyses of safety and ePRO endpoints will be', 'performed at end of study; there will be no further analyses of efficacy endpoints. The', 'subsections below are retained for reference.', '9.6.1', 'Statistical Methods for Efficacy Analyses', 'This section describes the statistical methods that address the primary and secondary efficacy', 'objectives. Methods related to exploratory objectives will be described in the sSAP. Efficacy', 'results that will be deemed to be statistically significant after consideration of the Type I', 'error control strategy are described in Section 9.8. Nominal p values will be computed for', 'other efficacy analyses, but should be interpreted with caution because of potential issues of', 'multiplicity.', 'The stratification factors used for randomization (see Section 6.3.2) will be applied to all', 'stratified analyses, in particular, the stratified log-rank test, stratified Cox model, and', 'stratified Miettinen and Nurminen method [Miettinen, O. 1985]. If there are small strata, for', 'the purpose of analysis, strata will be combined to ensure sufficient number of participants,', 'responses and events in each stratum. Details regarding the pooling strategy will be', 'prespecified in the sSAP prior to the database lock for the first analysis when each applicable', 'endpoint will be analyzed, and decisions regarding the pooling will be based on a blinded', 'review of response and event counts by stratum.', 'The efficacy analyses for OR, DOR and PFS will include responses and documented', 'progression events that occur prior to Second-course treatment.', 'A summary of the primary analysis strategy for the key efficacy endpoints is provided in', 'Table 7.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
113,page_114,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '113', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 7', 'Analysis Methods for Key Efficacy Endpoints', 'Analysis', 'Endpoint/Variable', 'Statistical Method', 'Population', 'Missing Data Approach', 'Primary Analyses:', 'PFS (RECIST 1.1)', 'Testing: stratified log-rank test', 'ITT', 'Censored according to rules in', 'by BICR', 'Estimation: Stratified Cox model', 'Table 8', ""with Efron's tie-handling method"", 'os', 'Testing: stratified log-rank test', 'ITT', 'Censored at last known alive date', 'Estimation: Stratified Cox model', ""with Efron's tie-handling method"", 'Secondary Analyses:', 'ORR (RECIST 1.1)', 'Testing and estimation:', 'ITT', 'Participants with missing data are', 'by BICR', 'stratified Miettinen and', 'considered nonresponders', 'Nurminen method', 'Abbreviations: BICR = blinded independent central review; ITT = intention-to-treat; ORR = objective response', 'rate; os = overall survival; PFS = progression-free survival; RECIST 1.1 = Response Evaluation Criteria in', 'Solid Tumors.', 'The strategy to address multiplicity issues with regard to multiple endpoints and interim', 'analyses is described in Section 9.7, Interim Analyses, and in Section 9.8, Multiplicity.', '9.6.1.1', 'Progression-free Survival', 'The nonparametric Kaplan-Meier method will be used to estimate the PFS curve in each', 'treatment group. The hypotheses of treatment difference in PFS will be tested by the', ""stratified log-rank test. A stratified Cox proportional hazard model with Efron's method of tie"", 'handling will be used to estimate the magnitude of the treatment difference (ie, HR) between', ""the treatment arms. The HR and its 95% CI from the stratified Cox model with Efron's"", 'method of tie handling and with a single treatment covariate will be reported.', 'Since PD is assessed periodically, PD can occur any time in the time interval between the last', 'assessment where PD was not documented and the assessment when PD is documented. For', 'the primary analysis, for the participants who have PD, the true date of PD will be', 'approximated by the date of the first assessment at which PD is objectively documented per', 'RECIST 1.1 by the BICR vendor, regardless of discontinuation of study drug. Additional', 'analyses will be performed for PFS per iRECIST.', 'To evaluate the robustness of the PFS endpoint per RECIST 1.1 via BICR by the imaging', 'vendor, 1 primary and 2 sensitivity analyses with a different set of censoring rules will be', 'performed. For the primary analysis, if the events (PD or death) are after more than 1 missed', 'disease assessment, the data are censored at the last disease assessment before missing visits.', 'Also, data after new anticancer therapy are censored at the last disease assessment before the', 'initiation of new anticancer therapy. The first sensitivity analysis follows ITT principles (ie,', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
114,page_115,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '114', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'PDs/deaths are counted as events regardless of missed study visits or initiation of new', 'anticancer therapy). The second sensitivity analysis considers discontinuation of treatment or', 'initiation of an anticancer treatment after discontinuation of study-specified treatments,', 'whichever occurs later, to be a PD event for participants without documented PD or death. If', 'a participant meets multiple criteria for censoring, the censoring criterion that occurs earliest', 'will be applied. The censoring rules for primary and sensitivity analyses are summarized in', 'Table 8.', 'Table 8', 'Censoring Rules for Primary and Sensitivity Analyses of Progression-free', 'Survival', 'Situation', 'Sensitivity', 'Sensitivity', 'Primary Analysis', 'Analysis 1', 'Analysis 2', 'No PD and no death; new', 'Censored at last disease', 'Censored at last', 'Progressed at treatment', 'anticancer treatment is not', 'assessment', 'disease assessment', 'discontinuation for reasons', 'initiated', 'other than CR; otherwise,', 'censored at last disease', 'assessment if still on study', 'intervention or completed', 'study intervention', 'No PD and no death; new', 'Censored at last disease', 'Censored at last', 'Progressed at date of new', 'anticancer treatment is', 'assessment before new', 'disease assessment', 'anticancer treatment', 'initiated', 'anticancer treatment', 'PD or death documented', 'Progressed at date of', 'Progressed at date of', 'Progressed at date of', 'after 1 missed disease', 'documented PD or death', 'documented PD or', 'documented PD or death', 'assessment and before new', 'death', 'anticancer therapy', 'PD or death documented', 'Censored at last disease', 'Progressed at date of', 'Progressed at date of', 'immediately after >2', 'assessment before the', 'documented PD or', 'documented PD or death', 'consecutive missed disease', 'earlier date of', 'death', 'assessments or after new', '>2 consecutive missed', 'anticancer therapy', 'disease assessment and', 'new anticancer therapy', 'Abbreviation: CR = complete response; PD = progressive disease.', '9.6.1.2', 'Overall Survival', 'The nonparametric Kaplan-Meier method will be used to estimate the survival curves. The', 'treatment difference in survival will be assessed by the stratified log-rank test (based on the', 'stratification factors defined in Section 6.3.2). A stratified Cox proportional hazard model', ""with Efron's method of tie handling will be used to assess the magnitude of the treatment"", 'difference (ie, the HR). The HR and its 95% CI from the stratified Cox model with a single', 'treatment covariate will be reported. The stratification factors used for randomization', '(Section 6.3.2) will be applied to both the stratified log-rank test and the stratified Cox', 'model. Participants without documented death at the time of analysis will be censored at the', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
115,page_116,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '115', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'date of last known contact. The analysis using the restricted mean survival time method may', 'be conducted for os to account for the possible nonproportional hazards effect.', '9.6.1.3', 'Objective Response Rate', 'The stratified Miettinen and Nurminen method will be used for comparison of ORR between', 'the treatment groups. The difference in ORR and its 95% CI from the stratified Miettinen and', 'Nurminen method with strata weighting by sample size will be provided.', '9.6.1.4', 'Duration of Response', 'For participants who demonstrate CR or PR, DOR is defined as the time from first', 'documented evidence of CR or PR until PD or death due to any cause, whichever occurs', 'first.', 'The nonparametric Kaplan-Meier method will be used to summarize the DOR. The median', 'and range of DOR will be provided.', 'Censoring rules for DOR are summarized in Table 9.', 'Table 9 Censoring Rules for Duration of Response', 'Situation', 'Date of Progression or Censoring', 'Outcome', 'No PD or death, no new anticancer', 'Last adequate disease assessment', 'Censor', 'therapy initiated', '(nonevent)', 'No PD or death, new anticancer', 'Last adequate disease assessment before new', 'Censor', 'therapy initiated', 'anticancer therapy initiated', '(nonevent)', 'Death or PD immediately after >2', 'Earlier date of last adequate disease assessment', 'Censor', 'consecutive missed disease', 'before >2 missed adequate disease assessments', '(nonevent)', 'assessments or after new anticancer', 'and new anticancer therapy, if any', 'therapy, if any', 'Death or PD after 1 missed disease', 'PD or death', 'End of response', 'assessments and before new', '(event)', 'anticancer therapy, if any', 'Abbreviation: PD = progressive disease.', 'Note: A missed disease assessment includes any assessment that is not obtained or is considered inadequate for', 'evaluation of response.', '9.6.2', 'Statistical Methods for Safety Analyses', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs, laboratory tests, vital signs, and ECG measurements.', 'The analysis of safety results will follow a tiered approach (Table 10). The tiers differ with', 'respect to the analyses that will be performed. AEs (specific terms as well as system organ', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
116,page_117,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '116', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'class terms) and events that meet predefined limits of change in laboratory, vital signs, and', 'ECG parameters are either prespecified as ""Tier 1"" endpoints or will be classified as', 'belonging to ""Tier 2"" or ""Tier 3,"" based on observed proportions of participants with an', 'event.', 'Tier 1 Events', 'Safety parameters or AEs of special interest that are identified a priori constitute ""Tier 1""', 'safety endpoints that will be subject to inferential testing for statistical significance. AEs that', 'are immune-mediated or potentially immune-mediated are well documented and will be', 'evaluated separately; however, these events have been characterized consistently throughout', 'the pembrolizumab clinical development program, and determination of statistical', 'significance is not expected to add value to the safety evaluation. Similarly, the combination', 'of pembrolizumab and lenvatinib has not been associated with any new safety signals.', 'Finally, there are no known AEs associated with participants with NSCLC for which', 'determination of a p value is expected to impact the safety assessment. Therefore, there are', 'no Tier 1 events for this protocol.', 'Tier 2 Events', 'Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences', 'in the proportion of participants with events using the Miettinen and Nurminen method, an', 'unconditional, asymptotic method [Miettinen, O. 1985].', 'Membership in Tier 2 requires that at least 10% of participants in any treatment group exhibit', 'the event; all other AEs and predefined limits of change will belong to Tier 3. The threshold', 'of at least 10% of participants was chosen for Tier 2 events because the population', 'randomized in this study are in critical conditions and usually experience various AEs of', 'similar types regardless of treatment; events reported less frequently than 10% of participants', 'would obscure the assessment of the overall safety profile and add little to the interpretation', 'of potentially meaningful treatment differences. In addition, Grade 3 to 5 AEs (>5% of', 'participants in one of the treatment groups) and SAEs (>5% of participants in one of the', 'treatment groups) will be considered Tier 2 endpoints. Because many 95% CIs may be', 'provided without adjustment for multiplicity, the CIs should be regarded as a helpful', 'descriptive measure to be used in safety review, not a formal method for assessing the', 'statistical significance of the between-group differences.', 'Tier 3 Events', 'Safety endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only point', 'estimates by treatment group are provided for Tier 3 safety parameters.', 'Continuous Safety Measures', 'For continuous measures such as changes from baseline in laboratory, vital signs, and ECG', 'parameters, summary statistics for baseline, on-treatment, and change from baseline values', 'will be provided by treatment group in table format.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
117,page_118,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '117', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 10 Analysis Strategy for Safety Parameters', '95% CI for', 'Safety', 'Treatment', 'Descriptive', 'Tier', 'Safety Endpoint', 'Comparison', 'Statistics', 'Any AE (10% of participants in one of the treatment groups)', 'X', 'X', 'Any Grade 3 to 5 AE (5% of participants in one of the', 'X', 'X', 'Tier 2', 'treatment groups)', 'Any serious AE (5% of participants in one of the treatment', 'X', 'X', 'groups)', 'Any AE', 'X', 'Tier 3', 'Change from baseline results (laboratory test toxicity grade)', 'X', 'Abbreviations: AE = adverse event; CI = confidence interval; X = results will be provided.', '9.6.3', 'Statistical Methods for Patient-reported Outcome Analyses', 'Mean change from baseline', 'The time point for the mean change from baseline will be determined based on blinded data', 'review prior to the database lock for any PRO analysis and documented in the sSAP.', 'To assess the treatment effects on the PRO score change from baseline in the PRO endpoints', 'defined in Section 9.4.3, a constrained longitudinal data analysis (cLDA) model proposed by', 'Liang and Zeger [Liang, Kung-Yee and Zeger, Scott L. 2000 will be applied, with the PRO', 'score as the response variable, and treatment, time, the treatment by time interaction, and', 'stratification factors used for randomization (See Section 6.3.2) as covariates. The treatment', 'difference in terms of least square (LS) mean change from baseline will be estimated from', 'this model together with 95% CI. Model-based LS mean with 95% CI will be provided by', 'treatment group for PRO scores at baseline and postbaseline time point.', 'Time to Deterioration (TTD)', 'For the TTD endpoints defined in Section 9.4.3, the Kaplan-Meier method will be used to', 'estimate the TTD curve for each treatment group. The estimate of median time to', 'deterioration and its 95% CI will be obtained from the Kaplan-Meier estimates. The', 'treatment difference in TTD will be assessed by the stratified log-rank test. A stratified Cox', ""proportional hazard model with Efron's method of tie handling and with a single treatment"", 'covariate will be used to assess the magnitude of the treatment difference (ie, HR). The HR', 'and its 95% CI will be reported. The same stratification factors used for the stratified PFS', 'and os analyses will be used as the stratification factors in both the stratified log-rank test', 'and the stratified Cox model.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
118,page_119,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '118', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.6.4', 'Demographic and Baseline Characteristics', 'The comparability of the treatment groups for each relevant demographic and baseline', 'characteristic will be assessed by the use of tables and/or graphs. No statistical hypothesis', 'tests will be performed on these characteristics. The number and percentage of participants', 'screened and randomized and the primary reason for screening failure and discontinuation', 'will be displayed. Demographic variables, baseline characteristics, primary and secondary', 'diagnoses, and prior and concomitant therapies will be summarized by treatment, either by', 'descriptive statistics or categorical tables.', '9.7', 'Interim Analyses', 'NOTE: As of Amendment 007-06, no interim analyses of the study will be performed.', 'This section is no longer applicable.', '9.7.1', 'Safety Interim Analyses', 'The DMC conducted regular safety monitoring. The timing of the safety monitoring was', 'specified in the DMC charter. No further analysis is warranted.', '9.8', 'Multiplicity', 'NOTE: As of Amendment 007-06, no interim or final analyses of the study will be', 'performed. This section is no longer applicable.', '9.9', 'Sample Size and Power Calculations', 'NOTE: As of Amendment 007-06, no interim or final analyses of the study will be', 'performed. This section is retained for reference.', 'The study will randomize 620 participants in a 1:1 ratio into the pembrolizumab + lenvatinib', 'and pembrolizumab + placebo arms. PFS and os are primary endpoints for the study, with', 'OR as the secondary endpoint.', 'For the PFS endpoint, based on a target number of 416 events at the final PFS analysis, the', 'study has approximately 86.5% power to detect an HR of 0.7 at the initially allocated', 'a=0.0055 (1-sided).', 'For the OS endpoint, based on a target number of 388 events and one interim analysis at', 'approximately 78% of the target number of events, the study has approximately 90% power', 'to detect an HR of 0.71 at the initially allocated x=0.0195 (1-sided).', 'Based on KEYNOTE-042 data, the above sample size and power calculations for PFS and', 'OS assume the following:', 'PFS follows a piecewise exponential distribution, with a median of 5 months up to 6.5', 'months and then a median of 12 months thereafter for the control group.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
119,page_120,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '119', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'OS follows an exponential distribution, with a median of 16.7 months for the control group.', 'Enrollment period is approximately 21.7 months.', 'Annual drop-out rate is 20% and 2% for PFS and OS, respectively.', 'Follow-up period is approximately 8.8 and 18.5 months for PFS and OS, respectively, after', 'the last participant is randomized.', 'The sample size and power calculations were performed in R (package ""gsDesign"") and', 'EAST 6.4.', 'Extension Study in China', 'As of amendment 007-06, enrollment in the Extension Study in China has been stopped.', 'In order to evaluate the consistency of efficacy and safety in the subpopulation in China', 'compared with the global population, following completion of global study enrollment,', 'participants in China will continue to be randomized in a 1:1 ratio into the pembrolizumab +', 'lenvatinib arm and pembrolizumab + placebo arm until the planned sample size of', 'approximately 120 participants in China is reached. Participants in China randomized after', 'completion of enrollment in the global study will not be included in the analysis of the global', 'study.', '9.10', 'Subgroup Analyses', 'To determine whether the treatment effect is consistent across various subgroups, the', 'between-group treatment effect for OS, PFS, and OR (with a nominal 95% CI) will be', 'estimated and plotted by treatment group within each category of the following subgroup', 'variables:', 'Geographic region (East Asia, non-East Asia)', 'ECOG performance status (0,1)', 'Predominant tumor histology (squamous, nonsquamous)', 'TPS (1%-49%, 50%)', 'Age category (<65, 265 years)', 'Sex (female, male)', 'Race (white, nonwhite)', 'Smoking status (never, former/current smoker)', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
120,page_121,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '120', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Brain metastasis at baseline (presence, absence)', 'Liver metastasis at baseline (presence, absence)', 'The consistency of the treatment effect will be assessed using descriptive statistics for each', 'category of the subgroup variables listed above. If the number of participants in a category of', 'a subgroup variable is less than 10% of the ITT population, the subgroup analysis will not be', 'performed for this category of the subgroup variable, and this subgroup variable will not be', 'displayed in the forest plot. The subgroup analyses for PFS and OS will be conducted using', 'unstratified Cox model, and the subgroup analyses for OR will be conducted using', 'unstratified Miettinen and Nurminen method.', '9.11 Compliance (Medication Adherence)', 'Drug accountability data for study intervention will be collected during the study. Any', 'deviation from protocol-directed administration will be reported.', '9.12', 'Extent of Exposure', 'Extent of exposure for a participant is defined as number of cycles in which the participant', 'receives the study intervention. Summary statistics will be provided on extent of exposure for', 'the APaT population.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
121,page_122,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '121', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10 SUPPORTING DOCUMENTATION AND OPERATIONAL', 'CONSIDERATIONS', '10.1', 'Appendix 1: Regulatory, Ethical, and Study Oversight Considerations', '10.1.1', 'Code of Conduct for Clinical Trials', 'Merk Sharp and Dohme Corp., a subsidiary of Merk & Co., Inc. (MSD)', 'Code of Conduct for Interventional Clinical Trials', 'I. Introduction', 'A. Purpose', 'MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our', 'products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials', 'in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the', 'overriding concern in the design and conduct of clinical trials. In all cases, MSD clinical trials will be conducted', 'in compliance with local and/or national regulations (including all applicable data protection laws and', 'regulations), and International Council for Harmonisation Good Clinical Practice (ICH-GCP), and also in', 'accordance with the ethical principles that have their origin in the Declaration of Helsinki.', 'B. Scope', 'Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by', 'MSD irrespective of the party (parties) employed for their execution (eg, contract research organizations,', 'collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or', 'which are retrospective. Further, this Code does not apply to investigator-initiated trials, which are not under the', 'full control of MSD.', 'II. Scientific Issues', 'A. Trial Conduct', '1. Trial Design', 'Except for pilot or estimation trials, clinical trial protocols will be hypothesis-driven to assess safety,', 'efficacy, and/or pharmacokinetic or pharmacodynamic indices of MSD or comparator products.', 'Alternatively, MSD may conduct outcomes research trials, trials to assess or validate various endpoint', 'measures, or trials to determine patient preferences, etc.', 'The design (ie, participant population, duration, statistical power) must be adequate to address the specific', 'purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where', 'applicable, third parties. Participants must meet protocol entry criteria to be enrolled in the trial.', '2. Site Selection', 'MSD selects investigative sites based on medical expertise, access to appropriate participants, adequacy of', 'facilities and staff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial', 'initiation, sites are evaluated by MSD personnel to assess the ability to successfully conduct the trial.', '3. Site Monitoring/Scientific Integrity', 'Investigative trial sites are monitored to assess compliance with the trial protocol and Good Clinical Practice', '(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus', 'source documentation according to standard operating procedures. Per MSD policies and procedures, if', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
122,page_123,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '122', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'potential fraud, scientific/research misconduct, privacy incidents/breaches or Clinical Trial-related', 'Significant Quality Issues are reported, such matters are investigated. When necessary, appropriate corrective', 'and/or preventative actions are defined and regulatory authorities and/or ethics review committees are', 'notified.', 'B. Publication and Authorship', 'Regardless of trial outcome, MSD commits to publish primary and secondary results of its registered trials of', 'marketed products in which treatment is assigned, according to the prespecified plans for data analysis. To the', 'extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important', 'to patients, physicians, and payers. Some early phase or pilot trials are intended to be hypothesis-generating rather', 'than hypothesis testing, in such cases, publication of results may not be appropriate since the trial may be', 'underpowered and the analyses complicated by statistical issues such as multiplicity.', ""MSD's policy on authorship is consistent with the recommendations published by the International Committee"", 'of', 'Medical Journal Editors (ICMJE). In summary, authorship should reflect significant contribution to the design and', 'conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named', 'authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in', 'publications.', 'III. Participant Protection', 'A. Ethics Committee Review (Institutional Review Board IRB]/Independent Ethics Committee [IEC])', 'All clinical trials will be reviewed and approved by an IRB/IEC before being initiated at each site. Significant', 'changes or revisions to the protocol will be approved by the ethics committee prior to implementation, except', 'changes required urgently to protect participant safety that may be enacted in anticipation of ethics committee', 'approval. For each site, the ethics committee and MSD will approve the participant informed consent form.', 'B. Safety', 'The guiding principle in decision-making in clinical trials is that participant welfare is of primary importance.', 'Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At', 'a minimum, trial designs will take into account the local standard of care.', 'All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is', 'obtained. Participants may withdraw from an MSD trial at any time, without any influence on their access to, or', 'receipt of, medical care that may otherwise be available to them.', 'C. Confidentiality', 'MSD is committed to safeguarding participant confidentiality, to the greatest extent possible, as well as all', 'applicable data protection rights. Unless required by law, only the investigator, Sponsor (or individuals acting on', 'behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical records', 'that might identify the participant by name.', 'D. Genomic Research', 'Genomic research will only be conducted in accordance with a protocol and informed consent authorized by an', 'ethics committee.', 'IV. Financial Considerations', 'A. Payments to Investigators', ""Clinical trials are time- and labor-intensive. It is MSD's policy to compensate investigators (or the sponsoring"", 'institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to', 'enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be', 'made to compensate for the time spent in extra recruiting efforts.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
123,page_124,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '123', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent', 'on chart review to identify potentially eligible participants.', 'B. Clinical Research Funding', 'Informed consent forms will disclose that the trial is sponsored by MSD and that the investigator or sponsoring', 'institution is being paid or provided a grant for performing the trial. However, the local ethics committee may', 'wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As', 'noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.', 'C. Funding for Travel and Other Requests', 'Funding of travel by investigators and support staff (eg, to scientific meetings, investigator meetings, etc.) will be', 'consistent with local guidelines and practices.', 'V. Investigator Commitment', ""Investigators will be expected to review MSD's Code of Conduct as an appendix to the trial protocol, and in signing the"", 'protocol, agree to support these ethical and scientific standards.', '10.1.2', 'Financial Disclosure', 'Financial Disclosure requirements are outlined in the US Food and Drug Administration', 'Regulations, Financial Disclosure by Clinical Investigators (21 CFR Part 54). It is the', ""Sponsor's responsibility to determine, based on these regulations, whether a request for"", ""Financial Disclosure information is required. It is the investigator's/subinvestigator's"", 'responsibility to comply with any such request.', 'The investigator/subinvestigator(s) agree, if requested by the Sponsor in accordance with 21', 'CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to', 'allow for the submission of complete and accurate certification and disclosure statements.', 'The investigator/subinvestigator(s) further agree to provide this information on a', 'Certification/Disclosure Form, commonly known as a financial disclosure form, provided by', 'the Sponsor. The investigator/subinvestigator(s) also consent to the transmission of this', 'information to the Sponsor in the United States for these purposes. This may involve the', 'transmission of information to countries that do not have laws protecting personal data.', '10.1.3', 'Data Protection', 'Participants will be assigned a unique identifier by the Sponsor. Any participant records or', 'datasets that are transferred to the Sponsor will contain the identifier only; participant names', 'or any information that would make the participant identifiable will not be transferred.', 'The participant must be informed that his/her personal study-related data will be used by the', 'Sponsor in accordance with local data protection law. The level of disclosure must also be', 'explained to the participant.', 'The participant must be informed that his/her medical records may be examined by Clinical', 'Quality Assurance auditors or other authorized personnel appointed by the Sponsor, by', 'appropriate IRB/IEC members, and by inspectors from regulatory authorities.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
124,page_125,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '124', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.1.3.1', 'Confidentiality of Data', 'By signing this protocol, the investigator affirms to the Sponsor that information furnished to', 'the investigator by the Sponsor will be maintained in confidence, and such information will', 'be divulged to the IRB, IEC, or similar or expert committee; affiliated institution and', 'employees, only under an appropriate understanding of confidentiality with such board or', 'committee, affiliated institution and employees. Data generated by this study will be', 'considered confidential by the investigator, except to the extent that it is included in a', 'publication as provided in the Publications section of this protocol.', '10.1.3.2', 'Confidentiality of Participant Records', 'By signing this protocol, the investigator agrees that the Sponsor (or Sponsor representative),', 'IRB/IEC, or regulatory authority representatives may consult and/or copy study documents to', 'verify worksheet/CRF data. By signing the consent form, the participant agrees to this', 'process. If study documents will be photocopied during the process of verifying', 'worksheet/CRF information, the participant will be identified by unique code only; full', 'names/initials will be masked prior to transmission to the Sponsor.', 'By signing this protocol, the investigator agrees to treat all participant data used and', 'disclosed in connection with this study in accordance with all applicable privacy laws, rules', 'and regulations.', '10.1.3.3', 'Confidentiality of IRB/IEC Information', 'The Sponsor is required to record the name and address of each IRB/IEC that reviews and', 'approves this study. The Sponsor is also required to document that each IRB/IEC meets', 'regulatory and ICH GCP requirements by requesting and maintaining records of the names', 'and qualifications of the IRB/IEC members and to make these records available for', 'regulatory agency review upon request by those agencies.', '10.1.4', 'Committees Structure', '10.1.4.1', 'Steering Committee', 'This study will be conducted in consultation with a Steering Committee. The Steering', 'Committee is composed of the following:', 'Sponsor personnel', 'Eisai personnel', 'Investigators participating in the study', 'Consulting therapeutic area and clinical study experts', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
125,page_126,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '125', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'The Steering Committee will provide guidance on the operational aspects of the study and', 'provide input with respect to study design, interpretation of results, and subsequent', 'peer-reviewed scientific publications.', 'Specific details regarding responsibilities and governance of the Steering Committee will be', 'described in a separate charter.', '10.1.4.2', 'Executive Oversight Committee', 'The EOC is composed of members of Sponsor Senior Management. The EOC will receive', 'and decide upon any recommendations made by the DMC or Steering Committee regarding', 'the study.', '10.1.4.3', 'External Data Monitoring Committee', 'To supplement the routine study monitoring outlined in this protocol, an external DMC will', 'monitor the interim data from this study. The voting members of the committee are external', 'to the Sponsor. The members of the DMC must not be involved with the study in any other', 'way (eg, they cannot be study investigators) and must have no competing interests that could', 'affect their roles with respect to the study.', 'The DMC will make recommendations to the EOC regarding steps to ensure both participant', 'safety and the continued ethical integrity of the study. Also, the DMC will review interim', 'study results, consider the overall risk and benefit to study participants (Section 9.7, Interim', 'Analysis) and recommend to the EOC whether the study should continue in accordance with', 'the protocol.', 'Specific details regarding composition, responsibilities, and governance, including the roles', 'and responsibilities of the various members and the Sponsor protocol team OR external', 'collaborating organization protocol team; meeting facilitation; the study governance', 'structure; and requirements for and proper documentation of DMC reports, minutes, and', 'recommendations will be described in the DMC charter that is reviewed and approved by all', 'the DMC members.', '10.1.5', 'Publication Policy', 'The results of this study may be published or presented at scientific meetings. The Sponsor', 'will comply with the requirements for publication of study results. In accordance with', 'standard editorial and ethical practice, the Sponsor will generally support publication of', 'multicenter studies only in their entirety and not as individual site data. In this case, a', 'coordinating investigator will be designated by mutual agreement.', 'If publication activity is not directed by the Sponsor, the investigator agrees to submit all', 'manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect', 'proprietary information and to provide comments.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
126,page_127,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '126', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Authorship will be determined by mutual agreement and in line with International Committee', 'of Medical Journal Editors authorship requirements.', '10.1.6', 'Compliance with Study Registration and Results Posting Requirements', 'Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007', 'and the European Medicines Agency (EMA) clinical trial Directive 2001/20/EC, the Sponsor', 'of the study is solely responsible for determining whether the study and its results are subject', 'to the requirements for submission to http://www.clinicaltrials.gov,', 'www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will', 'review this protocol and submit the information necessary to fulfill these requirements. MSD', 'entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.', 'Information posted will allow participants to identify potentially appropriate studies for their', 'disease conditions and pursue participation by calling a central contact number for further', 'information on appropriate study locations and study site contact information.', 'By signing this protocol, the investigator acknowledges that the statutory obligations under', 'FDAAA, the EMA clinical trials directive, or other locally mandated registries are that of the', 'Sponsor and agrees not to submit any information about this study or its results to those', 'registries.', '10.1.7', 'Compliance with Law, Audit, and Debarment', 'By signing this protocol, the investigator agrees to conduct the study in an efficient and', 'diligent manner and in conformance with this protocol; generally accepted standards of GCP', '(eg, International Conference on Harmonization of Technical Requirements for Registration', 'of Pharmaceuticals for Human Use GCP: Consolidated Guideline and other generally', 'accepted standards of GCP); and all applicable federal, state and local laws, rules and', 'regulations relating to the conduct of the clinical study.', 'The Code of Conduct, a collection of goals and considerations that govern the ethical and', 'scientific conduct of clinical investigations sponsored by MSD, is provided in this appendix', 'under the Code of Conduct for Clinical Studies.', 'The investigator agrees not to seek reimbursement from participants, their insurance', 'providers, or from government programs for procedures included as part of the study', 'reimbursed to the investigator by the Sponsor.', 'The investigator will promptly inform the Sponsor of any regulatory authority inspection', 'conducted for this study.', 'The investigator agrees to provide the Sponsor with relevant information from inspection', 'observations/findings to allow the Sponsor to assist in responding to any citations resulting', 'from regulatory authority inspection and will provide the Sponsor with a copy of the', 'proposed response for consultation before submission to the regulatory authority.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
127,page_128,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '127', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Persons debarred from conducting or working on clinical studies by any court or regulatory', ""authority will not be allowed to conduct or work on this Sponsor's studies. The investigator"", 'will immediately disclose in writing to the Sponsor if any person who is involved in', 'conducting the study is debarred or if any proceeding for debarment is pending or, to the best', ""of the investigator's knowledge, threatened."", '10.1.8', 'Data Quality Assurance', 'All participant data relating to the study will be recorded on printed or electronic CRF unless', 'transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator', 'or qualified designee is responsible for verifying that data entries are accurate and correct by', 'physically or electronically signing the CRF.', 'Detailed information regarding Data Management procedures for this protocol will be', 'provided separately.', 'The investigator must maintain accurate documentation (source data) that supports the', 'information entered in the CRF.', 'The investigator must permit study-related monitoring, audits, IRB/IEC review, and', 'regulatory agency inspections and provide direct access to source data documents.', 'Study documentation will be promptly and fully disclosed to the Sponsor by the investigator', 'upon request and also shall be made available at the study site upon request for inspection,', 'copying, review, and audit at reasonable times by representatives of the Sponsor or any', 'regulatory authorities. The investigator agrees to promptly take any reasonable steps that are', 'requested by the Sponsor or any regulatory authorities as a result of an audit or inspection to', 'cure deficiencies in the study documentation and worksheets/CRFs.', 'The Sponsor or designee is responsible for the data management of this study including', 'quality checking of the data.', 'Study monitors will perform ongoing source data review and verification to confirm that data', 'entered into the CRF by authorized site personnel are accurate, complete, and verifiable from', 'source documents; that the safety and rights of participants are being protected; and that the', 'study is being conducted in accordance with the currently approved protocol and any other', 'study agreements, ICH GCP, and all applicable regulatory requirements.', ""Records and documents, including participants' documented informed consent, pertaining to"", 'the conduct of this study must be retained by the investigator for 15 years after study', 'completion unless local regulations or institutional policies require a longer retention period.', 'No records may be destroyed during the retention period without the written approval of the', 'Sponsor. No records may be transferred to another location or party without written', 'notification to the Sponsor.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
128,page_129,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '128', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.1.9', 'Source Documents', 'Source documents provide evidence for the existence of the participant and substantiate the', 'integrity of the data collected. The investigator/institution should maintain adequate and', 'accurate source documents and study records that include all pertinent observations on each', ""of the site's participants. Source documents and data should be attributable, legible,"", 'contemporaneous, original, accurate, and complete. Changes to source data should be', 'traceable, should not obscure the original entry, and should be explained if necessary (eg, via', ""an audit trail). Source documents are filed at the investigator's site."", 'Data reported on the CRF or entered in the eCRF that are transcribed from source documents', 'must be consistent with the source documents or the discrepancies must be explained. The', 'investigator/institution may need to request previous medical records or transfer records,', 'depending on the study. Also, current medical records must be available.', '10.1.10 Study and Site Closure', 'The Sponsor or its designee may stop the study or study site participation in the study for', 'medical, safety, regulatory, administrative, or other reasons consistent with applicable laws,', 'regulations, and GCP.', 'In the event the Sponsor prematurely terminates a particular study site, the Sponsor will', ""promptly notify that study site's IRB/IEC."", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
129,page_130,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '129', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.2', 'Appendix 2: Clinical Laboratory Tests', 'The laboratory tests detailed in Table 11 will be performed by the local laboratory.', 'Protocol-specific requirements for inclusion or exclusion of participants are detailed', 'in Section 5 of the protocol.', 'Additional tests may be performed at any time during the study if determined', 'necessary by the investigator or required by local regulations.', 'Pregnancy testing requirements for study inclusion are described in Section 5.1 and', 'Section 8.3.5.2.', 'Pregnancy testing (urine or serum as required by local regulations) should be', 'conducted at monthly intervals during intervention.', 'Pregnancy testing (urine or serum as required by local regulations) should be', 'conducted at the end of relevant systemic exposure and correspond with the time', 'frame for female participant contraception in Section 5.1, Inclusion Criteria.', 'Additional serum or urine pregnancy tests may be performed, as determined', 'necessary by the investigator or required by local regulation, to establish the absence', ""of pregnancy at any time during the participant's participation in the study."", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
130,page_131,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '130', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 11', 'Protocol-Required Safety Laboratory Assessments', 'Comprehensive', 'Hematology', 'Urinalysis', 'Other', 'Chemistry Panel', 'Hematocrit', 'Albumin', 'Blood', 'FSHa', 'Hemoglobin', 'Alkaline phosphatase', 'Glucose', 'Pregnancy test (highly', 'sensitive serum or urine)', 'human chorionic', 'gonadotropin (hCG)b', 'Platelet count', 'ALT', 'Protein', 'PT/INR and aPTT/PTT', 'RBC', 'AST', 'Specific gravity', 'Total T3 (or FT3), total T4', 'WBC count with', '(or FT4), and TSHC,d', 'differential (absolute or', 'CO2 or bicarbonatee', 'Microscopic', 'HIV testing', 'percentage):', 'Calcium', 'examination, if', 'Hepatitis B and C testingt,g', 'Neutrophils', 'Chloride', 'abnormal results are', 'Blood for genetic analysis', 'Lymphocytes', 'noted', 'Monocytes', 'Creatinine', 'Eosinophils', 'Glucose', 'Basophils', 'Magnesium', 'Phosphorus', 'Potassium', 'Blood for serum', 'biomarkers', 'Sodium', 'Blood for RNA analysis', 'Total bilirubin', 'Blood for circulating tumor', 'nucleic acids', 'Direct bilirubinh', 'Blood for plasma', 'Total protein', 'biomarkers', 'BUN or urea¹', 'Amylase', 'Lipase', 'Abbreviations: ALT = alanine aminotransferase; aPTT = activated partial thromboplastin time; AST = aspartate', 'aminotransferase; BUN = blood urea nitrogen; C1D1 = Cycle 1 Day 1; CO2 = carbon dioxide; FSH = follicle-', 'stimulating hormone; FT3 = free triiodothyronine; FT4 = free thyroxine; HIV = human immunodeficiency', 'virus; INR = international normalized ratio; PT = prothrombin time; PTT = partial thromboplastin time;', 'RBC = red blood cells; SOC = standard of care; T3 = triiodothyronine; T4 = thyroxine;', 'TSH = thyroid-stimulating hormone; WBC = white blood cell; WOCBP = women of childbearing potential.', 'a', 'As needed, FSH to be performed at screening to confirm postmenopausal status.', 'b', 'Perform on WOCBP only 24 hours before first dose. Pregnancy tests must be repeated before every cycle.', 'c', 'T3 is preferred; if not available, free T3 may be tested.', 'd', 'Participants may be dosed in subsequent cycles after C1D1 while thyroid function tests are pending.', 'e', 'Bicarbonate only if available as SOC in the region.', 'f', 'If mandated by local health authority.', 'g', 'Hepatitis B surface antigen (HBsAg) or hepatitis B virus (HBV)-DNA. Hepatitis C virus (HCV)-RNA', '(qualitative) or HCV antibody.', 'h', 'If total bilirubin is elevated above the upper limit of normal.', 'i', 'BUN or urea (one or the other should be collected per institutional standard).', 'The investigator (or medically qualified designee) must document their review of each', 'laboratory safety report.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
131,page_132,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '131', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.3', 'Appendix 3: Adverse Events: Definitions and Procedures for Recording,', 'Evaluating, Follow-up, and Reporting', '10.3.1', 'Definition of AE', 'AE definition', 'An AE is any untoward medical occurrence in a clinical study participant, temporally', 'associated with the use of study intervention, whether or not considered related to the', 'study intervention.', 'NOTE: An AE can therefore be any unfavorable and unintended sign (including an', 'abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally', 'associated with the use of a study intervention.', 'NOTE: For purposes of AE definition, study intervention (also referred to as', ""Sponsor's product) includes any pharmaceutical product, biological product, vaccine,"", 'diagnostic agent, or protocol specified procedure whether investigational or marketed', '(including placebo, active comparator product, or run-in intervention), manufactured', 'by, licensed by, provided by, or distributed by the Sponsor for human use in this', 'study.', 'Events meeting the AE definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or', 'other safety assessments (eg, ECG, radiological scans, vital signs measurements),', 'including those that worsen from baseline, considered clinically significant in the', 'medical and scientific judgment of the investigator.', 'Exacerbation of a chronic or intermittent pre-existing condition including either an', 'increase in frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study intervention administration even', 'though it may have been present before the start of the study.', 'Note: Congenital disorders (eg, present from birth) not detected or diagnosed prior to', 'study intervention administration do not qualify for reporting as AE.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', 'Signs, symptoms, or the clinical sequelae of a suspected overdose of either study', 'intervention or a concomitant medication.', 'For all reports of overdose (whether accidental or intentional) with an associated AE,', 'the AE term should reflect the clinical symptoms or abnormal test result. An overdose', 'without any associated clinical symptoms or abnormal laboratory results is reported', 'using the terminology ""accidental or intentional overdose without adverse effect.\'', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
132,page_133,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '132', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Events NOT meeting the AE definition', 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that', 'leads to the procedure is the AE.', 'Situations in which an untoward medical occurrence did not occur (social and/or', 'convenience admission to a hospital).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present', 'or detected at the start of the study that do not worsen.', 'Surgery planned prior to informed consent to treat a pre-existing condition that has', 'not worsened.', 'Refer to Section 8.4.6 for protocol-specific exceptions.', '10.3.2', 'Definition of SAE', 'If an event is not an AE per definition above, then it cannot be an SAE even if serious', 'conditions are met.', 'An SAE is defined as any untoward medical occurrence that, at any dose:', 'a. Results in death', 'b. Is life-threatening', 'The term ""life-threatening"" in the definition of ""serious"" refers to an event in which', 'the participant was at risk of death at the time of the event. It does not refer to an', 'event, which hypothetically might have caused death, if it were more severe.', 'c.', 'Requires inpatient hospitalization or prolongation of existing hospitalization', 'Hospitalization is defined as an inpatient admission, regardless of length of stay, even', 'if the hospitalization is a precautionary measure for continued observation. (Note:', 'Hospitalization for an elective procedure to treat a pre-existing condition that has not', 'worsened is not an SAE. A pre-existing condition is a clinical condition that is', ""diagnosed prior to the use of an MSD product and is documented in the participant's"", 'medical history.', 'd. Results in persistent or significant disability/incapacity', ""The term disability means a substantial disruption of a person's ability to conduct"", 'normal life functions.', 'This definition is not intended to include experiences of relatively minor medical', 'significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
133,page_134,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '133', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'and accidental trauma (eg, sprained ankle) that may interfere with or prevent', 'everyday life functions but do not constitute a substantial disruption.', 'e. Is a congenital anomaly/birth defect', 'In offspring of participant taking the product regardless of time to diagnosis.', 'f.', 'Other important medical events', 'Medical or scientific judgment should be exercised in deciding whether SAE', 'reporting is appropriate in other situations such as important medical events that may', 'not be immediately life-threatening or result in death or hospitalization but may', 'jeopardize the participant or may require medical or surgical intervention to prevent 1', 'of the other outcomes listed in the above definition. These events should usually be', 'considered serious.', 'Examples of such events include invasive or malignant cancers, intensive treatment in', 'an emergency room or at home for allergic bronchospasm, blood dyscrasias or', 'convulsions that do not result in hospitalization, or development of drug dependency', 'or drug abuse.', '10.3.3', 'Additional Events Reported in the Same Manner as SAE', 'Additional events that require reporting in the same manner as SAE', 'In addition to the above criteria, AEs meeting either of the below criteria, although not', 'serious per ICH definition, are reportable to the Sponsor in the same time frame as SAEs to', 'meet certain local requirements. Therefore, these events are considered serious by the', 'Sponsor for collection purposes.', 'Is a new cancer (that is not a condition of the study)', 'Is associated with an overdose of pembrolizumab', '10.3.4', 'Recording AE and SAE', 'AE and SAE recording', 'When an AE/SAE occurs, it is the responsibility of the investigator to review all', 'documentation (eg, hospital progress notes, laboratory, and diagnostics reports) related to', 'the event.', 'The investigator will record all relevant AE/SAE information on the AE', 'CRFs/worksheets at each examination.', ""It is not acceptable for the investigator to send photocopies of the participant's medical"", 'records to the Sponsor in lieu of completion of the AE CRF page.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
134,page_135,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '134', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'There may be instances when copies of medical records for certain cases are requested by', 'the Sponsor. In this case, all participant identifiers, with the exception of the participant', 'number, will be blinded on the copies of the medical records before submission to the', 'Sponsor.', 'The investigator will attempt to establish a diagnosis of the event based on signs,', 'symptoms, and/or other clinical information. In such cases, the diagnosis (not the', 'individual signs/symptoms) will be documented as the AE/SAE.', 'Assessment of intensity/toxicity', 'An event is defined as ""serious"" when it meets at least 1 of the predefined outcomes as', 'described in the definition of an SAE, not when it is rated as severe.', '1.', 'The investigator will make an assessment of intensity for each AE and SAE (and', 'other reportable safety event) according to the NCI Common Terminology for', 'Adverse Events (CTCAE), version 4. Any AE that changes CTCAE grade over the', 'course of a given episode will have each change of grade recorded on the AE', 'CRFs/worksheets.', '-', 'Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic', 'observations only; intervention not indicated.', '- Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting', 'age-appropriate instrumental activities of daily living (ADL).', '-', 'Grade 3: Severe or medically significant but not immediately life-threatening;', 'hospitalization or prolongation of hospitalization indicated; disabling; limiting', 'self-care ADL.', '-', 'Grade 4: Life threatening consequences; urgent intervention indicated.', '-', 'Grade 5: Death related to AE.', 'Assessment of causality', '1.', ""Did the Sponsor's product cause the AE?"", '2.', ""The determination of the likelihood that the Sponsor's product caused the AE will be"", ""provided by an investigator who is a qualified physician. The investigator's"", 'signed/dated initials on the source document or worksheet that supports the causality', 'noted on the AE form, ensures that a medically qualified assessment of causality was', 'done. This initialed document must be retained for the required regulatory time frame.', 'The criteria below are intended as reference guidelines to assist the investigator in', 'assessing the likelihood of a relationship between the test product and the AE based', 'upon the available information.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
135,page_136,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '135', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '3.', 'The following components are to be used to assess the relationship between the', ""Sponsor's product and the AE; the greater the correlation with the components"", 'and their respective elements (in number and/or intensity), the more likely the', ""Sponsor's product caused the AE:"", '- Exposure: Is there evidence that the participant was actually exposed to the', ""Sponsor's product such as: reliable history, acceptable compliance assessment"", '(pill count, diary, etc.), expected pharmacologic effect, or measurement of', 'drug/metabolite in bodily specimen?', '-', 'Time Course: Did the AE follow in a reasonable temporal sequence from', ""administration of the Sponsor's product? Is the time of onset of the AE"", 'compatible with a drug-induced effect (applies to studies with investigational', 'medicinal product)?', '- Likely Cause: Is the AE not reasonably explained by another etiology such as', 'underlying disease, other drug(s)/vaccine(s), or other host or environmental', 'factors.', '-', ""Dechallenge: Was the Sponsor's product discontinued or"", 'dose/exposure/frequency reduced?', '- If yes, did the AE resolve or improve?', '- If yes, this is a positive dechallenge.', '- If no, this is a negative dechallenge.', '-', '(Note: This criterion is not applicable if: (1) the AE resulted in death or', 'permanent disability; (2) the AE resolved/improved despite continuation of the', ""Sponsor's product; (3) the study is a single-dose drug study; or (4) Sponsor's"", 'product(s) is/are only used 1 time.)', '-', ""Rechallenge: Was the participant re-exposed to the Sponsor's product in this"", 'study?', '-', 'If yes, did the AE recur or worsen?', '- If yes, this is a positive rechallenge.', '-', 'If no, this is a negative rechallenge.', '(Note: This criterion is not applicable if: (1) the initial AE resulted in death or', ""permanent disability, or (2) the study is a single-dose drug study; or (3) Sponsor's"", 'product(s) is/are used only 1 time.)', 'NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND', ""MAY HAVE BEEN CAUSED BY THE SPONSOR'S PRODUCT, OR IF RE-EXPOSURE"", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']"
136,page_137,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '136', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', ""TO THE SPONSOR'S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT"", 'RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN', 'ADVANCE BY THE SPONSOR CLINICAL DIRECTOR AS PER DOSE', 'MODIFICATION GUIDELINES IN THE PROTOCOL, AND IF REQUIRED, THE', 'INIRB/IEC.', '4.', 'Consistency with study intervention profile: Is the clinical/pathological', ""presentation of the AE consistent with previous knowledge regarding the Sponsor's"", 'product or drug class pharmacology or toxicology?', '5.', 'The assessment of relationship will be reported on the case report forms/worksheets', 'by an investigator who is a qualified physician according to his/her best clinical', 'judgment, including consideration of the above elements.', '6.', 'Use the following scale of criteria as guidance (not all criteria must be present to be', ""indicative of a Sponsor's product relationship)."", ""- Yes, there is a reasonable possibility of Sponsor's product relationship:"", ""- There is evidence of exposure to the Sponsor's product. The temporal sequence of"", ""the AE onset relative to the administration of the Sponsor's product is reasonable."", ""The AE is more likely explained by the Sponsor's product than by another cause."", ""- No, there is not a reasonable possibility of Sponsor's product relationship:"", ""- Participant did not receive the Sponsor's product OR temporal sequence of the"", ""AE onset relative to administration of the Sponsor's product is not reasonable OR"", ""the AE is more likely explained by another cause than the Sponsor's product."", '(Also entered for a participant with overdose without an associated AE.)', '7.', 'For each AE/SAE, the investigator must document in the medical notes that he/she', 'has reviewed the AE/SAE and has provided an assessment of causality.', '8.', 'There may be situations in which an SAE has occurred and the investigator has', 'minimal information to include in the initial report to the Sponsor. However, it is very', 'important that the investigator always make an assessment of causality for every', 'event before the initial transmission of the SAE data to the Sponsor.', '9.', 'The investigator may change his/her opinion of causality in light of follow-up', 'information and send an SAE follow-up report with the updated causality assessment.', '10.', 'The causality assessment is 1 of the criteria used when determining regulatory', 'reporting requirements.', '11.', 'For studies in which multiple agents are administered as part of a combination', 'regimen, the investigator may attribute each AE causality to the combination regimen', 'or to a single agent of the combination. In general, causality attribution should be', 'assigned to the combination regimen (ie, to all agents in the regimen). However,', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
137,page_138,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '137', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', ""causality attribution may be assigned to a single agent if in the investigator's opinion,"", 'there is sufficient data to support full attribution of the AE to the single agent.', 'Follow-up of AE and SAE', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as medically indicated or as requested by Sponsor to', 'elucidate the nature and/or causality of the AE or SAE as fully as possible. This may', 'include additional laboratory tests or investigations, histopathological examinations, or', 'consultation with other health care professionals.', 'New or updated information will be recorded in the CRF.', 'The investigator will submit any updated SAE data to the Sponsor within 24 hours of', 'receipt of the information.', '10.3.5', 'Reporting of AEs, SAEs, and Other Reportable Safety Events to the Sponsor', 'AE, SAE, and other reportable safety event reporting to Sponsor via electronic data', 'collection tool', 'The primary mechanism for reporting to the Sponsor will be the electronic data collection', '(EDC) tool.', 'Electronic reporting procedures can be found in the EDC data entry guidelines (or', 'equivalent).', 'If the electronic system is unavailable for more than 24 hours, then the site will use', 'the paper AE Reporting form.', 'Reference Section 8.4.1 for reporting time requirements.', 'The site will enter the SAE data into the electronic system as soon as it becomes', 'available.', 'After the study is completed at a given site, the EDC tool will be taken off-line to prevent', 'the entry of new data or changes to existing data.', 'If a site receives a report of a new SAE from a study participant or receives updated data', 'on a previously reported SAE after the EDC tool has been taken off-line, then the site can', 'report this information on a paper SAE form or by telephone (see next section).', 'Contacts for SAE reporting can be found in the Investigator Study File Binder (or', 'equivalent).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
138,page_139,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '138', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'SAE reporting to the Sponsor via paper CRF', 'If the EDC tool is not operational, facsimile transmission or secure e-mail of the SAE', 'paper CRF is the preferred method to transmit this information to the Sponsor.', 'In rare circumstances and in the absence of facsimile equipment, notification by', 'telephone is acceptable with a copy of the SAE data collection tool sent by overnight', 'mail or courier service.', 'Initial notification via telephone does not replace the need for the investigator to', 'complete and sign the SAE CRF pages within the designated reporting time frames.', 'Contacts and instructions for SAE reporting and paper reporting procedures can be found', 'in the Investigator Study File Binder (or equivalent).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
139,page_140,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '139', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.4', 'Appendix 4: Device Events, Adverse Device Events, and Medical Device', 'Incidents: Definitions, Collection, and Documentation', 'This section is not applicable.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
140,page_141,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '140', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.5', 'Appendix 5: Contraceptive Guidance and Pregnancy Testing', '10.5.1', 'Definitions', 'Women of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming postmenopausal', 'unless permanently sterile (see below).', 'If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot', 'be confirmed before first dose of study intervention, additional evaluation should be', 'considered.', 'Women in the following categories are not considered WOCBP:', 'Premenarchal', 'Premenopausal female with 1 of the following:', '- Documented hysterectomy', '- Documented bilateral salpingectomy', '- Documented bilateral oophorectomy', 'For individuals with permanent infertility due to an alternate medical cause other than the', 'above (eg, Mullerian agenesis, androgen insensitivity), investigator discretion should be', 'applied to determining study entry.', ""Note: Documentation can come from the site personnel's review of the participant's medical"", 'records, medical examination, or medical history interview.', 'Postmenopausal female', '-', 'A postmenopausal state is defined as no menses for 12 months without an', 'alternative medical cause.', 'A high follicle-stimulating hormone (FSH) level in the postmenopausal range', 'may be used to confirm a postmenopausal state in women not using hormonal', 'contraception or HRT. However, in the absence of 12 months of amenorrhea,', 'confirmation with 2 FSH measurements in the postmenopausal range is', 'required.', 'Females on HRT and whose menopausal status is in doubt will be required to', 'use one of the nonhormonal highly effective contraception methods if they', 'wish to continue their HRT during the study. Otherwise, they must', 'discontinue HRT to allow confirmation of postmenopausal status before study', 'enrollment.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
141,page_142,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '141', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.5.2', 'Contraception Requirements', 'Contraceptives allowed during the study includea:', 'Highly Effective Contraceptive Methods That Have Low User Dependency', 'Failure rate of <1% per year when used consistently and correctly.', 'Progestogen-only subdermal contraceptive implantb', 'Intrauterine hormone-releasing system (IUS)', 'Intrauterine device (IUD)', 'Bilateral tubal occlusion', 'Azoospermic partner (Vasectomized or secondary to medical cause)', 'This is a highly effective contraception method provided that the partner is the sole', 'male sexual partner of the WOCBP and the absence of sperm has been confirmed. If', 'not, an additional highly effective method of contraception should be used. A', 'spermatogenesis cycle is approximately 90 days.', ""Note: Documentation of azoospermia can come from the site personnel's review of"", ""the participant's medical records, medical examination, or medical history interview."", 'Sexual Abstinence', 'Sexual abstinence is considered a highly effective method only if defined as', 'refraining from heterosexual intercourse during the entire period of risk associated', 'with the study intervention. The reliability of sexual abstinence needs to be evaluated', 'in relation to the duration of the study and the preferred and usual lifestyle of the', 'participant.', 'a. Contraceptive use by men or women should be consistent with local regulations', 'regarding the use of contraceptive methods for participants of clinical studies.', 'b. If locally required, in accordance with Clinical Trial Facilitation Group (CTFG)', 'guidelines, acceptable contraceptive implants are limited to those which inhibit', 'ovulation.', 'c.', 'IUS is a progestin-releasing IUD.', 'Note: The following are not acceptable methods of contraception:', '-', 'Periodic abstinence (calendar, symptothermal, postovulation methods),', 'withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea', 'method (LAM).', '-', 'Male condom with cap, diaphragm, or sponge with spermicide.', '- Male and female condom should not be used together (due to risk of failure with', 'friction).', '10.5.3', 'Pregnancy Testing', 'WOCBP should only be included after a negative highly sensitive urine or serum pregnancy', 'test. Refer to Section 8.3.5.2 and Appendix 2 for further details.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
142,page_143,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '142', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'A urine pregnancy test will be obtained per the SoA (Section 1.3). Additional urine/serum', 'testing may be performed if clinically warranted and/or as defined by local regulations. If a', 'urine pregnancy test cannot be confirmed as negative, a serum pregnancy test is required.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
143,page_144,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '143', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.6 Appendix 6: Description of the iRECIST Process for Assessment of Disease', 'Progression', 'iRECIST is based on RECIST 1.1 but adapted to account for the unique tumor response seen', 'with immunotherapeutic drugs. iRECIST will be used by the investigator to assess tumor', 'response and progression, and to guide decisions about changes in management.', 'Assessment at Screening and Before RECIST 1.1 Progression', 'Until radiographic PD based on RECIST 1.1, there is no distinct iRECIST assessment.', 'Assessment and Decision at RECIST 1.1 Progression', 'For participants who show radiological PD by RECIST 1.1, the investigator will decide', 'whether to continue a participant on study intervention until repeat scans are obtained, as', 'described in Section 8.2.1.6.', 'Tumor flare may manifest as any factor causing radiographic progression per RECIST 1.1,', 'including:', 'Increase in the sum of diameters of target lesion(s) identified at baseline to >20% and', '>5 mm from nadir', 'Note: the iRECIST publication uses the terminology ""sum of measurements,"" but', '""sum of diameters"" will be used in this protocol, consistent with the original RECIST', '1.1 terminology', 'Unequivocal progression of nontarget lesion(s) identified at baseline', 'Development of new lesion(s)', 'iRECIST defines new response categories, including iUPD (unconfirmed PD) and iCPD', '(confirmed PD). For purposes of iRECIST assessment, the first visit showing PD according', 'to RECIST 1.1 will be assigned a visit (overall) response of iUPD, regardless of which', 'factors caused the PD.', 'At this visit, target and nontarget lesions identified at baseline by RECIST 1.1 will be', 'assessed as usual.', 'New lesions will be classified as measurable or nonmeasurable, using the same size', 'thresholds and rules as for baseline lesion assessment in RECIST 1.1. From measurable new', 'lesions, up to 5 lesions total (up to 2 per organ), may be selected as New Lesions - Target.', 'The sum of diameters of these lesions will be calculated and kept distinct from the sum of', 'diameters for target lesions at baseline. All other new lesions will be followed qualitatively', 'as New Lesions - Nontarget.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
144,page_145,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '144', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Assessment at the Confirmatory Imaging', 'On the confirmatory imaging, the participant will be classified as PD confirmed (with an', 'overall response of iCPD), or as showing persistent unconfirmed PD (with an overall', 'response of iUPD), or as showing disease stability or response (iSD/iPR/iCR).', 'Confirmation of PD', 'PD is considered confirmed, and the overall response will be iCPD, if ANY of the following', 'occur:', 'Any of the factors that were the basis for the iUPD at the previous visit show', 'worsening', '-', 'For target lesions, worsening is a further increase in the sum of diameters of', '>5 mm, compared with any prior iUPD time point', '- For nontarget lesions, worsening is any significant growth in lesions overall,', 'compared with a prior iUPD time point; this does not have to meet the', '""unequivocal"" standard of RECIST 1.1', '- For new lesions, worsening is any of these:', 'An increase in the new lesion sum of diameters by >5 mm from a prior iUPD', 'time point', 'Visible growth of new nontarget lesions', 'The appearance of additional new lesions', 'Any new factor appears that would have triggered PD by RECIST 1.1', 'Persistent iUPD', 'PD is considered not confirmed, and the overall response remains iUPD, if:', 'None of the PD-confirming factors identified above occurs AND', 'The target lesion sum of diameters (initial target lesions) remains above the initial PD', 'threshold (by RECIST 1.1)', 'Additional imaging for confirmation should be scheduled 4 to 8 weeks from the imaging on', 'which iUPD is seen. This may correspond to the next visit in the original visit schedule. The', 'assessment of the subsequent confirmation imaging proceeds in an identical manner, with', 'possible outcomes of iCPD, iUPD, and iSD, iPR, and iCR.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
145,page_146,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '145', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Resolution of iUPD', 'PD is considered not confirmed, and the overall response becomes iSD, iPR, or iCR, if:', 'None of the PD-confirming factors identified above occurs, AND', 'The target lesion sum of diameters (initial target lesions) is not above the initial PD', 'threshold.', 'The response is classified as iSD or iPR (depending on the sum of diameters of the target', 'lesions) or iCR if all lesions resolve.', 'In this case, the initial iUPD is considered to be pseudoprogression, and the level of', 'suspicion for progression is ""reset."" This means that the next visit that shows radiographic', 'progression, whenever it occurs, is again classified as iUPD by iRECIST, and the', 'confirmation process is repeated before a response of iCPD can be assigned.', 'Management Following the Confirmatory Imaging', 'If repeat imaging does not confirm PD per iRECIST, as assessed by the investigator, and the', 'participant continues to be clinically stable, study intervention may continue and follow the', 'regular imaging schedule. If PD is confirmed, participants will be discontinued from study', 'intervention.', 'NOTE: If a participant has confirmed radiographic progression (iCPD) as defined above, but', 'the participant is achieving a clinically meaningful benefit, an exception to continue study', 'intervention may be considered following consultation with the Sponsor. In this case, if study', 'intervention is continued, tumor imaging should continue to be performed following the', 'intervals as outlined in the SoA (Section 1.3).', 'Detection of Progression at Visits After Pseudo-progression Resolves', 'After resolution of pseudoprogression (ie, achievement of iSD, iPR, iCR, iUPD is indicated', 'by any of the following events):', 'Target lesions', '-', 'Sum of diameters reaches the PD threshold (20% and >5 mm increase from', 'nadir) either for the first time, or after resolution of previous pseudoprogression.', 'The nadir is always the smallest sum of diameters seen during the entire trial,', 'either before or after an instance of pseudoprogression.', 'Nontarget lesions', '-', 'If nontarget lesions have never shown unequivocal PD, their doing so for the first', 'time results in iUPD.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
146,page_147,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '146', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '-', 'If nontarget lesions have shown previous unequivocal PD, and this PD has not', 'resolved, iUPD results from any significant further growth of nontarget lesions,', 'taken as a whole.', 'New lesions', '- New lesions appear for the first time', '- Additional new lesions appear', '-', 'Previously identified new target lesions show an increase of >5 mm in the new', 'lesion sum of diameters, from the nadir value of that sum', '- Previously identified nontarget lesions show any significant growth', 'If any of the events above occur, the overall response for that visit is iUPD, and the iUPD', 'evaluation process (see Assessment at the Confirmatory Imaging above) is repeated. PD must', 'be confirmed before iCPD can occur.', 'The decision process is identical to the iUPD confirmation process for the initial PD, with', '1 exception: if new lesions occurred at a prior instance of iUPD, and at the confirmatory', 'imaging the burden of new lesions has increased from its smallest value (for new target', 'lesions, the sum of diameters is >5 mm increased from its nadir), then iUPD cannot resolve', 'to iSD or iPR. It will remain iUPD until either a decrease in the new lesion burden allows', 'resolution to iSD or iPR, or until a confirmatory factor causes iCPD.', 'Additional details about iRECIST are provided in the iRECIST publication [Seymour, L., et', 'al 2017].', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
147,page_148,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '147', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.7', 'Appendix 7: Country-specific Requirements', '10.7.1', 'Japan-specific Requirements', 'For the assistance to early diagnosis of pneumonitis/interstitia lung disease (ILD) in study', 'participants, the following items, such as pulse oximetry monitoring (peripheral capillary', 'oxygen saturation [SpO2]), C-reactive protein (CRP), Krebs von den Lungen-6 (KL-6), and', 'surfactant protein-D (SP-D), will be measured in this study. These items should be measured', 'as follows:', 'SpO2 at the timing of vital sign assessment', 'CRP, KL-6, and SP-D at screening*, predose on Day 1 of every cycle, end of', 'treatment, and the Safety Follow-up Visit (30 days after last dose)', '*Should be measured at the timing of clinical laboratory tests (such as', 'hematology/chemistry)', 'If pneumonitis/ILD occurs regardless of causality with study intervention, an independent', 'ILD evaluation committee will conduct adjudication of cases of the pneumonitis/ILD. For', 'this purpose, relevant data, such as chest imaging (from the baseline to the recovery of', 'pneumonitis/ILD) will be submitted to MSD K.K.', '10.7.2', 'France-specific Requirements', 'Treatment with pembrolizumab should be permanently discontinued in cases of confirmed', 'Stevens-Johnson syndrome or toxic epidermal necrolysis.', '10.7.3', 'Canada-specific Requirements', 'See Section 6.6.1 Immune-related Events and Dose Modification (Withhold, Treat,', 'Discontinue)', 'Treatment with pembrolizumab should be permanently discontinued in cases of confirmed', 'Stevens-Johnson syndrome or toxic epidermal necrolysis.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
148,page_149,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '148', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '10.8', 'Appendix 8: Abbreviations', 'Abbreviation', 'Expanded Term', '1L', 'first-line', 'ADA', 'antidrug antibody', 'ADL', 'activities of daily living', 'AE', 'adverse event', 'AJCC', 'American Joint Committee on Cancer', 'ALK', 'anaplastic lymphoma kinase', 'APaT', 'All Participants as Treated', 'BICR', 'blinded independent central review', 'CI', 'confidence interval', 'CL', 'clearance', 'COPD', 'chronic obstructive pulmonary disease', 'CR', 'complete response', 'CRF', 'case report form', 'CRP', 'C-reactive protein', 'CSR', 'clinical study report', 'CT', 'computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CTFG', 'Clinical Trial Facilitation Group', 'CVA', 'cerebrovascular accident', 'DILI', 'drug-induced liver injury', 'DMC', 'data monitoring committee', 'DNA', 'deoxyribonucleic acid', 'DOR', 'duration of response', 'ECG', 'electrocardiogram', 'ECI', 'event of clinical interest', 'ECOG', 'Eastern Cooperative Oncology Group', 'eCRF', 'electronic case report form', 'EDC', 'electronic data collection', 'EGFR', 'epidermal growth factor receptor', 'EMA', 'European Medicines Agency', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
149,page_150,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '149', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Abbreviation', 'Expanded Term', 'EOC', 'Executive Oversight Committee', 'EORTC', 'European Organization for Research and Treatment of Cancer', 'ePRO', 'electronic patient-reported outcome', 'EQ-5D-5L', 'EuroQoL-5D-5L', 'FAS', 'Full Analysis Set', 'FDA', 'Food and Drug Administration', 'FDAAA', 'Food and Drug Administration Amendments Act', 'FGF', 'fibroblast growth factor', 'FGFR', 'fibroblast growth factor receptor', 'FSH', 'follicle-stimulating hormone', 'GCP', 'Good Clinical Practice', 'HBsAg', 'hepatitis B surface antigen', 'HBV', 'hepatitis B virus', 'HCV', 'hepatitis C virus', 'HIV', 'human immunodeficiency virus', 'HR', 'hazard ratio', 'HRQoL', 'health-related quality of life', 'HRT', 'hormone replacement therapy', 'IA', 'interim analysis', 'IB', ""Investigator's Brochure"", 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation of Technical Requirements for', 'Pharmaceuticals for Human Use', 'iCPD', 'confirmed PD', 'iCR', 'confirmed CR', 'IEC', 'Independent Ethics Committee', 'irAE', 'immune-related adverse event', 'iPR', 'confirmed PR', 'IRB', 'Institutional Review Board', 'iRECIST', 'adjusted RECIST 1.1 for Immune-based Therapeutics', 'iSD', 'confirmed SD', 'ITT', 'Intention to Treat', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
150,page_151,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '150', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Abbreviation', 'Expanded Term', 'IUD', 'intrauterine device', 'iUPD', 'unconfirmed PD', 'IUS', 'intrauterine hormone-releasing system', 'IV', 'intravenous', 'KL-6', 'Krebs von den Lungen-6', 'LEAP', 'lenvatinib and pembrolizumab', 'LVEF', 'left ventricular ejection fraction', 'mAb', 'monoclonal antibody', 'MRI', 'magnetic resonance imaging', 'MTD', 'maximum tolerated dose', 'MUGA', 'multigated acquisition scan', 'NCI', 'National Cancer Institute', 'NSCLC', 'non-small cell lung cancer', 'OR', 'objective response', 'ORR', 'objective response rate', 'os', 'overall survival', 'PD', 'progressive disease', 'PD-1', 'programmed cell death protein', 'PDGFR', 'platelet-derived growth factor receptor', 'PD-L1', 'programmed cell death ligand 1', 'PD-L2', 'programmed cell death ligand 2', 'PFS', 'progression-free survival', 'Pgp', 'P-glycoprotein', 'PK', 'pharmacokinetic', 'PopPK', 'population pharmacokinetics', 'PR', 'partial response', 'PRES', 'posterior reversible encephalopathy syndrome', 'PRO', 'patient-reported outcomes', 'Q3W', 'every 3 weeks', 'QD', 'once daily', 'QLQ-LC13', 'Quality of Life Questionnaire and Lung Cancer Module 13', 'QoL', 'quality of life', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
151,page_152,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '151', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Abbreviation', 'Expanded Term', 'RCC', 'renal cell carcinoma', 'RECIST 1.1', 'Response Evaluation Criteria in Solid Tumors 1.1', 'RNA', 'ribonucleic acid', 'RP2D', 'recommended Phase 2 dose', 'RPLS', 'reversible posterior leukoencephalopathy syndrome', 'RTKi', 'receptor tyrosine kinase inhibitor', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'SD', 'stable disease', 'SoA', 'schedule of activities', 'SOC', 'standard of care', 'SP-D', 'surfactant protein-D', 'SpO2', 'peripheral capillary oxygen saturation', 'sSAP', 'supplemental statistical analysis plan', 'TAM', 'tumor-associated macrophage', 'TB', 'tuberculosis', 'TPS', 'tumor proportion score', 'TTD', 'time to true deterioration', 'UPCR', 'urine protein-to-creatinine ratio', 'V', 'volume of distribution', 'VEGF', 'vascular endothelial growth factor', 'VEGFR', 'vascular endothelial growth factor receptor', 'WOCBP', 'woman/women of childbearing potential', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
152,page_153,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '152', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '11 REFERENCES', '[Aaronson, N. K., et al 1993]', 'Aaronson NK, Ahmedzai S, Bergman', '[03Q3QL]', 'B, Bullinger M, Cull A, Duez NJ, et', 'al. The European Organization for', 'Research and Treatment of Cancer', 'QLQ-C30: a quality-of-life instrument', 'for use in international clinical trials in', 'oncology. J Natl Cancer Inst', '1993;85(5):365-76.', '[Bergman, B., et al 1994]', 'Bergman B, Aaronson NK, Ahmedzai', '[00VTZB]', 'S, Kaasa S, Sullivan M. The EORTC', 'QLQ-LC13: a modular supplement to', 'the EORTC core quality of life', 'questionnaire (QLQ-C30) for use in', 'lung cancer clinical trials. Eur J', 'Cancer 1994;30A(5):635-42.', '[Cross, M. J. 2001]', 'Cross MJ, Claesson-Welsh L. FGF', '[04XKP6]', 'and VEGF function in angiogenesis:', 'signalling pathways, biological', 'responses and therapeutic inhibition.', 'Trends Pharmacol Sci. 2001', 'Apr;22(4):201-7.', '[Disis, M. L. 2010]', 'Disis ML. Immune regulation of', '[058SQL]', 'cancer. J Clin Oncol', '2010;28(29):4531-8.', '[Dudley, M. E., et al 2005]', 'Dudley ME, Wunderlich JR, Yang JC, [00VMPR]', 'Sherry RM, Topalian SL, Restifo NP,', 'et al. Adoptive cell transfer therapy', 'following non-myeloablative but', 'lymphodepleting chemotherapy for the', 'treatment of patients with refractory', 'metastatic melanoma. J Clin Oncol', '2005;23(10):2346-57.', '[Ellis, L. M. 2008]', 'Ellis LM, Hicklin DJ. VEGF-targeted', '[04XKPD]', 'therapy: mechanisms of anti-tumour', 'activity. Nat Rev Cancer. 2008', 'Aug;8:579-91.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
153,page_154,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '153', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[Ferrara, N., et al 2003]', 'Ferrara N, Gerber HP, LeCouter J.', '[04XKQ2]', 'The biology of VEGF and its', 'receptors. Nat Med. 2003', 'Jun;9(6):669-76.', '[Havel, L., et al 2014]', 'Havel L, Lee JS, Lee KH, Bidoli P,', '[04X49Z]', 'Kim JH, Ferry D, et al. E7080', '(lenvatinib) in addition to best', 'supportive care (BSC) versus BSC', 'alone in third-line or greater', 'nonsquamous, non-small cell lung', 'cancer (NSCLC) [abstract]. Presented', 'at: The American Society of Clinical', 'Oncology (ASCO) Annual Meeting;', '2014 May 31; Alexandria, VA. J Clin', 'Oncol. 2014 May 20;32(15 suppl).', 'Abstract no. 8043.', '[Hodi, F.S., et al 2014]', 'Hodi FS, Ribas A, Daud A, Hamid O,', '[0465RW]', 'Robert C, Kefford R, et al. Patterns of', 'response in patients with advanced', 'melanoma treated with', 'Pembrolizumab (MK-3475) and', 'evaluation of immune-related response', 'criteria (irRC). J Immunother Cancer.', '2014;2( (Suppl 3): P103.', '[Hunder, N. N., et al 2008]', 'Hunder NN, Wallen H, Cao J,', '[00VMPX]', 'Hendricks DW, Reilly JZ, Rodmyre', 'R, et al. Treatment of metastatic', 'melanoma with autologous CD4+ T', 'cells against NY-ESO-1. N Engl J', 'Med 2008;358(25):2698-703.', '[IB Edition 15-Eisai 2018]', 'Lenvatinib (LENVIMAR,', '[04Z6DS]', ""KISPLYX®) Investigator's Brochure,"", 'Edition Number 15', '[IB Edition 16 2018 ]', 'KEYTRUDA (pembrolizumab)', '[04W7QW]', 'Investigator Brochure, Edition', 'Number 16, 29-JUN-2018.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
154,page_155,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '154', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[Kato, Y., et al 2019]', 'Kato Y, Tabata K, Kimura T, Yachie-', '[057JXY]', 'Kinoshita A, Ozawa Y, Yamada K, et', 'al. Lenvatinib plus anti-PD-1 antibody', 'combination treatment activates', 'CD8(+) T cells through reduction of', 'tumor-associated macrophage and', 'activation of the interferon pathway.', 'PLoS One. 2019 Feb', '27;14(2):e0212513.', '[Kimura, T., et al 2018]', 'Kimura T, Kato Y, Ozawa Y, Kodama [057LPH]', 'K, Ito J, Ichikawa K, et al.', 'Immunomodulatory activity of', 'lenvatinib contributes to antitumor', 'activity in the Hepal -6 hepatocellular', 'carcinoma model. Cancer Sci.', '2018;109:3993-4002.', '[Liang, Kung-Yee and Zeger,', 'Liang K-Y, Zeger SL. Longitudinal', '[00QJ0M]', 'Scott L. 2000]', 'data analysis of continuous and', 'discrete responses for pre-post', 'designs. Sankhya: The Indian Journal', 'of Statistics 2000;62(Series B, Pt.', '1):134-48.', '[Lieu, C., et al 2011]', 'Lieu C, Heymach J, Overman M, Tran [04XKQM]', 'H, Kopetz S. Beyond VEGF:', 'inhibition of the fibroblast growth', 'factor pathway and antiangiogenesis.', 'Clin Cancer Res. 2011 Oct', '1;17(19):6130-9.', '[Limaverde-Sousa, G., et al', 'Limaverde-Sousa G, Sternberg C,', '[04XKQW]', '2014]', 'Ferreira CG. Antiangiogenesis beyond', 'VEGF inhibition: a journey from', 'antiangiogenic single-target to broad-', 'spectrum agents. Cancer Treat Rev.', '2014;40:548-57.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
155,page_156,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '155', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[Lopes, G., et al 2018]', 'Lopes G, Wu Y, Kudaba I, Kowalski', '[04Y5G9]', 'D, Cho BC, Castro G, et al.', 'Pembrolizumab (pembro) versus', 'platinum-based chemotherapy', '(chemo) as first-line therapy for', 'advanced/metastatic NSCLC with a', 'PD-L1 tumor proportion score (TPS)', '> 1%: open-label, phase 3', 'KEYNOTE-042 study [abstract].', 'Presented at: The American Society of', 'Clinical Oncology (ASCO) Annual', 'Meeting; 2018 Jun 1-5; Chicago, IL. J', 'Clin Oncol. 2018;36(suppl). Abstract', 'no. LBA4.', '[Makker, V., et al 2018]', 'Makker V, Rasco D, Vogelzang NJ,', '[04YJ9J]', 'Messing M, Brose MS, Cohn AL, et', 'al. Lenvatinib + Pembrolizumab in', 'patients with advanced endometrial', 'cancer: updated results. Poster session', 'presented at: 2018 American Society', 'of Clinical Oncology (ASCO) Annual', 'Meeting; 2018 Jun 1-5; Chicago, IL.', 'Poster no. 5596.', '[Miettinen, O. 1985]', 'Miettinen O, Nurminen M.', '[00VMQY]', 'Comparative analysis of two rates.', 'Stat Med 1985;4:213-26.', '[National Cancer Institute 2018]', 'SEER*Stat [Internet]. Bethesda (MD): [0507C2]', 'National Cancer Institute. 2018.', 'Cancer stat facts: lung and bronchus', 'cancer; [about 12 screens]. Available', 'from:', 'https://seer.cancer.gov/statfacts/html/l', 'ungb.html.', '[Nishio, M., et al 2013]', 'Nishio M, Horai T, Horiike A,', '[04ZK34]', 'Nokihara H, Yamamoto N, Takahashi', 'T, et al. Phase 1 study of lenvatinib', 'combined with carboplatin and', 'paclitaxel in patients with non-small-', 'cell lung cancer. Br J Cancer.', '013;109:538-44.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
156,page_157,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '156', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[Pickard, A. S., et al 2007]', 'Pickard AS, Neary MP, Cella D.', '[00W0FM]', 'Estimation of minimally important', 'differences in EQ-5D utility and VAS', 'scores in cancer. Health Qual Life', 'Outcomes 2007;5:1-8.', '[Rabin, R. 2001]', 'Rabin R, de Charro F. EQ-5D: a', '[03QM46]', 'measure of health status from the', 'EuroQol group. Ann Med', '2001;33:337-43.', '[Reck, M., et al 2016]', 'Reck M, Rodriguez-Abreu D,', '[04JNM3]', 'Robinson AG, Hui R, Csoszi T, Fulop', 'A, et al. Pembrolizumab versus', 'Chemotherapy for PD-L1-Positive', 'Non-Small-Cell Lung Cancer. N Engl', 'J Med. 2016 Oct 8. [Epub ahead of', 'print].', '[Seymour, L., et al 2017]', 'Seymour L, Bogaerts J, Perrone A,', '[04P9RV]', 'Ford R, Schwartz LH, Mandrekar S, et', 'al. iRECIST: guidelines for response', 'criteria for use in trials testing', 'immunotherapeutics. Lancet Oncol.', '2017 Mar;18(3):e143-52', '[Sulpher, J. A., et al 2013]', 'Sulpher JA, Owen SP, Hon H, Tobros', '[040565]', 'K, Shepherd FA, Sabri E, et al.', 'Factors influencing a specific', 'pathologic diagnosis of non-small-cell', 'lung carcinoma. Clin Lung Cancer.', '2013 May;14(3):238-44.', '[Tammela, T. 2010]', 'Tammela T, Alitalo K.', '[04XKRB]', 'Lymphangiogenesis: molecular', 'mechanisms and future promise. Cell.', '2010 Feb 19;140:460-76.', '[Wolchok, J. D., et al 2009]', ""Wolchok JD, Hoos A, O'Day S,"", '[00VMNZ]', 'Weber JS, Hamid O, LebbéC, et al.', 'Guidelines for the evaluation of', 'immune therapy activity in solid', 'tumors: immune-related response', 'criteria. Clin Cancer Res', '2009;15(23):7412-20.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
157,page_158,"['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '157', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[World Health Organization', 'Globocan 2012: Lung Cancer', '[0402K4]', '2012]', 'Estimated Incidence, Mortality and', 'Prevalence Worldwide in 2012', '[Internet]. Lyon (FR): World Health', 'Organization, International Agency', 'for Research on Cancer (IARC).', 'c2014 - [updated 2014 Oct 3].', 'Available from:', 'http://globocan.iarc.fr/Pages/fact_shee', 'ts cancer.aspx', '[Yamamoto, Y., et al 2014]', 'Yamamoto Y, Matsui J, Matsushima', '[04XQ0S]', 'T, Obaishi H, Miyazaki K, Nakamura', 'K, et al. Lenvatinib, an angiogenesis', 'inhibitor targeting VEGFR/FGFR,', 'shows broad antitumor activity in', 'human tumor xenograft models', 'associated with microvessel density', 'and pericyte coverage. Vasc Cell.', '2014;6:18.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']"
158,page_159,"['MK-7902', 'PAGE 1', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Supplemental Statistical Analysis Plan (sSAP)', 'C', 'Confidential']"
159,page_160,"['MK-7902', 'PAGE 2', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table of Contents', '1.', 'INTRODUCTION', '7', '2.', 'SUMMARY OF CHANGES', '7', '3. ANALYTICAL AND METHODOLOGICAL DETAILS FOR GLOBAL STUDY', '7', '3.1.', 'Statistical Analysis Plan Summary', '7', '3.2.', 'Responsibility for Analyses/In-house Blinding', '8', '3.3.', 'Hypotheses/Estimation', '9', '3.4.', 'Analysis Enppoints', '9', '3.4.1.', 'Efficacy Enppoints', '9', '3.4.1.1.', 'Primary Endpoints', '9', '3.4.1.2.', 'Secondary Endpoints', '9', '3.4.1.3.', 'Exploratory Endpoints', '9', '3.4.2.', 'Safety Enppoints', '9', '3.4.3.', 'Patient-reported Outcome Enppoints', '9', '3.5.', 'Analysis Populations', '11', '3.5.1.', 'Efficacy Analysis Populations', '11', '3.5.2.', 'Safety Analysis Populations', '11', '3.5.3.', 'Patient-reported Outcome Analysis Population', '12', '3.5.4.', 'Pharmacokinetic Analysis Population', '12', '3.6.', 'Statistical Methods', '12', '3.6.1.', 'Statistical Methods for Efficacy Analyses', '12', '3.6.1.1.', 'Progression-free Survival', '13', '3.6.1.2.', 'Overall Survival', '14', '3.6.1.3.', 'Objective Response Rate', '15', '3.6.1.4.', 'Duration of Response', '15', '3.6.2.', 'Statistical Methods for Safety Analyses', '15', '3.6.3.', 'Statistical Methods for Patient-reported Outcome Analyses', '17', '3.6.3.1.', 'Scoring Algorithm', '17', '3.6.3.2.', 'PRO Compliance Summary', '19', '3.6.3.3.', 'Mean Change from Baseline', '20', '3.6.3.4.', 'Time-to-True Deterioration (TTD) Analysis', '21', '3.6.3.5.', 'Overall Improvement and Overall Improvement/Stability', '22', '3.6.3.6.', 'Analysis Strategy for Key PRO Enppoints', '22', 'Confidential']"
160,page_161,"['MK-7902', 'PAGE 3', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '3.6.4.', 'Demographic and Baseline Characteristics', '23', '3.7.', 'Interim Analyses', '23', '3.7.1.', 'Efficacy Interim Analysis', '24', '3.7.2.', 'Safety Interim Analyses', '25', '3.8.', 'Multiplicity', '25', '3.8.1.', 'Objective Response Rate', '26', '3.8.2.', 'Progression-free Survival', '26', '3.8.3.', 'Overall Survival', '27', '3.8.4.', 'Safety Analyses', '29', '3.9.', 'Sample Size and Power Calculations', '29', '3.10.', 'Subgroup Analyses', '30', '3.11.', 'Compliance (Medication Adherence)', '30', '3.12.', 'Extent of Exposure', '30', '4.', 'STATISTICAL ANALYSIS PLAN FOR EXTENSION', '31', '4.1.', 'Introduction', '31', '4.2.', 'Responsibility for Analyses/In-House Blinding', '31', '4.3.', 'Hypotheses/Estimation', '31', '4.4.', 'The Analysis Enppoints', '32', '4.4.1.', 'Efficacy Enppoints', '32', '4.4.1.1.', 'Primary Enppoints', '32', '4.4.1.2.', 'Secondary Enppoints', '32', '4.4.1.3.', 'Exploratory Enppoints', '32', '4.4.2.', 'Safety Enppoints', '32', '4.4.3.', 'Patient-reported Outcome Enppoints', '32', '4.5.', 'Analysis Populations', '33', '4.5.1.', 'Efficacy Analysis Populations', '33', '4.5.2.', 'Safety Analysis Populations', '33', '4.5.3.', 'Patient-reported Outcome Analysis Population', '33', '4.5.4.', 'Pharmacokinetic Analysis Population', '34', '4.6.', 'Statistical Methods', '34', '4.6.1.', 'Statistical Methods for Efficacy Analyses', '34', '4.6.1.1.', 'Progression-free Survival', '34', '4.6.1.2.', 'Overall Survival', '35', 'C', 'Confidential']"
161,page_162,"['MK-7902', 'PAGE 4', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '4.6.1.3.', 'Objective Response Rate', '35', '4.6.1.4.', 'Duration of Response', '35', '4.6.2.', 'Statistical Methods for Safety Analyses', '36', '4.6.3.', 'Statistical Methods for PRO Analysis', '36', '4.6.4.', 'Summaries of Baseline Characteristics, Demographics, and Other Analyses', '36', '4.7.', 'Interim Analysis and Final analysis', '36', '4.8.', 'Multiplicity', '36', '4.9.', 'Sample Size and Power Calculations', '36', '5. APPENDICES:', '37', '5.1.', 'Rules for Non-Binding Futility Analyses', '37', '5.2. ABBREVIATIONS', '39', '6.', 'REFERENCES', '42', 'C', 'Confidential']"
162,page_163,"['MK-7902', 'PAGE 5', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'List of Tables', 'Table 1 Analysis Methods for Key Efficacy Endpoints', '13', 'Table 2 Censoring Rules for Primary and Sensitivity Analyses of Progression-free Survival', '14', 'Table 3 Censoring Rules for Duration of Response', '15', 'Table 4 Analysis Strategy for Safety Parameters', '17', 'Table 5 PRO Data Collection Schedule and Mapping of Study visit to Analysis Visit', '20', 'Table 6 Censoring Rules for Time-to-Deterioration', '22', 'Table 7 Analysis Strategy for Key PRO Endpoints', '23', 'Table 8 Summary of Interim and Final Analyses Strategy', '25', 'Table 9 Efficacy Boundaries and Properties for Progression-free Survival Analyses', '27', 'Table 10 Efficacy Boundaries and Properties for Overall Survival Analyses', '28', 'Table 11 Futility Boundaries for OS in July 2021 and at IA', '38', 'Table 12 Non-binding Cumulative Probability of Stopping for OS', '38', 'C', 'Confidential']"
163,page_164,"['MK-7902', 'PAGE 6', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'List of Figures', 'Figure 1 Multiplicity Graph for Type I Error Control', '26', 'Figure 2 Decision Tree for Futility Assessment at July 2021 DMC', '39', 'C', 'Confidential']"
164,page_165,"['MK-7902', 'PAGE 7', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '1.', 'INTRODUCTION', 'This supplemental SAP (sSAP) is a companion document to the protocol. In addition to the', 'information presented in the protocol SAP, which provides the principal features of confirmatory', 'analyses for this trial, this supplemental SAP provides additional statistical analysis details/data', 'derivations and documents modifications or additions to the analysis plan that are not ""principal\'', 'in nature and result from information that was not available at the time of protocol finalization.', '2.', 'SUMMARY OF CHANGES', 'As the observed PFS event number at the July 2021 DMC was more than the expected PFS event', 'number at the IA (PFS final analysis), the sSAP was amended to update the non-binding futility', 'criteria for July 2021 DMC in Appendix 5.1..', '3.', 'ANALYTICAL AND METHODOLOGICAL DETAILS FOR GLOBAL STUDY', '3.1. Statistical Analysis Plan Summary', 'Study Design Overview', 'Phase 3 study of pembrolizumab plus lenvatinib VS pembrolizumab plus placebo', 'for 1L treatment of metastatic NSCLC in participants whose tumors express', 'PD-L1 (TPS 1%)', 'Treatment Assignment', 'Approximately 620 participants will be randomized in a 1:1 ratio between', '2 treatment arms: (1) pembrolizumab + lenvatinib and (2) pembrolizumab', '+', 'placebo.', 'Stratification factors are as follows:', 'Geographic region (East Asia VS non-East Asia)', 'ECOG PS (0 vs 1)', 'TPS (1%-49% VS 50%)', 'Analysis Populations', 'Efficacy: Intention to Treat (ITT)', 'Safety: All Participants as Treated (APaT)', 'PRO: Full Analysis Set (FAS)', 'Primary Enppoints', 'PFS per RECIST 1.1 based on BICR', 'OS', 'Secondary Enppoints', 'OR per RECIST 1.1 based on BICR', 'Safety and tolerability', 'Mean change from baseline in Global health status/QoL, cough, chest pain,', 'dyspnea and physical functioning scores', 'Time to True Deterioration (TTD) in global health status/QoL, cough, chest', 'pain, dyspnea, physical functioning, and composite endpoint (combination of', 'cough, chest pain, or dyspnea items)', 'Statistical Methods for', 'The primary hypotheses will be evaluated by comparing pembrolizumab +', 'Key Efficacy Analyses', 'lenvatinib to pembrolizumab + placebo in PFS and os using a stratified log-rank', 'test and in ORR using the stratified Miettinen and Nurminen method [Miettinen,', 'O. 1985]. The HR will be estimated using a stratified Cox regression model. Event', 'rates over time will be estimated within each treatment group using the Kaplan-', 'Meier method. The difference in ORR will be estimated using the stratified', 'Miettinen and Nurminen method with strata weighting by sample size.', 'Confidential']"
165,page_166,"['MK-7902', 'PAGE 8', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Statistical Methods for', 'The primary hypotheses will be evaluated by comparing pembrolizumab +', 'Key Safety Analyses', 'lenvatinib to pembrolizumab + placebo in PFS and os using a stratified log-rank', 'test and in ORR using the stratified Miettinen and Nurminen method [Miettinen,', 'O. 1985]. The HR will be estimated using a stratified Cox regression model. Event', 'rates over time will be estimated within each treatment group using the Kaplan-', 'Meier method. The difference in ORR will be estimated using the stratified', 'Miettinen and Nurminen method with strata weighting by sample size.', 'Interim Analyses', 'One interim analysis and one final analysis are planned for this study. Results will', 'be reviewed by an external Data Monitoring Committee (DMC). Details are', 'provided in Section 9.7.', 'Interim analysis (IA): to be performed after ~416 PFS events are observed', 'and', '~8.8 months after last participant randomized', 'Primary purpose: final PFS analysis and interim OS analysis', 'Final analysis: to be performed after ~388 deaths are observed and - -18.5', 'months after last participant randomized', 'Primary purpose: final OS analysis', 'Note that for the IA and the FA, if the events accrue slower than expected such', 'that the targeted number of events cannot be reached in the anticipated timeframe,', 'the Sponsor may conduct the analysis with an additional 2 months and 7 months of', 'follow-up for the IA and FA respectively, or the specified number of events is', 'observed, whichever occurs first.', 'Multiplicity', 'The overall Type I error rate over the multiple endpoints will be strongly', 'controlled at 2.5% (1-sided). A 0.55% (1-sided) will be initially allocated to test', 'PFS and 1.95% (1-sided) allocated to test OS. The graphical approach of Maurer', 'and Bretz [Maurer, W., et al 2011] will be applied to reallocate a among the', 'hypotheses for ORR, PFS, and OS. Lan-DeMets [Lan, K. K. G. and DeMets, D. L.', ""1983] and O'Brien-Fleming [O'Brien, P. C. and Fleming, T. R. 1979] group"", 'sequential methods will be used to allocate a among the interim and final analysis', 'for the os endpoint.', 'Sample Size and Power', 'The planned sample size is approximately 620 participants. For PFS, based on 416', 'events, the study has 86.5% power to detect a HR of 0.7 (pembrolizumab +', 'lenvatinib VS pembrolizumab + placebo) at =0.55% (1-sided). For OS, based on', '388 events, the study has 90% power to detect a HR of 0.71 (pembrolizumab +', 'lenvatinib vs pembrolizumab + placebo) at =1.95% (1-sided).', 'China Extension Study', 'China participants randomized during the global study phase will be included in all', 'global study analyses (efficacy and safety). China participants randomized during', 'the China extension phase will be excluded from all global study analyses. China', 'participants randomized during global and extension phases will both be included', 'in the China-specific analyses.', '3.2. Responsibility for Analyses/In-house Blinding', 'The statistical analysis of the data obtained from this study will be the responsibility of the', 'Clinical Biostatistics department of the Sponsor.', 'This study will be conducted as a double-blind study under in-house blinding procedures. The', 'official, final database will not be unblinded until medical/scientific review has been performed,', 'protocol deviations have been identified, and data have been declared final and complete.', 'Confidential']"
166,page_167,"['MK-7902', 'PAGE 9', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'The Sponsor will generate the randomized allocation schedule(s) for study intervention', 'assignment.', 'Blinding issues related to the planned interim analyses are described in Section 3.7.', '3.3. Hypotheses/Estimation', 'Objectives and hypotheses of the study are stated in Section 3 of the study protocol.', '3.4. Analysis Enppoints', 'Efficacy and safety endpoints that will be evaluated for within- and between-treatment', 'differences are listed below.', '3.4.1.', 'Efficacy Enppoints', '3.4.1.1.', 'Primary Enppoints', 'PFS: the time from randomization to the first documented PD per RECIST 1.1, adjusted to', 'follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, based on', 'BICR or death due to any cause, whichever occurs first. See Section 9.6.1 for the definition of', 'censoring.', 'OS: the time from randomization to death due to any cause.', '3.4.1.2.', 'Secondary Enppoints', 'OR: a confirmed CR or PR per RECIST 1.1, adjusted to follow a maximum of 10 target lesions', 'and a maximum of 5 target lesions per organ, based on BICR.', '3.4.1.3.', 'Exploratory Endpoints', 'DOR: the time from the earliest date of qualifying response until earliest date of PD or death', 'from any cause, whichever comes first.', '3.4.2.', 'Safety Enppoints', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs, SAEs, fatal AEs, laboratory tests, and vital signs. Furthermore, specific events will be', 'collected and designated as ECIs as described in Section 8.4.7 of the study protocol.', '3.4.3.', 'Patient-reported Outcome Endpoints', 'Secondary', 'Mean change from baseline in EORTO QLQ-C30 global health status/QoL (items 29-30),', 'physical functioning (items 1-5), and dyspnea scores (item 8), and EORTC QLQ-LC13', 'cough (item 31) and chest pain (item 40) scores.', 'Confidential']"
167,page_168,"['MK-7902', 'PAGE 10', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'TTD as measured by each of the EORTC QLQ-C30 global health status/QoL, physical', 'functioning, and dyspnea scores, and EORTC QLQ-LC13 cough and chest pain scores.', 'TTD as measured by a composite symptom endpoint: cough (QLQ-LC13 item 31), chest pain', '(QLQ-LC13 item 40), or dyspnea (QLQ-C30 item 8)', 'Based on prior literature (Osoba D et al., 1998; King et al., 1996, Maringwa et al., 2011), a >10', 'point or greater worsening from baseline for each scale represents a minimally important', 'difference (MID) that represents a clinically relevant deterioration. TTD in the individual scores', 'specified above is defined as the time to first onset of >10 (out of 100) point deterioration from', 'baseline in a given scale/subscale/item and confirmed by a second adjacent >10 point', 'deterioration from baseline. TTD in the composite endpoint is defined as the time to first onset of', 'point deterioration (i.e., increase in score) from baseline in any one of the 3 lung cancer', 'symptom scale items (EORTC-QLQ-C30 [dyspnea] and EORTC-QLQ-LC13 [cough and chest', 'pain]) with confirmation by the subsequent visit of a >10 point deterioration (i.e., increase in', 'score) from baseline in the same scale as the first onset. Changes from baseline in EORTC QLQ-', 'C30 scores will also be interpreted according to recent subscale-specific guidelines, which', 'indicate that clinically meaningful differences vary by scale (Cocks et al., 2012)', 'Exploratory', 'Change from baseline in the additional scales of the EORTO QLQ-C30, EORTC QLQ-LC13,', 'and EuroQoL EQ-5D visual analogue scale (VAS) scores. Specifically:', 'Each EORTC QLQ-C30 functional scales: role functioning, emotional functioning,', 'cognitive functioning, and social functioning', 'Each of three EORTO QLQ-C30 symptom scales (fatigue, nausea/vomiting, and', 'pain), and single item measures (sleep disturbance, appetite loss, constipation,', 'diarrhea, and financial difficulties)', 'Each EORTO QLQ-LC13 item: site-specific pain (pain in arm or shoulder, and pain', 'in other parts), sore mouth, dysphagia, peripheral neuropathy, alopecia, and', 'hemoptysis', 'The EQ-5D VAS', 'Proportions of improvement / stability / stability + improvement / deterioration in EORTC', 'QLQ-C30 global health status / QoL, physical functioning, and dyspnea scores, and EORTO', 'QLQ-LC13 cough and chest pain scores where', 'Improvement', 'Improvement for the global health status/QoL and physical functioning scores is', 'defined by an increase of 10 points or more in score from baseline at any time', 'during the study and confirmed by an increase of 10 points or more in score at', 'the next consecutive visit.', 'Confidential']"
168,page_169,"['MK-7902', 'PAGE 11', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Improvement for the dyspnea, cough, and chest pain scores is defined by a', 'decrease of 10 points or more in score from baseline at any time during the study', 'and confirmed by a decrease of 10 points or more in score at the next consecutive', 'visit.', 'Stability is defined as follows, when the criteria for improvement are not met:', 'an improvement confirmed by a less than 10 points change from baseline at', 'the next consecutive visit', 'less than 10 points change in score confirmed by a less than 10 points change', 'in score at the next consecutive visit', 'less than 10 points change in score and confirmed by an improvement at the', 'next consecutive visit', 'Stability + improvement is defined as the sum of proportions with stability and', 'improvement as specified above.', 'Deterioration is defined as a 10 points or greater worsening from baseline at any time', 'during the study when the criteria for improvement or stability are not met.', '3.5. Analysis Populations', '3.5.1.', 'Efficacy Analysis Populations', 'The analyses of the primary efficacy endpoints are based on the ITT population. All randomized', 'participants will be included in this population. Participants will be analyzed in the treatment', 'group to which they were randomized. Based on actual enrollment, all participants who were', 'randomized on or prior to January 28, 2021 will be included in the ITT population of the global', 'study. All participants who failed screening in addition to all randomized participants on or prior', 'to January 28, 2021will be included in the screening population. Details on the approach to', 'handling missing data are provided in Section 3.6.', '3.5.2.', 'Safety Analysis Populations', 'Safety analyses will be conducted in the APaT population, which consists of all randomized', 'participants who received at least 1 dose of study intervention. Participants will be included in', 'the treatment group corresponding to the study intervention they actually received for the', 'analysis of safety data using the APaT population. This will be the treatment group to which they', 'are randomized, except for participants who take incorrect study intervention for the entire', 'treatment period; such participants will be included in the treatment group corresponding to the', 'study intervention actually received. Any participant who receives the incorrect study', 'intervention for 1 cycle, but receives the randomized treatment for all other cycles, will be', 'analyzed according to the randomized treatment group, and a narrative will be provided for any', 'events that occur during the cycle for which the participant is incorrectly dosed.', 'Confidential']"
169,page_170,"['MK-7902', 'PAGE 12', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'At least 1 laboratory, vital sign, or ECG measurement obtained subsequent to at least 1 dose of', 'study intervention is required for inclusion in the analysis of the respective safety parameter. To', 'assess change from baseline, a baseline measurement is also required.', '3.5.3.', 'Patient-reported Outcome Analysis Population', 'The PRO analyses are based on the PRO Full Analysis Set (PRO FAS) population, defined as all', 'randomized participants who have at least one PRO assessment available and have received at', 'least one dose of the study intervention. Participants will be analyzed in the treatment group to', 'which they were randomized.', '3.5.4.', 'Pharmacokinetic Analysis Population', 'The population of PK analysis set includes all the participants who have received at least 1 dose', 'of study intervention with documented dosing history in the lenvatinib + pembrolizumab arm', 'and have measurable plasma levels of lenvatinib or serum levels of pembrolizumab.', '3.6. Statistical Methods', '3.6.1.', 'Statistical Methods for Efficacy Analyses', 'This section describes the statistical methods that address the primary and secondary efficacy', 'objectives. Efficacy results that will be deemed to be statistically significant after consideration', 'of the Type I error control strategy are described in Section 3.8. Nominal p values will be', 'computed for other efficacy analyses, but should be interpreted with caution because of potential', 'issues of multiplicity.', 'The stratification factors used for randomization (see Section 6.3.2 in the protocol) will be', 'applied to all stratified analyses, in particular, the stratified log-rank test, stratified Cox model,', 'and stratified Miettinen and Nurminen method [Miettinen, O. 1985].', 'The efficacy analyses for OR, DOR and PFS will include responses and documented progression', 'events that occur prior to second course treatment.', 'A summary of the primary analysis strategy for the key efficacy endpoints is provided in Table', '1.', 'C', 'Confidential']"
170,page_171,"['MK-7902', 'PAGE 13', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 1 Analysis Methods for Key Efficacy Endpoints', 'Endpoint/Variable', 'Statistical Method', 'Analysis', 'Population', 'Missing Data Approach', 'Primary Analyses:', 'PFS (RECIST 1.1)', 'Testing: stratified log-rank test', 'ITT', 'Censored according to rules in', 'by BICR', 'Estimation: Stratified Cox model', 'Table 2', ""with Efron's tie-handling method"", 'OS', 'Testing: stratified log-rank test', 'ITT', 'Censored at last known alive date', 'Estimation: Stratified Cox model', ""with Efron's tie-handling method"", 'Secondary Analyses:', 'ORR (RECIST 1.1)', 'Testing and estimation:', 'ITT', 'Participants with missing data are', 'by BICR', 'stratified Miettinen and Nurminen', 'considered nonresponders', 'method', 'Abbreviations: BICR = blinded independent central review; ITT = intention-to-treat ORR = objective response', 'rate; os = overall survival; PFS = progression-free survival; RECIST 1.1 = Response Evaluation Criteria in Solid', 'Tumors.', 'The strategy to address multiplicity issues with regard to multiple endpoints and interim analyses', 'is described in Section 3.7, Interim Analyses, and in Section 3.8, Multiplicity.', '3.6.1.1.', 'Progression-free Survival', 'The nonparametric Kaplan-Meier method will be used to estimate the PFS curve in each', 'treatment group. The hypotheses of treatment difference in PFS will be tested by the stratified', ""log-rank test. A stratified Cox proportional hazard model with Efron's method of tie handling"", 'will be used to estimate the magnitude of the treatment difference (ie, HR) between the treatment', ""arms. The HR and its 95% CI from the stratified Cox model with Efron's method of tie handling"", 'and with a single treatment covariate will be reported. The stratification factors used for', 'randomization (Section 6.3.2 in the protocol) will be applied to both the stratified log-rank test', 'and the stratified Cox model.', 'Since PD is assessed periodically, PD can occur any time in the time interval between the last', 'assessment where PD was not documented and the assessment when PD is documented. For the', 'primary analysis, for the participants who have PD, the true date of PD will be approximated by', 'the date of the first assessment at which PD is objectively documented per RECIST 1.1 by the', 'BICR vendor, regardless of discontinuation of study drug.', 'To evaluate the robustness of the PFS endpoint per RECIST 1.1 via BICR by the imaging', 'vendor, 1 primary and 2 sensitivity analyses with a different set of censoring rules will be', 'performed. For the primary analysis, if the events (PD or death) are immediately after more than', '1 consecutive missed disease assessment, the data are censored at the last disease assessment', 'before missing visits. Also data after new anticancer therapy are censored at the last disease', 'assessment before the initiation of new anticancer therapy. The first sensitivity analysis follows', 'ITT principles (ie, PDs/deaths are counted as events regardless of missed study visits or initiation', 'Confidential']"
171,page_172,"['MK-7902', 'PAGE 14', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'of new anticancer therapy). The second sensitivity analysis considers discontinuation of', 'treatment or initiation of an anticancer treatment subsequent to discontinuation of study-specified', 'treatments, whichever occurs later, to be a PD event for participants without documented PD or', 'death. If a participant meets multiple criteria for censoring, the censoring criterion that occurs', 'earliest will be applied. The censoring rules for primary and sensitivity analyses are summarized', 'in Table 2.', 'Table 2 Censoring Rules for Primary and Sensitivity Analyses of Progression-free Survival', 'Situation', 'Sensitivity', 'Sensitivity', 'Primary Analysis', 'Analysis 1', 'Analysis 2', 'No PD and no death; new', 'Censored at last disease', 'Censored at last', 'Progressed at treatment', 'anticancer treatment is not', 'assessment', 'disease assessment', 'discontinuation for reasons', 'initiated', 'other than CR; otherwise,', 'censored at last disease', 'assessment if still on study', 'intervention or completed', 'study intervention', 'No PD and no death; new', 'Censored at last disease', 'Censored at last', 'Progressed at date of new', 'anticancer treatment is', 'assessment before new', 'disease assessment', 'anticancer treatment', 'initiated', 'anticancer treatment', 'PD or death documented', 'Progressed at date of', 'Progressed at date of', 'Progressed at date of', 'after 1 missed disease', 'documented PD or death', 'documented PD or', 'documented PD or death', 'assessment and before new', 'death', 'anticancer therapy', 'PD or death documented', 'Censored at last disease', 'Progressed at date of', 'Progressed at date of', 'immediately after >2', 'assessment before the', 'documented PD or', 'documented PD or death', 'consecutive missed disease', 'earlier date of', 'death', 'assessments or after new', '>2 consecutive missed', 'anticancer therapy', 'disease assessment and', 'new anticancer therapy', 'Abbreviation: CR = complete response; PD = progressive disease.', 'In case the proportional hazards assumption is not valid, Restricted Mean Survival Time (RMST)', 'method may be conducted for PFS to account for the possible non-proportional hazards effect as', 'a sensitivity analysis.', '3.6.1.2.', 'Overall Survival', 'The nonparametric Kaplan-Meier method will be used to estimate the survival curves. The', 'treatment difference in survival will be assessed by the stratified log-rank test (based on the', 'stratification factors defined in Section 6.3.2 in the protocol). A stratified Cox proportional', ""hazard model with Efron's method of tie handling will be used to assess the magnitude of the"", 'treatment difference (ie, the HR). The HR and its 95% CI from the stratified Cox model with a', 'single treatment covariate will be reported. The stratification factors used for randomization', '(Section 6.3.2 in the protocol) will be applied to both the stratified log-rank test and the stratified', 'Confidential']"
172,page_173,"['MK-7902', 'PAGE 15', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Cox model. Participants without documented death at the time of analysis will be censored at the', 'date of last known contact.', 'In case the proportional hazards assumption is not valid, RMST method may be conducted for', 'OS to account for the possible non-proportional hazards effect as a sensitivity analysis.', '3.6.1.3.', 'Objective Response Rate', 'The stratified Miettinen and Nurminen method will be used for comparison of ORR between the', 'treatment groups. The difference in ORR and its 95% CI from the stratified Miettinen and', 'Nurminen method with strata weighting by sample size will be provided. The same stratification', 'factors used for randomization (Section 6.3.2 in the protocol) will be used as stratification factors', 'in the analysis.', '3.6.1.4.', 'Duration of Response', 'For subjects who demonstrate CR or PR, DOR is defined as the time from first documented', 'evidence of CR or PR until PD or death due to any cause, whichever occurs first.', 'The nonparametric Kaplan-Meier method will be used to summarize the DOR. The median and', 'range of DOR will be provided.', 'Censoring rules for DOR are summarized in Table 3.', 'Table 3 Censoring Rules for Duration of Response', 'Situation', 'Date of Progression or Censoring', 'Outcome', 'No PD or death, no new anticancer', 'Censor', 'Last adequate disease assessment', 'therapy initiated', '(nonevent)', 'No PD or death, new anticancer', 'Last adequate disease assessment before new', 'Censor', 'therapy initiated', 'anticancer therapy initiated', '(nonevent)', 'Death or PD immediately after >2', 'consecutive missed disease', 'Earlier date of last adequate disease assessment', 'Censor', 'assessments or after new anticancer', 'before >2 missed adequate disease assessments', '(nonevent)', 'and new anticancer therapy, if any', 'therapy, if any', 'Death or PD after 1 missed disease', 'End of response', 'assessments and before new anticancer', 'PD or death', '(event)', 'therapy, if any', 'Abbreviation: PD = progressive disease.', 'Note: A missed disease assessment includes any assessment that is not obtained or is considered inadequate for', 'evaluation of response.', '3.6.2.', 'Statistical Methods for Safety Analyses', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs, laboratory tests, vital signs, and ECG measurements.', 'C', 'Confidential']"
173,page_174,"['MK-7902', 'PAGE 16', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'The analysis of safety results will follow a tiered approach (Table 4). The tiers differ with', 'respect to the analyses that will be performed. AEs (specific terms as well as system organ class', 'terms) and events that meet predefined limits of change in laboratory, vital signs, and ECG', 'parameters are either prespecified as ""Tier 1"" endpoints or will be classified as belonging to', '""Tier 2"" or ""Tier 3,"" based on observed proportions of participants with an event.', 'Tier 1 Events', 'Safety parameters or AEs of special interest that are identified a priori constitute ""Tier 1"" safety', 'endpoints that will be subject to inferential testing for statistical significance. AEs that are', 'immune-mediated or potentially immune-mediated are well documented and will be evaluated', 'separately; however, these events have been characterized consistently throughout the', 'pembrolizumab clinical development program, and determination of statistical significance is not', 'expected to add value to the safety evaluation. Similarly, the combination of pembrolizumab and', 'lenvatinib has not been associated with any new safety signals. Finally, there are no known AEs', 'associated with participants with NSCLC for which determination of a p value is expected to', 'impact the safety assessment. Therefore, there are no Tier 1 events for this protocol.', 'Tier 2 Events', 'Tier 2 parameters will be assessed via point estimates with 95% CIs provided for differences in', 'the proportion of participants with events using the Miettinen and Nurminen method, an', 'unconditional, asymptotic method [Miettinen, O. 1985].', 'Membership in Tier 2 requires that at least 10% of participants in any treatment group exhibit the', 'event; all other AEs and predefined limits of change will belong to Tier 3. The threshold of at', 'least 10% of participants was chosen for Tier 2 events because the population randomized in this', 'study are in critical conditions and usually experience various AEs of similar types regardless of', 'treatment; events reported less frequently than 10% of participants would obscure the assessment', 'of the overall safety profile and add little to the interpretation of potentially meaningful treatment', 'differences. In addition, Grade 3 to 5 AEs (>5% of participants in one of the treatment groups)', 'and SAEs (5% of participants in one of the treatment groups) will be considered Tier 2', 'endpoints. Because many 95% CIs may be provided without adjustment for multiplicity, the CIs', 'should be regarded as a helpful descriptive measure to be used in safety review, not a formal', 'method for assessing the statistical significance of the between-group differences.', 'Tier 3 Events', 'Safety endpoints that are not Tier 1 or 2 events are considered Tier 3 events. Only point', 'estimates by treatment group are provided for Tier 3 safety parameters.', 'Continuous Safety Measures', 'For continuous measures such as changes from baseline in laboratory, vital signs, and ECG', 'parameters, summary statistics for baseline, on-treatment, and change from baseline values will', 'be provided by treatment group in table format.', 'Confidential']"
174,page_175,"['MK-7902', 'PAGE 17', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 4 Analysis Strategy for Safety Parameters', '95% CI for', 'Safety', 'Safety Endpoint', 'Treatment', 'Descriptive', 'Tier', 'p-Value', 'Statistics', 'Comparison', 'Tier 2', 'Grade 3-5 AE (incidence >5% of participants in one', 'X', 'X', 'of the treatment groups)', 'Serious AE (incidence >5% of participants in one of', 'X', 'X', 'the treatment groups)', 'AEs (incidence >10% of participants in one of the', 'X', 'X', 'treatment groups)', 'Tier 3', 'Any AE', 'X', 'Any Grade 3-5 AE', 'X', 'Any Serious AE', 'X', 'Any Drug-Related AE', 'X', 'Any Serious and Drug-Related AE', 'X', 'Any Grade 3-5 and Drug-Related AE', 'X', 'Discontinuation due to AE', 'X', 'Death', 'X', 'Specific AEs, SOCs (incidence <10% of participants', 'X', 'in all of the treatment groups)', 'Change from Baseline Results (lab toxicity shift)', 'X', 'Abbreviations: AE = adverse event; CI = confidence interval; SOC = system organ class.', 'Exposure-Adjusted Approach', 'To properly account for the potential difference in follow-up time between the study arms, AE', 'incidence adjusted for treatment exposure analyses may be performed as appropriate.', 'Time to Grade 3-5 AE', 'In addition to the tiered approach, exploratory analysis may be performed on the time to the first', 'Grade 3-5 AE. The time to the first Grade 3-5 AE is defined as the time from the first day of', 'study drug to the first event of a Grade 3-5 AE. Summary statistics will be provided.', '3.6.3.', 'Statistical Methods for Patient-reported Outcome Analyses', '3.6.3.1.', 'Scoring Algorithm', 'EORTC QLQ-C30:', 'For each scale or item, a linear transformation will be applied to standardize the score as between', '0 and 100, according to the corresponding scoring standard. For global health status/quality of', 'life and all functional scales, a higher value indicates a better level of function; for symptom', 'scales and items, a higher value indicates increased severity of symptoms.', 'Confidential']"
175,page_176,"['MK-7902', 'PAGE 18', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'The scoring method for each subscale of the EORTC-QLQ-C30 will be performed according to', 'the scoring manual (Scott, et al., 2008). According to the EORTC QLQ-C30 manual, if items', '11, 12,***, , In are included in a scale, the linear transformation procedure is as follows:', '1. Compute the raw score:', 'RS =', '2. Linear transformation to obtain the score S:', 'Functional scales: S = (1-155-1 Range RS-1 )', 'X 100', 'Symptom scales/items: S =', '100', 'Global health status/quality of life scale: S = Range X', '100', 'The range is defined as the difference between the maximum possible value of RS and the', 'minimum possible value for RS. If more than half of the items within one scale are missing, then', 'the scale is considered missing; otherwise, the score will be calculated as the average score of', 'those available items.', 'EORTC QLQ-LC13:', 'The lung cancer questionnaire module is a validated self-reported PRO questionnaire that is', 'intended to be used in conjunction with the QLQ-C30 and includes 13 questions that share the', 'four level ordinal response with the QLQ-C30 and can be summarized and scored as described', 'above (1= ""not at all""; 2=\' ""a little""; 3= ""quite a bit""; 4= ""very much""). The LC13 comprises', 'both multi-item and single-item measures of lung cancer-associated symptoms (i.e. coughing,', 'hemoptysis, dyspnea, and pain) and treatment related symptoms (i.e., sore mouth, dysphagia,', 'peripheral neuropathy, and alopecia). A linear transformation will be applied to standardize the', 'scores between 0 (least severe symptom) and 100 (most severe symptom) as described above for', 'the EORTC QLQ-C30 symptom scales/items scoring.', 'EQ-5D:', 'The EQ-5D-5L is primarily designed for self-completion and consists of 2 parts: a descriptive', 'system and the VAS. The EQ-5D-5L descriptive system includes 5 dimensions: mobility, self-', 'care, usual activities, pain/discomfort, and anxiety/depression. The 5 dimensions each have 5', 'levels: no problems, slight, moderate, severe problems, and extreme problems. The responses', 'patterns on the 5 dimensions are scored using country-specific population weights to provide an', 'aggregate index score anchored at 0 (death) and 1 (perfect health); depending on the algorithm', 'used some states may be considered worse than death.', ""The EQ-5D VAS records the respondent's self-rated health on a vertical, visual analogue scale"", '(0-100), with endpoints labeled ""the best health you can imagine\' and ""the worst health you can', 'Confidential']"
176,page_177,"['MK-7902', 'PAGE 19', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', ""imagine'. The recall period is current health today (the day of completion). For the EQ-5D VAS"", 'scale, A 7-point change from baseline in VAS is considered to be a MID (Packard et al., 2007).', '3.6.3.2.', 'PRO Compliance Summary', 'Completion and compliance of EORTC QLQ-C30, EORTC-QLQ-LC13, and EQ-5D by visit and', 'by treatment will be described. Numbers and percentages of complete and missing data at each', 'visit will be summarized. An instrument is considered complete if at least one valid score is', 'available according to the missing item rules outlined in the scoring manual for each respective', 'instrument.', 'Completion rate of treated participants (CR-T) at a specific time point is defined as the number of', 'treated participants who complete at least one item over the number of treated participants in the', 'PRO analysis population.', 'Number of treated participants who complete at least one item', 'CR-T =', 'Number of treated participants in the PRO analysis population', 'The completion rate is expected to shrink in the later visit during study period due to the', 'participants who discontinued early. Therefore, another measurement, compliance rate of eligible', 'participants (CR-E) will also be employed as the support for completion rate. CR-E is defined as', 'the number of treated participants who complete at least one item over number of eligible', 'participants who are expected to complete the PRO assessment, not including the participants', 'missing by design such as death, discontinuation, translation not available.', 'Number of treated participants who complete at least one item', 'CR-E =', 'Number of eligible participants who are expected to complete', 'The reasons of non-completion and non-compliance will be provided in supplementary table:', '- Completed as scheduled', '- Not completed as scheduled', '- Off-study: not scheduled to be completed.', 'In addition, reasons for non-completion as scheduled of these measures will be collected using', '""miss mode"" forms filled by site personnel and will be summarized in table format. The schedule', '(study visits and estimated study times) and mapping of study visit to analysis visit for PRO data', 'collection is provided in Table 5. If there are multiple PRO collections within any of the stated', 'time windows, the assessment completed closest to the target collection day will be used in the', 'analyses.', 'C', 'Confidential']"
177,page_178,"['MK-7902', 'PAGE 20', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 5 PRO Data Collection Schedule and Mapping of Study visit to Analysis Visit', 'Treatment Week', 'Target Day', 'Range', '0', '1', '-28 to 1', '3', '22', '2 to 32', '6', '43', '33 to 53', '9', '64', '54 to 74', '12', '85', '75 to 95', '15', '106', '96 to 116', '18', '127', '117 to 137', '21', '148', '138 to 158', '24', '169', '159 to 179', '27', '190', '180 to 200', '30', '211', '201 to 221', '33', '232', '222 to 242', '36', '253', '243 to 263', '39', '274', '264 to 284', '42', '295', '285 to 305', '45', '316', '306 to 326', '48', '337', '327 to 358', '54', '379', '359 to 400', '60', '421', '401 to 442', '66', '463', '443 to 484', '72', '505', '485 to 526', '78', '547', '527 to 568', '84', '589', '569 to 610', '90', '631', '611 to 652', '96', '673', '653 to 694', '102', '715', '695 to 736', '3.6.3.3.', 'Mean Change from Baseline', 'The time point for the mean change from baseline analysis will be defined as the latest time point', 'at', 'which approximately CR-T > 60% and CR-E > 80% based on blinded data review prior to the', 'database lock for any PRO analysis.', 'To assess the treatment effects on the PRO score change from baseline in the global health', 'status/QoL, physical functioning and dyspnea scores of the EORTC QLQ-C30 and the cough and', 'chest pain scores of the EORTC QLQ-LC13 scales a constrained longitudinal data analysis (cLDA)', 'model proposed by Liang and Zeger [Liang, K-Y. and Zeger, S. L. 2000] will be applied, with the', 'PRO score as the response variable, and treatment, time, the treatment by time interaction, and', 'stratification factors used for randomization (See Section 6.3.2 in the protocol) as covariates. The', 'treatment difference in terms of least square (LS) mean change from baseline will be estimated', 'from this model together with 95% CI and nominal two-sided p-value. Model-based LS mean', 'with 95% CI will be provided by treatment group for PRO scores at baseline and post-baseline', 'time point.', 'The cLDA model assumes a common mean across treatment groups at baseline and a different', 'mean for each treatment at each of the post-baseline time points. In this model, the response vector', 'consists of baseline and the values observed at each post-baseline time point. Time is treated as a', 'Confidential']"
178,page_179,"['MK-7902', 'PAGE 21', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'categorical variable so that no restriction is imposed on the trajectory of the means over time. The', 'cLDA model is specified as follows:', 'j = 1,2,,3, , n; t = 0,1,2,3, k', 'where Yijt is the PRO score for participant i, with treatment assignment j at visit t; yo is the baseline', 'mean for all treatment groups, Yjt is the mean change from baseline for treatment group j at time t;', 'Xi is the stratification factor (binary) vector for this participant, and B is the coefficient vector for', 'stratification factors. An unstructured covariance matrix will be used to model the correlation', 'among repeated measurements. If the unstructured covariance model fails to converge with the', 'default algorithm, then Fisher scoring algorithm or other appropriate methods can be used to', 'provide initial values of the covariance parameters. In the rare event that none of the above', 'methods yield convergence, a structured covariance such as Toeplitz can be used to model the', 'correlation among repeated measurements. In this case, the asymptotically unbiased sandwich', 'variance estimator will be used. The cLDA model implicitly treats missing data as missing at', 'random (MAR).', 'Line plots for the empirical mean change from baseline in the EORTC QLQ-C30 global health', 'status/QoL, physical functioning and dyspnea scores and EORTC QLQ-LC13 cough and chest', 'pain scores (as specified in section 3.4.3) will be provided across all time points as a supportive', 'analysis.', 'In addition, the model-based LS mean change from baseline to the specified post-baseline time', 'point together with 95% CI will be plotted in bar charts for the EORTC QLQ-C30 global health', 'status/QoL, physical functioning and symptom scales, and EORTC QLQ-LC13 symptom scales', '(as specified in section 3.4.3).', '3.6.3.4.', 'Time-to-True Deterioration (TTD) Analysis', 'The non-parametric Kaplan-Meier method will be used to estimate the deterioration curve in', 'each group. The estimate of median time to deterioration and its 95% confidence interval will be', 'obtained from the Kaplan-Meier survival estimates. The treatment difference in TTD will be', 'assessed by the stratified log-rank test, and nominal two-sided p-values will be reported. A', ""stratified Cox proportional hazard model with Efron's method of tie handling will be used to"", 'assess the magnitude of the treatment difference (hazard ratio) between treatment arms.', 'Stratification factors used for randomization (See Section 6.3.2 in the protocol) will be applied to', 'the analysis will be used in the stratified Cox PH model.', 'The approach for the time-to-deterioration analysis will be based on the assumption of non-', 'informative censoring. The participants who do not have deterioration on the last date of evaluation', 'will be censored. Table 6 provides censoring rule for TTD analysis.', 'C', 'Confidential']"
179,page_180,"['MK-7902', 'PAGE 22', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 6 Censoring Rules for Time-to-Deterioration', 'Scenario', 'Outcome', 'Deterioration documented', 'Event observed at time of assessment (first deterioration)', 'Ongoing, death or discontinued from study', 'Right censored at time of last assessment', 'without deterioration', 'No baseline assessments', 'Right censored at treatment start date', '3.6.3.5.', 'Overall Improvement and Overall Improvement/Stability', 'Overall improvement rate will be analyzed, which is defined as the proportion of participants', 'who have achieved an improvement as defined in Section 3.4.3 PRO Endpoints. The point', 'estimate of overall proportions of participants who have achieved an improvement, stability, and', 'deterioration will be provided by treatment group together with 95% CI using exact binomial', ""method by Clopper and Pearson (1934). Stratified Miettinen and Nurminen's method will be"", 'used for comparison of the overall improvement rate between the treatment groups. The', 'difference in overall improvement rate and its 95% CI, along with nominal two-sided p-values,', ""from the stratified Miettinen and Nurminen's method with strata weighting by sample size will"", 'be provided. The stratification factors used for randomization (see Section 6.3.2 in protocol) will', 'be applied to the analysis.', 'The same method will be used to analyze overall improvement/stability rate, which is defined', 'as', 'the proportion of participants who have achieved improvement/stability as defined in Section', '3.4.3 PRO Endpoints.', '3.6.3.6.', 'Analysis Strategy for Key PRO Enppoints', 'A summary of the analysis strategy for the key PRO endpoints is provided in Table 7.', 'C', 'Confidential']"
180,page_181,"['MK-7902', 'PAGE 23', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 7 Analysis Strategy for Key PRO Endpoints', 'Endpoint/Variable', 'Statistical Method', 'Analysis', 'Missing Data Approach', 'Population', 'Mean change from baseline in', 'cLDA model', 'FAS', 'Model-based.=cLDA', '- EORTC QLQ-C30', 'Global health status/QoL', 'Physical functioning', 'dyspnea', '- EORTC QLQ-LC13', 'Cough', 'Chest pain', 'TTD in', 'Stratified log-rank test and', 'FAS', 'Censored according to', '- EORTC QLQ-C30', 'HR estimation using', 'rules in Table 6.', 'Global health status/QoL', 'stratified Cox model with', 'Physical functioning', ""Efron's tie handling method"", 'dyspnea', '- EORTC QLQ-LC13', 'Cough', 'Chest pain', 'Overall improvement and', 'Stratified Miettinen and', 'FAS', 'Participants with missing', 'overall improvement/stability', 'Nurminen method', 'data are considered not', 'in', 'achieving', '- EORTC QLQ-C30', 'improvement/stability.', 'Global health status/QoL', 'Physical functioning', 'dyspnea', '- EORTC QLQ-LC13', 'Cough', 'Chest pain', 'Abbreviations: cLDA = constrained longitudinal data analysis, FAS = full analysis set, QoL = quality of life.', '3.6.4.', 'Demographic and Baseline Characteristics', 'The comparability of the treatment groups for each relevant demographic and baseline', 'characteristic will be assessed by the use of tables and/or graphs. No statistical hypothesis tests', 'will be performed on these characteristics. The number and percentage of participants screened', 'and randomized and the primary reason for screening failure and discontinuation will be', 'displayed. Demographic variables, baseline characteristics, primary and secondary diagnoses,', 'and prior and concomitant therapies will be summarized by treatment, either by descriptive', 'statistics or categorical tables.', '3.7. Interim Analyses', 'Blinding to treatment assignment will be maintained at all investigational sites. The results of', 'interim analyses will not be shared with the investigators before the completion of the study.', 'Participant-level unblinding will be restricted to an external unblinded statistician and scientific', 'Confidential']"
181,page_182,"['MK-7902', 'PAGE 24', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'programmer performing the interim analysis, who will have no other responsibilities associated', 'with the study.', 'An external DMC will serve as the primary reviewer of the results of the interim analyses of the', 'study and will make recommendations for discontinuation of the study or protocol modifications', 'to the study Executive Oversight Committee (EOC). If the DMC recommends modifications to', 'the design of the protocol or discontinuation of the study, the EOC (and potentially other limited', 'Sponsor personnel) may be unblinded to results at the treatment level to act on these', 'recommendations. The extent to which individuals are unblinded with respect to results of', 'interim analyses will be documented by the unblinded statistician. Additional logistical details', 'will be provided in the DMC charter. Key aspects of the interim analyses are described below.', 'Treatment-level results from the interim analysis will be provided to the DMC by the unblinded', 'statistician. The unblinded statistician will not be involved in any discussions regarding', 'modifications to the protocol, statistical methods, identification of protocol deviations, or data', 'validation efforts after the interim analyses.', 'If the study is positive at an interim analysis for both primary endpoints, additional analyses,', 'including but not limited to the protocol-specified final analysis, may be carried out for', 'exploratory purpose or upon regulatory request.', '3.7.1.', 'Efficacy Interim Analysis', 'One interim analysis is planned in addition to the final analysis for this study. For the interim and', 'final analyses, all the randomized participants will be included. Results of the interim analysis', 'will be reviewed by the DMC. Details on the boundaries for establishing statistical significance', 'with regard to efficacy are discussed further in Section 3.8.', 'The analyses planned, endpoints evaluated, and drivers of timing are summarized in Table 8.', 'C', 'Confidential']"
182,page_183,"['MK-7902', 'PAGE 25', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 8 Summary of Interim and Final Analyses Strategy', 'Estimated Time', 'After First', 'Key', 'Participant', 'Primary Purpose of', 'Analyses', 'Endpoints', 'Timing', 'Randomized', 'Analysis', 'IA', 'PFS', 'Both ~416 PFS events have', '~30.5 months', 'Final PFS analysis', 'OS', 'been observed and ~8.8', 'Interim os', 'months after last participant', 'analysis', 'randomized', 'Final analysis', 'OS', 'Both ~388 deaths have', '~40.2 months', 'Final os analysis', 'occurred and ~ ~18.5 months', 'after', 'last', 'participant', 'randomized', 'Note that for the IA and the FA, if the events accrue slower than expected such that the targeted number of', 'events cannot be reached in the anticipated timeframe, the Sponsor may conduct the analysis with an additional', '2 months and 7 months of follow-up for the IA and FA respectively, or the specified number of events is', 'observed, whichever occurs first.', 'Abbreviations: IA = interim analysis; os = overall survival; PFS = progression-free survival.', 'Non-binding futility analyses will be conducted in July 2021 (data cutoff in May 2021) to', 'coincide with an anticipated safety DMC meeting and at the IA as per DMC recommendation.', 'Further details of any evaluation are specified in the Appendix 5.1.', '3.7.2.', 'Safety Interim Analyses', 'The DMC will conduct regular safety monitoring. The timing of the safety monitoring will be', 'specified in the DMC charter.', '3.8. Multiplicity', 'The study uses the graphical method of Maurer and Bretz [Maurer, W., et al 2011] to control', 'multiplicity for multiple hypotheses as well as interim analysis. According to this approach,', 'study hypotheses may be tested more than once, and when a particular null hypothesis is', 'rejected, the a allocated to that hypothesis can be reallocated to other hypothesis tests.', 'Figure 1 shows the initial 1-sided a allocation for each hypothesis in the ellipse representing the', 'hypothesis. The weights for reallocation from each hypothesis to the others are represented in the', 'boxes on the lines connecting the hypotheses.', 'C', 'Confidential']"
183,page_184,"['MK-7902', 'PAGE 26', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'ORR', '1', 'PFS', 'a=0', '0.001', 'a=0.0055', '0.999', '0.999', '0.001', 'os', 'a=0.0195', 'Abbreviations: ORR = objective response rate; OS = overall survival; PFS = progression-free survival.', 'Note: If both PFS and os null hypotheses are rejected, the reallocation strategy allows retesting of ORR at', 'a = 0.025.', 'Figure 1 Multiplicity Graph for Type I Error Control', '3.8.1.', 'Objective Response Rate', 'No initial alpha is allocated to test ORR. If superiorities for both the PFS and OS hypotheses are', 'declared, a = 0.025 will be rolled over to the hypothesis for ORR and the test statistics computed', 'at the IA for the ORR hypothesis will be used for inferential testing with an updated alpha level', 'of 0.025. The power at the a-level of 0.025 is 99.9%, with an approximate treatment difference', '(AORR) required for reaching the efficacy bound being 7.5%, assuming underlying 28% and', '48% ORR in the control and experimental groups, respectively.', '3.8.2.', 'Progression-free Survival', 'The study will test PFS only at the interim analysis, at an initial a level of 0.0055. Table 9 shows', 'the boundary properties for each of these a-levels for the PFS analysis. Note that the final row', 'indicates the total power to reject the null hypothesis for PFS at each a level. Also note that if the', 'os null hypothesis is rejected at the FA, the previously computed PFS test statistics may be used', 'for inferential testing with its updated bounds considering the a re-allocation from the OS', 'hypothesis. Following the multiplicity strategy as outlined in Figure 1, if superiority for both the', 'ORR and OS hypotheses are declared, a = 0.025 will be rolled over to the hypothesis for PFS.', 'C', 'Confidential']"
184,page_185,"['MK-7902', 'PAGE 27', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 9 Efficacy Boundaries and Properties for Progression-free Survival Analyses', 'Analysis', 'Value', '=0.0055', '=0.025', 'IA: 100%', 'Z', '2.5427', '1.9600', 'N: 620', 'p (1-sided)b', '0.0055', '0.0250', 'Events: 416', '~HR at bound', '0.7793', '0.8252', 'Month: 30.5', 'P(Cross) if HR=1d', '0.0055', '0.0250', 'P(Cross) if HR=0.7e', '0.8650', '0.9536', 'Abbreviations: HR = hazard ratio; IA = interim analysis.', 'The number of events and timings are estimated.', 'a', 'Percentage of total planned events at the interim analysis.', 'b', 'The nominal a for testing.', 'c', 'The approximate HR required to reach an efficacy bound', 'd', 'The probability of crossing a bound under the null hypothesis', 'e', 'The probability of crossing a bound under the alternative hypothesis', 'f', 'The approximate number of months since first participant randomized', '3.8.3.', 'Overall Survival', 'The study will test OS at IA and FA. Following the multiplicity strategy as outlined in', 'Figure 1, the os hypothesis may be tested at a=0.0195 (initially allocated a) or a=0.025 (if the', 'null hypotheses for both PFS and ORR are rejected). Table 10 shows the boundary properties for', 'each of these a-levels for OS at IA and FA, which were derived using a Lan-DeMets and', ""O l'Brien-Fleming spending function. Note that if the PFS null hypothesis is rejected at IA, OS"", 'interim and final analysis test may be compared with its updated bounds considering the a', 'reallocation from the PFS hypothesis.', 'C', 'Confidential']"
185,page_186,"['MK-7902', 'PAGE 28', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Table 10 Efficacy Boundaries and Properties for Overall Survival Analyses', 'Analysis', 'Value', '=0.0195', 'a=0.025', 'IA: 78%a', 'Z', '2.4029', '2.2869', 'N: 620', 'p (1-sided)b', '0.0081', '0.0111', 'Events: 302', '~HR at bound', '0.7584', 'Month:30.5 f', '0.7686', 'P(Cross) if HR=1d', '0.0081', '0.0111', 'P(Cross) if HR=0.71e', '0.7173', '0.7548', 'Final', 'Z', '2.1181', '2.0193', 'N: 620', 'p (1-sided)b', '0.0171', '0.0217', 'Events: 388', '~HR at bound', '0.8064', '0.8145', 'Month: 40.2 f', 'P(Cross) if HR=1 =', '0.0195', '0.0250', 'P(Cross) if HR=0.71e', '0.9000', '0.9165', 'Abbreviations: HR = hazard ratio; IA = interim analysis.', 'The number of events and timings are estimated.', 'a', 'Percentage of total planned events at each interim analysis.', 'b', 'The nominal a for group sequential testing.', 'c', 'The approximate HR required to reach an efficacy bound', 'd', 'The probability of crossing a bound under the null hypothesis', 'e', 'The probability of crossing a bound under the alternative hypothesis', 'f', 'The approximate number of months since first participant randomized', 'The bounds provided in Table 10 are based on the assumption that the expected number of', 'events at the IA and FA for os are 302 and 388, respectively. At the time of an analysis, the', 'observed number of events may differ substantially from the expected. To avoid overspending at', 'an interim analysis and leave reasonable alpha for the final analysis, the minimum alpha', 'spending strategy will be adopted. At an IA, the information fraction used in Lan-DeMets', 'spending function to determine the alpha spending at the IA will be based on the minimum of the', 'expected information fraction and the actual information fraction at each analysis. Specifically,', 'In the scenario that the events accrue slower than expected and the observed number of', 'events is less than the expected number of events at a given analysis, the information fraction', 'will be calculated as the observed number of events at the interim analysis over the target', 'number of events at FA.', 'In the scenario that the events accrue faster than expected and the observed number of events', 'exceeds the expected number of events at a given analysis, then the information fraction will', 'be calculated as the expected number of events at the interim analysis over the target number', 'of events at FA.', 'Confidential']"
186,page_187,"['MK-7902', 'PAGE 29', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'The final analysis will use the remaining Type I error that has not been spent at the earlier', 'analyses. The event counts for all analyses will be used to compute correlations.', 'Of note, while the information fraction used for alpha spending calculation will be the minimum', 'of the actual information fraction and the expected information fraction, the correlations required', 'for deriving the bounds will still be computed using the actual information fraction based on the', 'observed number of events at each analysis over the target number of events at FA.', 'The minimum spending approach assumes timing is not based on any observed Z-value and thus', 'the Z test statistics used for testing conditioned on timing are multivariate normal. Given the', 'probabilities derived with the proposed spending method, the correlations based on actual event', 'counts are used to compute bounds that control the Type I error at the specified alpha level for a', 'given hypothesis conditioned on the interim analysis timing. Since this is true regardless of what', 'is conditioned on, the overall Type I error for a given hypothesis unconditionally is controlled at', 'the specified level. By using more conservative spending early in the study, power can be', 'retained to detect situations where the treatment effect may be delayed.', '3.8.4.', 'Safety Analyses', 'The DMC has responsibility for assessment of overall risk:benefit. When prompted by safety', 'concerns, the DMC can request corresponding efficacy data. DMC review of efficacy data to', 'assess the overall risk:benefit to study participants will not require a multiplicity adjustment', 'typically associated with a planned efficacy interim analysis.', '3.9. Sample Size and Power Calculations', 'The study will randomize 620 participants in a 1:1 ratio into the pembrolizumab + lenvatinib and', 'pembrolizumab + placebo arms. PFS and os are primary endpoints for the study, with OR as the', 'secondary endpoint.', 'For the PFS endpoint, based on a target number of 416 events at the final PFS analysis the', 'study has approximately 86.5% power to detect an HR of 0.7 at the initially allocated a=0.0055', '(1-sided).', 'For the os endpoint, based on a target number of 388 events and one interim analysis at', 'approximately 78% of the target number of events, the study has approximately 90% power to', 'detect an HR of 0.71 at the initially allocated a=0.0195 (1-sided).', 'Based on KEYNOTE-042 data, the above sample size and power calculations for PFS and OS', 'assume the following:', 'PFS follows a piecewise exponential distribution, with a median of 5 months up to 6.5', 'months and then a median of 12 months thereafter for the control group', 'OS follows an exponential distribution, with a median of 16.7 months for the control group', 'Enrollment period is approximately 21.7 months', 'Annual drop-out rate is 20% and 2% for PFS and OS, respectively', 'C', 'Confidential']"
187,page_188,"['MK-7902', 'PAGE 30', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Follow-up period is approximately 8.8 and 18.5 months for PFS and OS, respectively, after', 'the last participant is randomized', 'The sample size and power calculations were performed in R (package ""gsDesign"") and EAST', '6.4.', '3.10. Subgroup Analyses', 'To determine whether the treatment effect is consistent across various subgroups, the between-', 'group treatment effect for OS, PFS, and OR (with a nominal 95% CI) will be estimated and', 'plotted by treatment group within each category of the following subgroup variables:', 'Geographic region (East Asia, non-East Asia)', 'ECOG performance status (0, 1)', 'Predominant tumor histology (squamous, nonsquamous)', 'TPS', 'Age category (<65, >65 years)', 'Sex (female, male)', 'Race (white, nonwhite)', 'Smoking status (never, former/current smoker)', 'Brain metastasis at baseline (presence, absence)', 'Liver metastasis at baseline (presence, absence)', 'The consistency of the treatment effect will be assessed using descriptive statistics for each', 'category of the subgroup variables listed above. If the number of participants in a category of a', 'subgroup variable is less than 10% of the ITT population, the subgroup analysis will not be', 'performed for this category of the subgroup variable, and this subgroup variable will not be', 'displayed in the forest plot. The subgroup analyses for PFS and os will be conducted using', 'unstratified Cox model, and the subgroup analyses for OR will be conducted using unstratified', 'Miettinen and Nurminen method.', '3.11. Compliance (Medication Adherence)', 'Drug accountability data for study intervention will be collected during the study. Any deviation', 'from protocol-directed administration will be reported.', '3.12. Extent of Exposure', 'Extent of exposure for a participant is defined as number of cycles in which the participant', 'receives the study intervention. Summary statistics will be provided on extent of exposure for the', 'APaT population.', 'Confidential']"
188,page_189,"['MK-7902', 'PAGE 31', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '4.', 'STATISTICAL ANALYSIS PLAN FOR EXTENSION', 'This section outlines the statistical analysis strategy and procedures for China specific subgroup', 'analysis, which is required by the Chinese regulatory authority.', '4.1. Introduction', 'After the global study enrollment is closed, subjects from China will continue to be enrolled in an', 'extension portion designed to meet China local registration needs. The extension portion will be', 'identical to the global study (e.g., inclusion and exclusion criteria, primary and secondary', 'endpoints, study procedures) in general, with the additional statistical analysis plan for the Chinese', 'subpopulation. The purpose of this extension portion is to evaluate the consistency of efficacy and', 'safety in the Chinese subpopulation to the global population. Country-specific analysis may also', 'be conducted per local regulatory requirement.', 'After the enrollment for the global study is completed, subjects in China will continue to be', 'enrolled in a 1:1 ratio into the pembrolizumab + lenvatinib arm and pembrolizumab + placebo', 'arm until the sample size for the Chinese subpopulation reaches approximately 120 in total', 'between the global and extension portion.', 'After the cut-off date for the primary analyses of the global study (including interim and final', 'analyses), all Chinese subjects, including subjects enrolled in the global study and the extension', 'portion, will continue their randomized treatment and continue to be followed up for PFS and OS', 'events for China registration purpose. The extension portion will be completed after target number', 'of PFS or OS events (Section 4.7) has been observed between the two arms in the Chinese', 'subpopulation.', 'However, if the target number of PFS or OS events in the Chinese subpopulation is reached before', 'an IA for the global study, the corresponding analysis for Chinese subpopulation will occur at the', 'same time as the global IA or the final analysis (global study).', '4.2. Responsibility for Analyses/In-House Blinding', 'For all Chinese subjects, including subjects randomized in the global study and the extension', 'portion, patient level treatment randomization information will be blinded for the', 'statistician(s)/programmer(s) responsible for the China extension portion analysis until the', 'extension portion data base lock is achieved. The extent to which individuals are unblinded to the', 'results will be limited. Blinded and unblinded members will be clearly documented with blinding', 'status along with time information.', '4.3. Hypotheses/Estimation', 'No hypothesis testing is planned for the China extension portion. Nominal p values will be', 'reported for efficacy analyses if applicable but should be interpreted with caution due to potential', 'issues of multiplicity.', 'After succeeding in the global study, the consistency of efficacy and safety in the Chinese', 'subpopulation to the global population will be evaluated. Consistency of efficacy will be evaluated', 'using the percentage of risk reduction preserved in the Chinese subpopulation from the empirical', 'Confidential']"
189,page_190,"['MK-7902', 'PAGE 32', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'risk reduction from the global primary efficacy analyses (based on point estimates). Sample size', 'is designed to provide about 80% chance of observing the point estimate of Chinese subpopulation', 'preserves > approximately 50% of empirical risk reduction from the global primary efficacy', 'analysis assuming the same hazard ratio used in the sample size and power calculation for the', 'global study.', '4.4. The Analysis Endpoints', '4.4.1.', 'Efficacy Enppoints', '4.4.1.1.', 'Primary Enppoints', 'PFS: the time from randomization to the first documented PD per RECIST 1.1, adjusted to', 'follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, based on', 'BICR or death due to any cause, whichever occurs first. See Section 3.6.1 for the definition of', 'censoring.', 'OS: the time from randomization to death due to any cause.', '4.4.1.2.', 'Secondary Enppoints', 'OR: a confirmed CR or PR per RECIST 1.1, adjusted to follow a maximum of 10 target lesions', 'and a maximum of 5 target lesions per organ, based on BICR.', '4.4.1.3.', 'Exploratory Enppoints', 'DOR: the time from the earliest date of qualifying response until earliest date of PD or death', 'from any cause, whichever comes first.', '4.4.2.', 'Safety Enppoints', 'Safety and tolerability will be assessed by clinical review of all relevant parameters including', 'AEs, SAEs, fatal AEs, laboratory tests, and vital signs. Furthermore, specific events will be', 'collected and designated as ECIs as described in Section 8.4.7 of the study protocol.', '4.4.3.', 'Patient-reported Outcome Enppoints', 'Secondary', 'Mean change from baseline in EORTO QLQ-C30 global health status/QoL (items 29-30),', 'physical functioning (items 1-5), and dyspnea scores (item 8), and EORTC QLQ-LC13', 'cough (item 31) and chest pain (item 40) scores.', 'TTD as measured by each of the EORTC QLQ-C30 global health status/QoL. physical', 'functioning, and dyspnea scores, and EORTC QLQ-LC13 cough and chest pain scores.', 'TTD as measured by a composite symptom endpoint: cough (QLQ-LC13 item 31), chest', 'pain (QLQ-LC13 item 40), or dyspnea (QLQ-C30 item 8)', 'C', 'Confidential']"
190,page_191,"['MK-7902', 'PAGE 33', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Based on prior literature (Osoba D et al., 1998; King et al., 1996, Marringwa et al., 2011),', 'point or greater worsening from baseline for each scale represents a minimally important', 'difference (MID) that represents a clinically relevant deterioration. TTD in the individual scores', 'specified above is defined as the time to first onset of >>10 (out of 100) point deterioration from', 'baseline in a given scale/subscale/item and confirmed by a second adjacent >10 point', 'deterioration from baseline. TTD in the composite endpoint is defined as the time to first onset of', 'a >10 point deterioration (i.e., increase in score) from baseline in any one of the 3 lung cancer', 'symptom scale items (EORTC-QLQ-C30 [dyspnea] and EORTC-QLQ-LC13 [cough and chest', 'pain]) with confirmation by the subsequent visit of a >10 point deterioration (i.e., increase in', 'score) from baseline in the same scale as the first onset. Changes from baseline in EORTC QLQ-', 'C30 scores will also be interpreted according to recent subscale-specific guidelines, which', 'indicate that clinically meaningful differences vary by scale (Cocks et al., 2012)', '4.5. Analysis Populations', '4.5.1.', 'Efficacy Analysis Populations', 'Efficacy analysis will be carried out in the intention-to-treat (ITT) China subpopulation. This', 'population will include all Chinese participants who are randomized in the global study and all', 'participants who are randomized in the extension portion.', 'Participants from China enrolled in the extension portion of this study after completion of the', 'global enrollment will not be included in the primary efficacy analysis population for the global', 'study.', '4.5.2.', 'Safety Analysis Populations', 'Safety analysis will be carried out in the All Patients as Treated (APaT) China subpopulation, i.e.,', 'all randomized Chinese participants (in the global study and extension portion) who received at', 'least 1 dose of study treatment.', 'Participants from China randomized and treated in the extension portion of this study after', 'completion of the global enrollment will not be included in the primary safety analysis', 'population for the global study.', '4.5.3.', 'Patient-reported Outcome Analysis Population', 'The PRO analyses are based on the PRO Full Analysis Set (PRO FAS) China subpopulation,', 'defined as all randomized participants who have at least one PRO assessment available for the', 'specific endpoint and have received at least one dose of the study intervention. Participants will', 'be analyzed in the treatment group to which they are randomized. The PRO FAS China', 'subpopulation will include all Chinese participants (in the global study and extension portion) in', 'this population.', 'Confidential', '06Y9H6K']"
191,page_192,"['MK-7902', 'PAGE 34', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Participants from China enrolled in the extension portion of this study after completion of the', 'global enrollment will not be included in the primary PRO analysis population for the global', 'study.', '4.5.4.', 'Pharmacokinetic Analysis Population', 'The analysis of PK data will be carried out in the population PK analysis set China subpopulation.', 'The Population PK Analysis set will include all participants who have received at least 1 dose of', 'study intervention with documented dosing history in the lenvatinib + pembrolizumab arm and', 'have measurable plasma levels of lenvatinib or serum levels of pembrolizumab. Population PK', 'Analysis Set China subpopulation will include all Chinese participants (in the global study and', 'extension portion) in this population.', 'Participants from China enrolled in the extension portion of this study after completion of the', 'global enrollment will not be included in the primary PK analysis population for the global', 'study.', '4.6. Statistical Methods', 'Regarding the analysis for extension, no formal hypothesis testing is planned. No multiplicity', 'adjustment will be applied to the analysis for extension.', '4.6.1.', 'Statistical Methods for Efficacy Analyses', 'Analyses regarding objective response and disease progression will include all events in all', 'participants excluding events that occur in the Second Course Treatment.', '4.6.1.1.', 'Progression-free Survival', 'Analysis of PFS for extension is the same to that for the global study if applicable.', 'The nonparametric Kaplan-Meier method will be used to estimate the PFS curve in each', 'treatment group. The treatment difference in PFS will be assessed by the stratified log-rank test', '(based on the stratification factors defined in Section 6.3.2 in the protocol) A stratified Cox', ""proportional hazard model with Efron's method of tie handling will be used to estimate the"", 'magnitude of the treatment difference (ie, HR) between the treatment arms. The HR and its 95%', ""CI from the stratified Cox model with Efron's method of tie handling and with a single treatment"", 'covariate will be reported. The same stratification factors used in the global study will be used', '(see section 6.3.2 in the protocol). For the Chinese subgroup analyses, the stratified method will', 'only be used if applicable. The factor of geographic region (East Asia vs. non-East Asia) will not', 'be included in the Chinese subgroup stratified analyses. An analysis using the restricted mean', 'survival time method may be conducted for PFS to account for the possible nonproportional', 'hazards effect.', 'Consistency of efficacy will be evaluated using the percentage of risk reduction preserved in the', 'Chinese subpopulation from the empirical risk reduction from the global primary efficacy analyses', '(based on point estimates). Sample size is designed to provide about 80% chance of observing the', 'point estimate of Chinese subpopulation preserves > approximately 50% of empirical risk', 'Confidential']"
192,page_193,"['MK-7902', 'PAGE 35', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'reduction from the global primary efficacy analysis assuming the same hazard ratio used in the', 'sample size and power calculation for the global study. The primary analysis for PFS will be', 'conducted in the Chinese subpopulation when approximately 75 PFS events have been collected.', '4.6.1.2.', 'Overall Survival', 'Analysis of OS for extension is the same to that for the global study if applicable.', 'The nonparametric Kaplan-Meier method will be used to estimate the survival curves. The', 'treatment difference in os will be assessed by the stratified log-rank test (based on the', 'stratification factors defined in Section 6.3.2 in the protocol). A stratified Cox proportional', ""hazard model with Efron's method of tie handling will be used to assess the magnitude of the"", 'treatment difference (ie, the HR). The HR and its 95% CI from the stratified Cox model with a', 'single treatment covariate will be reported. The stratification factors used for randomization', '(Section 6.3.2 in the protocol) will be applied to both the stratified log-rank test and the stratified', 'Cox model. The same stratification factors used in the global study will be used. For the Chinese', 'subgroup analysis, the stratified method will only be used if applicable. The factor of Geography', '(East Asia VS. non-East Asia) will not be included in the stratified analysis for the Chinese', 'subgroup analysis. Participants without documented death at the time of analysis will be', 'censored at the date of last known contact. An analysis using the restricted mean survival time', 'method may be conducted for os to account for the possible nonproportional hazards effect.', 'Consistency in os will be evaluated similarly as that in PFS. The primary analysis for OS will be', 'conducted in the Chinese subpopulation when approximately 75 OS events have been collected.', '4.6.1.3.', 'Objective Response Rate', 'Analysis of ORR or DOR for extension is the same to that for the global study if applicable.', 'The stratified Miettinen and Nurminen method will be used for comparison of ORR between the', 'treatment groups. The difference in ORR and its 95% CI from the stratified Miettinen and', 'Nurminen method with strata weighting by sample size will be provided. The same stratification', 'factors used for randomization (Section 6.3.2 of the study protocol) will be used as stratification', 'factors in the analysis. The same stratification factors used in the global study will be used. For', 'the Chinese subpopulation analysis, the stratified method will only be used if applicable. The', 'factor of Geography (East Asia vs. non-East Asia) will not be included in the stratified analysis', 'for Chinese subgroup analysis.', '4.6.1.4.', 'Duration of Response', 'For subjects who demonstrate CR or PR, DOR is defined as the time from first documented', 'evidence of CR or PR until PD or death due to any cause, whichever occurs first.', 'The nonparametric Kaplan-Meier method will be used to summarize the DOR. The median and', 'range of DOR will be provided.', 'Confidential']"
193,page_194,"['MK-7902', 'PAGE 36', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '4.6.2.', 'Statistical Methods for Safety Analyses', 'Safety analyses for extension are the same to that for the global study as described in Section 3.6.2.', '4.6.3.', 'Statistical Methods for PRO Analysis', 'PRO Analysis are the same for extension to that for the global study as described in Section 3.6.3.', '4.6.4.', 'Summaries of Baseline Characteristics, Demographics, and Other Analyses', 'They are the same for extension to that for the global study as described in Section 3.6.4.', '4.7. Interim Analysis and Final analysis', 'The primary analysis for PFS will be conducted in the Chinese subpopulation when approximately', '75 PFS events have been collected. OS will also be analyzed.', 'The primary analysis for os will be conducted in the Chinese subpopulation when approximately', '75 os events have been collected.', '4.8. Multiplicity', 'No multiplicity adjustment will be applied to the analysis of China.', '4.9. Sample Size and Power Calculations', 'After the completion of global study enrollment, the extension portion will continue to enroll', 'participants and randomize eligible participants until the sample size for the overall randomized', 'Chinese subpopulation reaches approximately 120. Participants from China enrolled in the', 'extension portion of this study after completion of the global enrollment will not be included in', 'the primary efficacy analysis population for the global study.', 'The extension portion will complete after approximately 75 OS events have been observed', 'between the two arms in the Chinese subpopulation. With 75 os events and a true hazard ratio of', '0.7, the extension portion has ~80% chance to observe a point estimate of os that preserves', '>', 'approximately 50% of the empirical risk reduction from the global analysis in the Chinese', 'subpopulation. With 75 PFS events and a true hazard ratio of 0.7, the extension portion has ~80%', 'chance to observe a point estimate of PFS that preserves > approximately 50% of the empirical', 'risk reduction from the global analysis in the Chinese subpopulation.', 'The above calculations for the consistency evaluation in OS and PFS are based on the same', 'assumptions in the global study for sample size and power evaluation as specified in Section 3.9.', 'C', 'Confidential']"
194,page_195,"['MK-7902', 'PAGE 37', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '5. APPENDICES:', '5.1. Rules for Non-Binding Futility Analyses', 'Non-binding futility analyses will be conducted to coincide with the safety DMC meeting in July', '2021 (data cutoff in May 2021) and at the IA as per DMC recommendation. For each futility', 'analysis, the DMC committee will evaluate the totality of the data and discuss with the EOC. The', 'futility boundary for os is based upon the Hwang-Shih-DeCani (HSD) beta-spending function', 'with parameter of - -15. The futility criteria are non-binding and only intended to provide guidance.', 'C', 'Confidential']"
195,page_196,"['MK-7902', 'PAGE 38', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'C', 'Confidential']"
196,page_197,"['MK-7902', 'PAGE 39', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '5.2. ABBREVIATIONS', 'Abbreviation', 'Expanded Term', '1L', 'First-line', 'APaT', 'All Participants as Treated', 'BICR', 'blinded independent central review', 'CI', 'confidence interval', 'C', 'Confidential']"
197,page_198,"['MK-7902', 'PAGE 40', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Abbreviation', 'Expanded Term', 'cLDA', 'constrained longitudinal data analysis', 'CR', 'complete response', 'CRF', 'case report form', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'DMC', 'data monitoring committee', 'DOR', 'duration of response', 'ECG', 'electrocardiogram', 'ECI', 'event of clinical interest', 'EOC', 'Executive Oversight Committee', 'EORTC', 'European Organisation for Research and Treatment of Cancer', 'ePRO', 'electronic patient-reported outcome', 'EQ-5D', 'EuroQoL-5D-5L', 'FAS', 'Full Analysis Set', 'HR', 'hazard ratio', 'HRQoL', 'health-related quality of life', 'HSD', 'Hwang-Shih-DeCani', 'IA', 'interim analysis', 'ICH', 'International Conference on Harmonization', 'iRECIST', 'Modified RECIST 1.1 for Immune-based Therapeutics', 'ITT', 'Intention to Treat', 'NPH', 'Non-proportional Hazards', 'PH', 'Proportional Hazards', 'NSCLC', 'non-small cell lung cancer', 'OR', 'objective response', 'ORR', 'objective response rate', 'OS', 'overall survival', 'PD', 'progressive disease', 'PD-L1', 'programmed cell death ligand 1', 'PFS', 'progression-free survival', 'PH', 'proportional hazards', 'Confidential']"
198,page_199,"['MK-7902', 'PAGE 41', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', 'Abbreviation', 'Expanded Term', 'PK', 'pharmacokinetic', 'PR', 'partial response', 'PRO', 'patient-reported outcomes', 'QLQ-LC13', 'Quality of Life Questionnaire and Lung Cancer Module 13', 'QoL', 'quality of life', 'RECIST 1.1', 'Response Evaluation Criteria in Solid Tumors 1.1', 'SAE', 'serious adverse event', 'SAP', 'statistical analysis plan', 'sSAP', 'supplemental statistical analysis plan', 'TPS', 'tumor proportion score', 'TTD', 'time to true deterioration', 'C', 'Confidential']"
199,page_200,"['MK-7902', 'PAGE 42', 'PROTOCOL NO.007-05 (E7080-G000-314)', 'Supplemental SAP', '15JUL2021', '6.', 'REFERENCES', 'Cocks K, King MT, Velikova G, de Castro G, Martyn St-James M, Fayers PM, et al. Evidence-based', 'guidelines for interpreting change scores for the European organisation for the research and treatment of', 'cancer quality of life questionnaire core 30. Eur J Cancer. 2012 Jul;48(11):1713-21.', 'Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of the new five-level version', 'of EQ-5D (EQ-5D-5L). Quality of life research : an international journal of quality of life aspects of', 'treatment, care and rehabilitation. 2011;20(10):1727-1736.', 'King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Quality of', 'Life Research 1996;5:555-67.', 'Lan, K. K., & DeMetes, D. L. (1983). Discrete sequential boundaries for clinical trials. Biometrika, 70(3):', '659-63.', 'Liang K, Zeger, S (2000). Longitudinal data analysis of continuous and discrete responses for pre-post', 'designs. Sankhyã: The Indian Journal of Statistics, 62 (Series B), 134-148.', 'Maringwa JT, Quinten C, King M, et al. Minimal important differences for interpreting health-related', 'quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized', 'controlled trials. Supportive care in cancer : official journal of the Multinational Association of Supportive', 'Care in Cancer. 2011;19(11):1753-1760.', 'Maurer, W., & Bretz, F. (2013). Multiple Testing in Group Sequential Trials using Graphical Approaches.', 'Statistics in Biopharmaceutical Research, 5(4): 311-320.', 'Miettinen, O., & Nurminen, M. (1985). Comparative analysis of two rates. Statistics in Medicine, 4:213-', '226.', ""O'Brien, P. C., & Fleming, T. R. (1979). A Multiple Testing Procedure for Clinical Trials. Biometrics,"", '35(3): 549-556.', 'Osoba, D., Rodrigues, G., Myles, J., Zee, B., & Pater, J. (1998). Interpreting the significance of changes', 'in health-related quality-of-life scores. J Clin Oncol, 16:139-44.', 'Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and', 'VAS scores in cancer. Health and Quality of Life Outcomes. 2007;5:70.', 'Scott, N. W., Fayers, P. M., Aaronson, N. K., Bottomley, A., Graeff, A. d., Groenvold, M.,', 'Sprangers, M. A. (2008). EORTO QLQ-C30 Reference Values. Retrieved from', 'ttps://www.eortc.org/app/uploads/sites/2/2018/02/reference_values_manual2008.pdf', 'C', 'Confidential']"
